Tuesday Research Poster Presentations

POSTER SESSION III:
Poster Display Hours – 8:45-13:45
Poster Author Discussion Hour – 12:45-13:45

POSTER SESSION IV:
Poster Display Hours – 15:45-19:15
Poster Author Discussion Hour – 18:15-19:15

POSTER SESSION III:
PHP: HEALTH CARE USE & POLICY STUDIES ROWS A-L
PIN: INFECTION ROWS L-P

POSTER SESSION IV:
PDB: DIABETES/ENDOCRINE DISORDERS ROWS A-E
PGI: GASTROINTESTINAL DISORDERS ROWS E-H
PMS: MUSCULAR-SKELETAL DISORDERS ROWS H-L
PSY: SYSTEMIC DISORDERS/CONDITIONS ROWS L-P
Research Poster Presentations – Session III

<table>
<thead>
<tr>
<th>Acceptance Code</th>
<th>VIH Page #</th>
<th>Topic – Subtopic</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHP1–PHP6</td>
<td>A514</td>
<td>Health Care Use &amp; Policy Studies – Consumer Role In Health Care:</td>
</tr>
<tr>
<td>PHP7</td>
<td>A515</td>
<td>Health Care Use &amp; Policy Studies – Diagnosis Related Group:</td>
</tr>
<tr>
<td>PHP8–PHP10</td>
<td>A515</td>
<td>Health Care Use &amp; Policy Studies – Disease Management:</td>
</tr>
<tr>
<td>PHP11–PHP63</td>
<td>A516</td>
<td>Health Care Use &amp; Policy Studies – Drug/Device/Diagnostic Use &amp; Policy:</td>
</tr>
<tr>
<td>PHP64–PHP84</td>
<td>A525</td>
<td>Health Care Use &amp; Policy Studies – Equity and Access:</td>
</tr>
<tr>
<td>PHP85–PHP220</td>
<td>A538</td>
<td>Health Care Use &amp; Policy Studies – Health Care Costs &amp; Management:</td>
</tr>
<tr>
<td>PHP221–PHP239</td>
<td>A552</td>
<td>Health Care Use &amp; Policy Studies – Health Care Research &amp; Education:</td>
</tr>
<tr>
<td>PHP240–PHP279</td>
<td>A555</td>
<td>Health Care Use &amp; Policy Studies – Health Technology Assessment Programs:</td>
</tr>
<tr>
<td>PHP280–PHP281</td>
<td>A562</td>
<td>Health Care Use &amp; Policy Studies – Patient Registries &amp; Post-Marketing Studies:</td>
</tr>
<tr>
<td>PHP282–289</td>
<td>A563</td>
<td>Health Care Use &amp; Policy Studies – Population Health:</td>
</tr>
<tr>
<td>PHP290–PHP297</td>
<td>A564</td>
<td>Health Care Use &amp; Policy Studies – Prescribing Behavior &amp; Treatment Guidelines:</td>
</tr>
<tr>
<td>PHP298–PHP299</td>
<td>A566</td>
<td>Health Care Use &amp; Policy Studies – Quality Of Care:</td>
</tr>
<tr>
<td>PHP300–PHP305</td>
<td>A566</td>
<td>Health Care Use &amp; Policy Studies – Regulation Of Health Care Sector:</td>
</tr>
<tr>
<td>PHP306–PHP315</td>
<td>A567</td>
<td>Health Care Use &amp; Policy Studies – Risk Sharing/Performance-Based Agreements:</td>
</tr>
<tr>
<td>PHP316–PHP355</td>
<td>A569</td>
<td>Health Care Use &amp; Policy Studies – Conceptual Papers:</td>
</tr>
<tr>
<td>PIN1–PIN21</td>
<td>A575</td>
<td>Infection – Clinical Outcomes Studies:</td>
</tr>
<tr>
<td>PIN22–PIN81</td>
<td>A579</td>
<td>Infection – Cost Studies:</td>
</tr>
<tr>
<td>PIN82–PIN93</td>
<td>A590</td>
<td>Infection – Patient-Reported Outcomes &amp; Patient Preference Studies:</td>
</tr>
<tr>
<td>PIN94–PIN120</td>
<td>A592</td>
<td>Infection – Health Care Use &amp; Policy Studies:</td>
</tr>
</tbody>
</table>

Research Poster Presentations – Session IV

<table>
<thead>
<tr>
<th>Acceptance Code</th>
<th>VIH Page #</th>
<th>Topic – Subtopic</th>
</tr>
</thead>
<tbody>
<tr>
<td>PDB1–PDB23</td>
<td>A597</td>
<td>Diabetes/Endocrine Disorders – Clinical Outcomes Studies:</td>
</tr>
<tr>
<td>PDB24–PDB78</td>
<td>A601</td>
<td>Diabetes/Endocrine Disorders – Cost Studies:</td>
</tr>
<tr>
<td>PDB79–PDB111</td>
<td>A611</td>
<td>Diabetes/Endocrine Disorders – Patient-Reported Outcomes &amp; Patient Preference Studies:</td>
</tr>
<tr>
<td>PDB112–PDB140</td>
<td>A617</td>
<td>Diabetes/Endocrine Disorders – Health Care Use &amp; Policy Studies:</td>
</tr>
<tr>
<td>PGI1–PGI3</td>
<td>A622</td>
<td>Gastrointestinal Disorders – Clinical Outcomes Studies:</td>
</tr>
<tr>
<td>PGI4–PGI39</td>
<td>A622</td>
<td>Gastrointestinal Disorders – Cost Studies:</td>
</tr>
<tr>
<td>PGI40–PGI51</td>
<td>A629</td>
<td>Gastrointestinal Disorders – Patient-Reported Outcomes &amp; Patient Preference Studies:</td>
</tr>
<tr>
<td>PGI52–PGI63</td>
<td>A631</td>
<td>Gastrointestinal Disorders – Health Care Use &amp; Policy Studies:</td>
</tr>
<tr>
<td>PMS1–PMS27</td>
<td>A634</td>
<td>Muscular-Skeletal Disorders – Clinical Outcomes Studies:</td>
</tr>
<tr>
<td>PMS28–PMS90</td>
<td>A638</td>
<td>Muscular-Skeletal Disorders – Cost Studies:</td>
</tr>
<tr>
<td>PMS91–PMS115</td>
<td>A650</td>
<td>Muscular-Skeletal Disorders – Patient-Reported Outcomes &amp; Patient Preference Studies:</td>
</tr>
<tr>
<td>PMS116–PMS138</td>
<td>A654</td>
<td>Muscular-Skeletal Disorders – Health Care Use &amp; Policy Studies:</td>
</tr>
<tr>
<td>PSY1–PSY25</td>
<td>A658</td>
<td>Systemic Disorders/Conditions – Clinical Outcomes Studies:</td>
</tr>
<tr>
<td>PSY26–PSY78</td>
<td>A663</td>
<td>Systemic Disorders/Conditions – Cost Studies:</td>
</tr>
<tr>
<td>PSY79–PSY99</td>
<td>A672</td>
<td>Systemic Disorders/Conditions – Patient-Reported Outcomes &amp; Patient Preference Studies:</td>
</tr>
<tr>
<td>PSY100–PSY134</td>
<td>A676</td>
<td>Systemic Disorders/Conditions – Health Care Use &amp; Policy Studies:</td>
</tr>
</tbody>
</table>
### HEALTH CARE USE & POLICY STUDIES - Consumer Role in Health Care

**PHP1 A** PATIENT INVOLVEMENT WITH PHARMACEUTICAL INDUSTRY DRUG DEVELOPMENT AND RESEARCH: A REVIEW OF THE LITERATURE  

**PHP2 A** ARE THE ELDERLY CITIZENS READY FOR ASSISTED LIVING TECHNOLOGIES? AN ITALIAN CASE STUDY  
*Cavallo F*, Trieste L**, Esposito R*, Aquilano M*, Dario P*, Turchetti G*, Scuola Superiore Sant'Anna, Pontedera (Pisa), Italy, 1Scuola Superiore Sant'Anna, Pisa, Italy

**PHP3 A** BUILDING INTENTIONS WITH THE THEORY OF PLANNED BEHAVIOUR: A QUALITATIVE ASSESSMENT OF SALIENT BELIEFS ABOUT PHARMACY VALUE ADDED SERVICES IN MALAYSIA  
*Hoay TL*, Hassali MA*, Saleem F*, Gan V*, Universiti Sains Malaysia, Penang, Malaysia, 1Universiti Sains Malaysia (USM), Pulau Pinang, Malaysia, 2Universiti Putra Malaysia, Serdang, Malaysia

**PHP4 A** ANALYSIS OF HEALTH SERVICES UTILIZATION AMONG ELDERLY IN SLOVENIA  
*Hren R*, Prevolnik Rupel V*, Srakar A*, 1University of Ljubljana, Ljubljana, Slovenia, 2Institute for Economic Research, Ljubljana, Slovenia

**PHP5 A** DEVELOPMENT, TEST-RETEST RELIABILITY AND VALIDITY OF THE PHARMACY VALUE ADDED SERVICES QUESTIONNAIRE  
*Hoay TL*, Hassali MA*, Saleem F*, Gan V*, Universiti Sains Malaysia, Penang, Malaysia, 1Universiti Sains Malaysia (USM), Pulau Pinang, Malaysia, 2Universiti Putra Malaysia, Serdang, Malaysia

**PHP6 A** THE IMPACT OF CONSUMER-DIRECTED HEALTH PLANS ON PRICE SHOPPING  
*Sood N*, *Zhang X*, Wagner Z*, Mehrrota A*, Huckfeldt P*, Haviland A*, 1University of Southern California, Los Angeles, CA, USA, 2UC Berkeley, Berkeley, CA, USA, 3Harvard University, Boston, MA, USA, 4University of Minnesota, Minneapolis, MN, USA, 5Carnegie Mellon University, Pittsburgh, PA, USA

### HEALTH CARE USE & POLICY STUDIES - Diagnosis Related Group

**PHP7 A** A NEW METHODOLOGY TO DEFINE THE SCOPE OF THE FRENCH « LISTE-EN-SUS »  

### HEALTH CARE USE & POLICY STUDIES - Disease Management

**PHP8 A** PECULIARITY, ENVIRONMENTAL AND CHRONIC DISEASES: USING ECOLOGICAL MODELS AS A FRAMEWORK FOR ANALYSING RISK FACTORS OF CHRONIC DISEASES  
*Zhu B*, Liu J, Wu J, *Mao Y*, Xi'an Jiaotong University, Xi'an, China

**PHP9 A** INVESTIGATING LEVELS OF BACTERIAL RESISTANCE AND ANTIBIOTIC CONSUMPTION IN THE ST. PETERSBURG STATE MEDICAL UNIVERSITY  
*Kolbin A*, Lawson R*, Kurylev A*, Arepieva M*, Balykina Y*, Spiridonova A*, Mukhina N*, Sidorenko S*, 1First Pavlov State Medical University of St. Petersburg, Saint Petersburg, Russia, 2AstraZeneca, Cheshire, UK, 3Saint Petersburg State University, Saint Petersburg, Russia, 4Research Institute for Paediatric Infections, Saint Petersburg, Russia

**PHP10 A** THE UNDER-RECOGNISED HUMAN AND ECONOMIC IMPACT OF CHRONIC RHINOSINUSITIS  

### HEALTH CARE USE & POLICY STUDIES - Drug/Device/Diagnostic Use & Policy

**PHP11 A** SYSTEMATIC REVIEW ON USE OF ECONOMIC EVIDENCE IN CLINICAL GUIDELINES  
*Aggarwal S*, Topaloglu H*, Kumar S*, NOVEL Health Strategies, Chevy Chase, MD, USA, 2GLOBAL ACCESS Monitor, Bethesda, MD, USA

**PHP12 A** EPIDEMIOLOGICAL DATA PRESENTED IN GERMAN BENEFIT ASSESSMENTS – A COMPARISON BETWEEN PHARMACEUTICAL COMPANIES AND G-BA  
*El Malahi Z*, Hirsch R, Boehler Y, Cologne University of Applied Sciences, Leverkusen, Germany

**PHP13 A** PRICES CHANGES FOR PATENT-PROTECTED INNOVATIVE DRUGS IN THE TOP 5 EU PHARMACEUTICAL MARKETS  

**PHP14 A** OUTPATIENT UTILIZATION AND QUALITY APPRAISAL OF ANTIBIOTICS IN TURKEY  
*Demir C*, Gursoy K, Ozturk Y, Koselerli R, Turkish Social Security Institution, Ankara, Turkey

**PHP15 A** THE IMPACT OF THE INCREASING PENETRATION OF ON-PATENT MEDICINES ON THE GREEK PHARMACEUTICAL MARKET  
*Manias NG*, Kyriopoulos I*, Ollandezos M*, Athanasakis K*, Kyriopoulos J*, 1MINTE, ATHENS, Greece, 2National School of Public Health, Athens, Greece

**PHP16 A** ANALYSIS OF BIOTECHNOLOGY DRUGS MARKET IN TURKEY
PHP17 A17 COSTS OF ADVERSE DRUG EVENTS: SYSTEMATIC REVIEW
Gursoy K, Ozturk Y, Demir C, Celik HD, Koselerli R, Dogru ST, Turkish Social Security Institution, Ankara, Turkey

PHP18 A18 FAST-TRACKING INNOVATION: A SCORECARD FOR THE FDA’S EXPEDITED REVIEW PROCESS
Batel-Marques F¹, Penedones A², Alves C¹, Mendes D¹, University of Coimbra, Coimbra, Portugal, AIBILI, Coimbra, Portugal

PHP19 A19 COST OF ADVERSE DRUG EVENTS ON HEALTH RESOURCES UTILIZATION IN OLDER ADULT SINGAPOREANS
Chen LL, Krishnan SS, Gui HS, Ong KY, Mamun K, Singapore General Hospital, Singapore, Singapore

PHP20 A20 ADVANCED THERAPY MEDICINAL PRODUCTS MAY DRAMATICALLY IMPACT PAYERS’ BUDGET
Hanna E¹, Rémuza C¹, Auquier P², Toumi M², Creativ-Ceutical, Paris, France, Université de la Méditerranée, Marseille, France, Aix-Marseille University, Marseille, France

PHP21 A21 POLICY IMPLICATIONS OF AFFORDABLE CARE ACT ON US MARKET ACCESS
Aggarwal S¹, Topaloglu H², Kumar S³, NOVEL Health Strategies, Chevy Chase, MD, USA, GLOBAL ACCESS Monitor, Bethesda, MD, USA

PHP22 A22 HOW REDUCING THE EQUIVALENCE BAND CAP TO BASE PRICE FOR SELECTED 15 GROUPS IMPACTS SAVING AND PRICE EROSION IN TURKEY: PRELIMINARY RESULTS

PHP23 A23 HAVE INFliximAB DISCOUNTED PRICES IN NORWAY HAD AN IMPACT ON PRICES AROUND THE WORLD?
Reinaud F¹, Ando G², IHS Life Sciences, Paris, France, IHS Life Sciences, London, UK

PHP24 A24 DEFIBROTIDE IN VENO-OCLUSION DIS EASE IN PUBLIC HOSPITALS OF PARIS: FUNDING ISSUES AND PERSPECTIVES
Steelandt J¹, Boquet F², Fusier I³, Cordonnier A², Paubel P³, AGEPS, Paris, France, AP-HP, AGEPS, Paris, France

PHP25 A25 EFFECT OF PARALLEL REVIEW PROCESSES FOR THE MARKETING AUTHORIZATION AND REIMBURSEMENT TO PATIENTS AND BUDGET
Park HK, Chae JY, So SM, Health Insurance Review & Assessment Service (HIRA), Seoul, South Korea

PHP26 A26 MARKET ACCESS OF ATMPS: OVERVIEW AND EXPECTED CHALLENGES
Hanna E¹, Tavella F², Rémuza C¹, Auquier P², Toumi M³, Creativ-Ceutical, Paris, France, Creativ-Ceutical, London, UK, Université de la Méditerranée, Marseille, France, Aix-Marseille University, Marseille, France

PHP27 A27 PRMA REFORM IN POLAND – IMPACT ON PHARMACEUTICAL INDUSTRY AND MARKET ACCESS
Caban A¹, Jaros P², Toumi M³, Creativ-Ceutical, Krakow, Poland, Aix-Marseille University, Marseille, France

PHP28 A28 THE EVOLVING LANDSCAPE OF EARLY ACCESS PROGRAMMES: COMPARISONS AND IMPLICATIONS FOR MARKET ACCESS
Heathfield A¹, Lebieck J¹, Young KE¹, Urbinati D², Soussi I³, Toumi M³, Pfizer, Surrey, UK, Creativ-Ceutical, Milan, Italy, Creativ-Ceutical, Luxembourg, Luxembourg, Creativ-Ceutical, Tunis, Tunisia, Aix-Marseille University, Marseille, France

PHP29 A29 THE EXPANSION OF USE OF DISCOUNTED PRICES FOR INTERNATIONAL REFERENCE PRICING PURPOSES
Ando G¹, Lockwood C¹, Izmirlieva M², Honore a³, IHS Life Sciences, London, UK, IHS, London, UK

PHP30 A30 FASTER DRUG MARKET ACCESS IN ITALY: IS CLASS C-NN THE ANSWER?
Negrini C¹, Camera A², Dobreva M³, Ciampa B³, Molchanova E¹, Pilli S¹, De Risi C², Simon-Kucher & Partners, Milano, Italy, Simon-Kucher & Partners, London, UK

PHP31 A31 THE END OF THE EXCEPTIONAL FINANCING OF ERYTHROPOIESIS-STIMULATING AGENTS IN FRENCH HOSPITALS: WHAT ARE THE IMPACTS FOR PUBLIC HOSPITALS OF PARIS?
Therasse C, Fusier I, Cordonnier A, Paubel P, General Agency of Equipment and Health Products (AGEPS), AP-HP, Paris, France

PHP32 A32 COMPLIANCE WITH THE RECENTLY INTRODUCED SYSTEM OF GENERIC SUBSTITUTION AND REFERENCE PRICING IN IRELAND: IMPLICATIONS FOR FURTHER POLICY ROLLOUT
Spillane S¹, Bennett K², Usher C¹, Adams R¹, Barry M¹, National Centre for Pharmacoeconomics, Dublin, Ireland, Trinity College Dublin, Dublin, Ireland

PHP33 A33 EVALUATION OF WHO/INRUD PRESCRIBING INDICATORS AND PRESCRIBING TREND OF ANTIBIOTICS IN ACCIDENTS AND EMERGENCY DEPARTMENT, BAHAWAL VICTORIA HOSPITAL, BAHAWALPUR, PAKISTAN
Azeem M, Sidra J, Samia S, Huria I, Uzma B, Rehan Sarwar M, Atif M, The Islamia University of Bahawalpur, Bahawalpur, Pakistan

PHP34 A34 THE UK PHARMACEUTICAL PRICE REGULATION SCHEME (PPRS) – CONSIDERATIONS OF VOLUNTARY VERSUS STATUTORY REGULATIONS AND HOW TO NEGOTIATE PRICING
Hill CA, Harries M, MAP BioPharma Limited, Cambridge, UK
null
IS THE PROOF OF AN ADDITIONAL BENEFIT UNDER AMNOG IN GERMANY MORE DIFFICULT FOR CERTAIN DRUGS THAN FOR OTHER ONES?

Kotowa W¹, Reindl S², Mathes J¹, Doyno T¹, Höer A², IGES Institut GmbH, Nuremberg, Germany, ²IGES Institut GmbH, Berlin, Germany

REAL WORLD DATA: BIOLOGIC TREATMENT FOR NAIVE PATIENT IN THE LAZIO REGION

Marcellusi A¹, Mecozzi A², Salvitti T¹, Sciattella P¹, Mennini FS³, University of Rome “Tor Vergata” Italy, Rome, Italy, ²Lazio Region, Rome, Italy, ³Faculty of Economics, Centre for Economic and International Studies (CEIS)-Economic Evaluation and HTA (EEHTA), University of Rome, Rome, Italy

CAPTURING ACCURATE CONCOMITANT MEDICATIONS INFORMATION IN GLOBAL TRIALS

O’Donohoe P¹, Lambe J², Acquadoro C³, CRF Health, London, UK, ²Mapi, Lyon, France, ³Mapi Research Trust, Lyon, France

PREVALENCE AND PERCEPTION OF USE OF NON-PRESCRIPTION MEDICINES AMONG MEDICAL STUDENT IN QUETTA, PAKISTAN

ul Haq N, Iqbal Q, Nasim A, Raiz S, Ahmed N, Razaq G, University of Balochistan, Quetta, Pakistan

DRUG UTILIZATION STUDY ON INDIAN ELDERLY AMBULATORY PATIENTS USING WHO PRESCRIBING INDICATORS

Kashyap M¹, D Cruz S², Sachdev A², Tiwari P³, AIIMST University, Semeling, Malaysia, ²Government Medical College & Hospital, Chandigarh, Chandigarh, Malaysia, ³National Institute of Pharmaceutical Education and Research, S.A.S. Nagar, Punjab, INDIA, Mohali, India

DYNAMICS OF PUBLIC OUTPATIENT DRUG EXPENDITURES IN AUSTRIA, 2005-2015

Hinteregger M, Main Association of Austrian Social Security Institutions (HVB), Vienna, Austria

ASSESSMENT OF WHO/INRUD CORE DRUG USE INDICATORS IN TWO TERTIARY CARE HOSPITALS OF BAHAWALPUR, PUNJAB, PAKISTAN


A CROSS-SECTIONAL ANALYSIS OF RECENTLY PUBLISHED SYSTEMATIC LITERATURE REVIEWS ON PHARMACOLOGICAL INTERVENTIONS IN ONCOLOGY

Dreitlein WB¹, Fowler R², Jones CA², Lula S², McCracken R², Smoyer KE¹, Envision Pharma Group, Madison, NJ, USA, ²Envision Pharma Group, London, UK, ³Envision Pharma Group, Southport, CT, USA, ⁴Envision Pharma Group, Philadelphia, PA, USA

DISPENSING OF VITAMIN PRODUCTS BY RETAIL PHARMACIES IN SOUTH AFRICA

Truter I, Nelson Mandela Metropolitan University, Port Elizabeth, South Africa

BIOSIMILAR SUBSTITUTION POLICIES: AN OVERVIEW

Mendoza G¹, Ionescu D¹, Radière G¹, Rémuzat C¹, Young KE¹, Toumi M², Sandoz International GmbH, Holzkirchen, Germany, ¹Creative-Ceutical, Paris, France, ²Creative-Ceutical, Milan, Italy, ³Aix-Marseille University, Marseille, France

MULTIPLE USE OF ANTIBIOTIC IN POST OPERATIVE PATIENTS IN TERTIARY CARE HOSPITAL OF QUETTA, PAKISTAN

ul Haq N, Zehri Q, Iqbal Q, Nasim A, Riaz S, Razaq G, Ahmed N, University of Balochistan, Quetta, Pakistan

HEALTH CARE USE & POLICY STUDIES - Equity and Access

ASSESSING EQUITY OF HEALTH SERVICE UTILIZATION OF RURAL RESIDENTS IN CHINA: A CASE STUDY OF Z COUNTY, SHAANXI PROVINCE

Wu J, Liu J, Zhu B, Mao Y, Xi'an Jiaotong University, Xi'an, China

ASSESSING EQUITY OF HEALTH SERVICE UTILIZATION OF URBAN RESIDENTS IN CHINA: A CASE STUDY OF B CITY, SHAANXI PROVINCE

Wu J, Liu J, Zhu B, Mao Y, Xi'an Jiaotong University, Xi'an, China

THE INTERTEMPORAL CHANGES OF HEALTH SERVICES UTILIZATION DURING THE LAST DECADE: THE CASE OF AUSTERITY INFLICTED ON GREECE

Charonis A, Kyriopoulos I, Athanasakis K, Pavi E, Kyriopoulos J, National School of Public Health, Athens, Greece

ASSESSING JAPAN’S THREE EARLY ACCESS PROGRAMS BASED ON RECENT DISCUSSIONS: SCOPE AND FINANCIAL AID

Mita N¹, Iwata R¹, Kazuo K¹, Onda T¹, Daichi K¹, Akitoku Y¹, “Bayer Yakuhin, Ltd., Tokyo, Japan, “Bayer Yakuhin, Ltd., Osaka, Japan

DOES CHINA’S NEW MEDICAL REFORM IMPROVE HEALTH EQUITY OF RURAL RESIDENTS? EVIDENCE FROM HOUSEHOLD SURVEYS BEFORE AND AFTER THE IMPLEMENTATION OF NEW MEDICAL REFORM IN SHAANXI PROVINCE, CHINA

Wu J, Liu J, Zhu B, Mao Y, Xi'an Jiaotong University, Xi'an, China

ALL QALYS ARE EQUAL, BUT SOME QALYS ARE MORE EQUAL THAN OTHERS; A COMPARISON OF THE NICE END OF LIFE CRITERIA AND SMC PACE PROCESS

...
**PHP120 D20** HOW IMPORTANT IS THE TIME FACTOR? SAVING LIVES USING FIRE AND RESCUE SERVICES  
Jaldell H, Karlstad University, Karlstad, Sweden

**PHP121 D21** THE COMPARATIVE PHARMAECONOMIC ANALYSIS OF USING DIFFERENT VARIANTS OF BALANCED CRYSTALLOIDS DURING INFUSION THERAPY  
Krysanova V1, Krysanov I2, M. Sechenov First Moscow State Medical University, Moscow, Russia; Postgraduate Medical Institute, Moscow National University of Food Production, Moscow, Russia

**PHP122 D22** CHANGES IN THE PRICES OF REFERENCE BIOTECHNOLOGY PRODUCTS BY THE PENETRATION OF BIOSIMILARS INTO THE TURKISH PHARMACEUTICAL MARKET  
Tuna E1, Kockaya G2, Hacettepe University, Ankara, Turkey; Health Economics and Policy Association, Ankara, Turkey

**PHP123 D23** DEFINING VALUE WHEN LAUNCHING BIOSIMILARS TREATMENTS WITHIN EUROPEAN HEALTHCARE SYSTEMS  

**PHP124 D24** ECONOMIC EVALUATION OF THE USE OF HUMAN ALBUMIN IN A BRAZILIAN PUBLIC HOSPITAL  
Taguti E1, Teleken JL1, Steimbach LM2, Sanches AC1, Universidade Estadual do Oeste do Paraná, Cascavel, Brazil; Universidade Federal do Paraná, Curitiba, Brazil

**PHP125 D25** COST-SAVINGS AND COST-UTILITY OF AN EHR SYSTEM SMARTPHONE APP IN A TRAUMA INTENSIVE CARE UNIT  
Pugliese L, HITLAB, New York, NY, USA

**PHP126 D26** USING AN ECONOMIC MODEL TO CHOOSE INITIAL APPROPRIATE ANTIBIOTIC THERAPY BASED ON DIFFERENCES IN IN-VITRO SUSCEPTIBILITY TO CEFTOLOZANE/TAZOBACTAM AND PIPERACILLIN/TAZOBACTAM  
Prabhu V1, Sen S2, Miller B3, Basu A4, Medic G5, Merck & Co., Inc., North Wales, PA, USA; Merck & Co., Inc., Lebanon, NJ, USA; Merck & Co., Inc., Zurich, Switzerland; University of Washington, Seattle, WA, USA; MAPI Group, Houten, The Netherlands

**PHP128 D27** THE INFLUENCE OF THE REVISION OF THE MEDICAL FEE SCHEDULE ON NATIONAL HOSPITAL ORGANISATION HOSPITALS IN JAPAN  
Nakagawa Y1, Tomita N2, Irísa K1, Nakagawa Y3, National Hospital Organization Shikoku Medical Center for Children and Adults, Zentju city, Japan; National Institute of Public Health, Saitama, Japan

**PHP129 D28** PREDICTION OF FUTURE HEALTH INSURANCE EXPENDITURES IN HUNGARY ACCORDING TO POPULATION FORECAST SCENARIOS  
Boncz I1, Endrei D1, Agoston I1, Csákvári T2, Danku N1, Brodsky V3, University of Pécs, Pécs, Hungary; University of Pécs, Zalaegerszeg, Hungary; Corvinus University of Budapest, Budapest, Hungary

**PHP130 D29** ITALIAN HEALTHCARE EXPENDITURE TRENDS FROM 2002 TO 2013  
D’Ausilio A1, Daniel F1, Aiello A1, Touni M2, Creativ Cheetah, Milano, Italy; Aix-Marseille University, Marseille, France

**PHP131 D30** THE IMPACT OF PHARMACEUTICAL INNOVATION ON LONGEVITY IN PORTUGAL, 2002–2010  
Lichtenberg F1, Laires PA2, Columbia University, New York, NY, USA; Merck Sharp & Dohme, Oeiras, Portugal

**PHP132 D31** THE ECONOMIC CONSEQUENCES OF THE USE OF ANTIBIOTICS IN BELGIUM  
Caekelbergh K, Ramos M, Lamotte M, IMS Health, Vilvoorde, Belgium

**PHP133 D32** COST OF MULTIMORBIDITY: THE INFLUENCE OF AMBULATORY PHARMACEUTICAL AND HOSPITAL EXPENDITURE  
Caballer-Tarazona V1, Vivas-Consuelo D1, Guadalajara-Olmeda N1, Clemente-Collado A2, Politecnico University of Valencia, Valencia, Spain; Marina Salud, Denia, Spain

**PHP134 D33** HEALTHCARE EXPENDITURE ON PREVENTION IN THE SPENDING REVIEW ERA  
Coretti S, Ruggeri M, ALTEMS, Università Cattolica del Sacro Cuore (UCSC), Postgraduate School of Health Economics and Management, Rome, Italy

**PHP135 E1** GENERAL ASSESSMENT OF UNLICENSED ANTI NEOPLASTIC AND IMMUNOMODULATING MEDICINE USAGE SUBGROUPS IN TURKEY  
Yenilmez FB1, Kockaya G2, Dogan E3, Tunca E1, Vural IM4, Akbulat A5, Artiran G6, Tatar M7, Unal O8, Hacettepe University, Ankara, Turkey; Health Economics and Policy Association, Ankara, Turkey; Turkish Medicines and Medical Devices Agency, Ankara, Turkey

**PHP136 E2** AVOIDABLE HOSPITALIZATIONS DUE TO MEDICATION ERRORS IN BELGIUM  
Ramos M, Caekelbergh K, Lamotte M, IMS Health, Vilvoorde, Belgium

**PHP137 E3** DRUG PRICING INFORMATION MANAGEMENT: DEVELOPMENT OF A WEB BASED E-PRICING SYSTEM  
Tsourougiannis D1, Odeyemi IA2, Astellas Pharma EMEA, Chertsey, UK; Astellas Pharma Europe Ltd, Chertsey, UK

**PHP138 E4** FOLLOWING NORWAY, WHICH MARKET WILL BE NEXT TO SEE EXTREME BIOSIMILAR DISCOUNTING?  
Overington RJ, Kumar A, Staples O, ZS Associates, London, UK
**LISTE-EN-SUS REFORM IN FRANCE - WHAT ARE THE CONSEQUENCES?**
Mitrano M, Flostrand S, IMS Consulting Group, Paris, France

**THE MOST PROFITABLE HEALTH INSURANCE “COMPANY” IN TURKEY**
Kockaya G, Atikeler K, Health Economics and Policy Association, Ankara, Turkey, Hacettepe University, Ankara, Turkey

**COMPARISON OF CURRENT AND PREFERRED STATUS OF HTA IMPLEMENTATION IN CENTRAL AND EASTERN EUROPEAN COUNTRIES**
Kalo Z, Čsanadi M, Vitezic D, Huic M, Husereau D, Kristensen FB, Eötvös Loránd University, Budapest, Hungary, Syreon Research Institute, Budapest, Hungary, University of Rijeka, School of Medicine and University Hospital Centre Rijeka, Rijeka, Croatia, Agency for Quality and Accreditation in Health Care and Social Welfare, Zagreb, Croatia, Epidemiology and Community Medicine, University of Ottawa, Ottawa, ON, Canada, Danish Health and Medicines Authority, Copenhagen, Denmark

**IMPACT OF A PAYMENT BY RESULTS ACCESS SCHEME IN ITALY: BETTER VALUE FOR MONEY?**
Tourner C, Giuliani G, Hoffmann-La Roche AG, Basel, Switzerland, Roche SpA, Monza, Italy

**PATIENT ACCESS SCHEMES WITHIN THE UK: A RETROSPECTIVE ANALYSIS**
Maguire PT, Gibson E, Wickenstones, Goring Heath, UK

**EARLY BENEFIT ASSESSMENT AND UPTAKE OF PHARMACEUTICAL INNOVATIONS – EXPERIENCES FROM GERMANY 2011 TO 2014**
Witte J, Greiner W, School of Public Health, Bielefeld University, Bielefeld, Germany

**IMPACT OF THE CHANGES IN THE PORTUGUESE PHARMACY REMUNERATION SYSTEM**
Teixeira J, Guerreiro JP, Costa S, Center for Health Evaluation & Research, Lisbon, Portugal

**ANALYSIS OF NURSING ACTIVITIES AND HEALTH CARE NEED IN RESIDENTIAL SOCIAL CARE INSTITUTIONS IN HUNGARY**
Dózsa C, Cseh B, Borcsék B, University of Miskolc, Miskolc, Hungary, National Health Care Centre, Budapest, Hungary, Med-Econ Ltd., Vereco, Hungary

**METHODOLOGY OF INTERNATIONAL COMPARISON OF PHARMACEUTICAL PRICES**
Čsanadi M, Fasseeh AN, Kalo Z, Syreon Research Institute, Budapest, Hungary, Eötvös Loránd University, Budapest, Hungary

**EVALUATION OF FRACTURES IN THE ELDERLY IN AUSTRIA AND DRUG RISK FACTOR ANALYSIS BASED ON CLAIMS DATA**
Zauner G, Popper N, Wilbacher I, dwh GmbH, Vienna, Austria, University of Technology Vienna, Vienna, Austria, Association of Austrian Social Insurance Institutions, Vienna, Austria

**USE OF ECONOMIC EVALUATIONS OF HEALTH TECHNOLOGIES IN DUTCH HEALTHCARE DECISION-MAKING: BARRIERS AND FACILITATORS**
Roseboom KJ, van Dongen JM, Tompa E, van Tulder MW, Bosmans JE, VU University Amsterdam, Amsterdam, The Netherlands, Institute for Work & Health, Toronto, ON, Canada

**SUCCESS RATE OF INCLUDING MEDICINES TO THE REIMBURSEMENT SYSTEM IN SLOVAKIA**
Psenkova M, Mackovicova S, Pharm-In Ltd, Bratislava, Slovak Republic

**USE OF HEALTH SERVICES IN BRAZIL: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PREVALENCE STUDIES**
Araújo E, Andrade KR, Galvão TF, Tolentino M, Araujo FA, Pereira MG, University of Brasilia, Brasilia / DF, Brazil, Federal University of Amazonas, Manaus, Brazil

**HURDLES THAT IMPED ECONOMIC EVALUATIONS OF HEALTH CARE INTERVENTIONS TESTED BY GENERAL PRACTITIONERS IN FLANDERS: A QUALITATIVE STUDY**

**ASSOCIATION BETWEEN DEPRESSION AND DISCONTINUATION WITH ANTIDIABETIC DRUGS**
Lunghi C, Moisan J, Grégoire J, Guénette L, Laval University, Quebec City, QC, Canada

**EFFECTIVENESS OF A COMMUNITY-BASED FALLS PREVENTION PROGRAM FOR THE ELDERLY**
Molina JA, Ismail NH, Heng BH, Leong IY, National Healthcare Group, Singapore, Singapore, Singapore, Tan Tock Seng Hospital, Singapore, Singapore

**SYSTEMATIC REVIEW OF FDA BREAKTHROUGH THERAPY DESIGNATED PRODUCTS**
Aggarwal S, Kumar S, Topolglu H, NOVEL Health Strategies, Chevy Chase, MD, USA, GLOBAL ACCESS Monitor, Bethesda, MD, USA

**THE USE COMPARATIVE EFFECTIVENESS RESEARCH AND EVIDENCE BASED MEDICINE IN US PAYOR DECISION MAKING**
Sax MJ, Smeeding JE, Brook RA, The Pharmacy Group (TPG), Glastonbury, CT, USA, TPG-NPRT, Glastonbury, CT, USA

**IMPACT OF CLERKSHIP ATTACHMENTS ON STUDENTS’ ATTITUDE TOWARDS PHARMACEUTICAL CARE IN ...NOVEL Health Strategies, Chevy Chase, MD, USA,
ETHIOPIA
Sabe ZS, University of Gondar, Gondar, Ethiopia

PHP158 F7 RELATIONSHIP BETWEEN COMMUNITY PHARMACY ATTRIBUTION AND PATIENT’S OUTCOMES IN HEALTHCARE SERVICE OF HOME-VISITING
Nanaumi Y1, Onda M2, Imai H3, Advance Pharma Research Office, Nara, Japan, 2Osaka University of Pharmaceutical Sciences, Osaka, Japan, 3National Institution of Public Health, Wako, Japan

PHP159 F8 A STUDY OF KNOWLEDGE, ATTITUDE AND PRACTICE OF COMMUNITY PHARMACISTS TOWARDS ADVERSE DRUG REACTION REPORTING & MONITORING
Srikanth MS, Adepu R, Himanshu Patel., Parthasarathii G, JSS College of Pharmacy, Mysore, JSS University, Mysore, India

PHP160 F9 TAKING MEDICATION SAFELY: IMPLEMENTING AND DEVELOPING A MEDICATION REVIEW PROGRAM IN GERMAN COMMUNITY PHARMACIES OVER 4 YEARS
Hessemer S1, Wunder S2, Brummer C2, Gertis A3, Schoeffski O1, Friedrich-Alexander-University Erlangen-Nuremberg, Nuremberg, Germany, AOK Bavaria, Nuremberg, Germany

PHP161 F10 CAN GRAPEFRUIT JUICE MAKE SAFE DRUGS UNSAFE OR INEFFECTIVE? AN EVIDENCE-BASED ANSWER
Quignot N1, Amzal B2, LASER Analytica, Paris, France, Decision Analytics, LASER Analytica, London, UK and, Paris, France

PHP162 F11 APPLYING KARNOFSKY PERFORMANCE SCALE IN HOSPITALIZED PATIENTS FOR PROMOTING RATIONAL THERAPY
Juang HJ, Diamente LM, HOSPITAL MUNICIPAL, SÃO PAULO, Brazil

PHP163 F12 SURVEY ON ROMANIAN HOSPITALS FINANCING REVEALS MAJOR DYSFUNCTIONS IN COVERING DRUG TREATMENT DURING HOSPITALIZATION
Paveliu MS, Titu Maiorascal University, Bucharest, Romania

PHP164 F13 ISOLATION, IDENTIFICATION AND ANTIMICROBIAL SUSCEPTIBILITY TESTING OF SALMONELLA FROM SELECTED POULTRY FARMS IN DEBRE ZEIT
Yizengaw HA, Dilla University, Dilla, Ethiopia

PHP165 F14 OBSERVATIONAL (OBS), PRAGMATIC (PRA), AND INDIRECT (IND) METHODOLOGIES FOR COMPARATIVE RELATIVE EFFECTIVENESS (RE) AND BENEFIT-RISK (BR) ANALYSES
Eichmann F1, Kreyenberg K, Inventiv Health Clinical, Munich, Germany

PHP166 F15 INTRA- AND EXTRA-ORGANIZATIONAL FACTORS AFFECTING COMMUNITY PHARMACY PERFORMANCE
Rangchian M1, Mehralian G2, Salamzadeh J3, Vatanpour H4, Shahid Beheshi university of medical Sciences, School of Pharmacy, Tehran, Iran, Shahid Beheshi University of Medical Sciences, School of Pharmacy, Tehran, Iran

PHP167 F16 INFLUENCE OF SOME FACTORS ON THE MORPHOLOGICAL STRUCTURE OF SPERMATOZOA IN STRAIGHT INTESTINE DURING FORENSIC - MEDICAL EXAMINATION OF SODOMY
Zhakupova T1, Turgambayeva A2, Mussina A1, Bukeyeva Z1, Kossovom A2, Astana Medical University, Astana, Kazakhstan, Nazarbayev University, Astana, Kazakhstan

PHP168 F17 EFFICIENCY ANALYSIS OF SURGICAL STAPLERS COMPARED TO MANUAL SUTURE FOR OPEN AND LAPAROSCOPIC SURGERY
Psaltikkis EM, Resende MR, Bustorff-Silva JM, Clinical Hospital of State University of Campinas, Campinas, Brazil

PHP169 G1 REAL-WORLD DATA ON MULTIPLE COMORBIDITIES AMONG PATIENTS WITH HEPATITIS C: CONSIDERATIONS FOR PATIENT CARE AND PROGNOSIS
Weil C1, Nwanwko C2, Friedman M3, Shalev V3, Chodick G3, Maccabi Healthcare Services, Tel Aviv, Israel, 3Merck & Co., Inc., Kenilworth, NJ, USA, Medical Division, Maccabi Healthcare Services, Tel Aviv, Israel, Maccabi Healthcare Services and Tel-Aviv University, Tel-Aviv, Israel

PHP170 G2 ACCEPTANCE OF CLINICALLY RELEVANT PRIMARY STUDY ENDPOINTS IN THE GERMAN HEALTH TECHNOLOGY ASSESSMENT PROCESS: ANALYSIS OF FIVE DIFFERENT DISEASE AREAS
Staab TR1, Isbary G1, Amelung VE2, Ruof J1, Roche Pharma, Grenzach-Wyhlen, Germany, Institute for Applied Health Services Research, Berlin, Germany

PHP171 G3 AN OVERVIEW OF REVIEWS OF THE CLINICAL EFFECTIVENESS OF GENERIC CHRONIC DISEASE SELF MANAGEMENT SUPPORT INTERVENTIONS
Murphy L1, Cianci F1, Harrington P2, Teljeur C3, Moran P4, Ryan M5, Health Information and Quality Authority, Dublin, Ireland, Health Information and Quality Authority (HIQA), Dublin, Ireland

PHP172 G4 DOES A SHORTER PROTOCOL TIME FOR CHEST PAIN PATIENTS IMPACT EMERGENCY DEPARTMENT FLOW? A QUEUING MODEL TO DISCUSS EMERGENCY DEPARTMENT MANAGEMENT METRICS
Giusepi I, Juelicher P, Abbott, Wiesbaden, Germany

PHP173 G5 VALIDATION OF PERIODIC SAFETY UPDATE REPORTING SYSTEM IN A TERTIARY CARE TEACHING HOSPITAL USING ADVERSE DRUG REACTION MONITORING OF THREE COMMONLY PRESCRIBED DRUGS
Lokhande A1, Unnikrishnan MK1, Prabhu MM2, Thunga G3, Mallayasmy SR4, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India, Kasturba Medical College, Manipal University, Manipal, India
PHP174 G6 THE RELATIONSHIP BETWEEN KNOWLEDGE AND PERFORMANCE: THE CASE OF IRAN COMMUNITY PHARMACIES

Rangchian M1, Mehralian G1, Vatanpour H1, Salamzadeh J1, Shahid Beheshti university of medical Sciences, School of Pharmacy, Tehran, Iran, 2Shahid Beheshti University of Medical Sciences, School of Pharmacy, Tehran, Iran

PHP175 G7 CHARACTER OF TOXIC DAMAGE OF LIVER IN INFLUENCES OF SUBSTANCES OF MEDIATOR TO FETAL CELLS ON HEPATOCYTES IN ACUTE LIVER FAILURE

Akhnnetova Z1, Bukeyeva Z, Zhanaliyeva M, Shaizadina G, Turgambayeva A, Astana Medical University, Astana, Kazakhstan


Prada M1, Bertozzi C1, Proietti B1, Urbiniati D1, Intexo, Roma, Italy, 2IMS Health, Milano, Italy

PHP177 G9 WILLING TO PROVIDE MEDICATION ANALYSIS? PREDICTING PHARMACISTS' INTENTION TO PROVIDE MEDICATION ANALYSIS IN COMMUNITY PHARMACIES IN GERMANY

Hessemer S1, Schmid K2, Schoeffski O1, Friedrich-Alexander-University Erlangen-Nuremberg, Nuremberg, Germany, 2Bavarian Academy for Clinical Pharmacy, Munich, Germany

PHP178 G10 CAN PATIENTS RELY ON RESULTS OF PHYSICIAN RATING WEBSITES WHEN SELECTING A PHYSICIAN? - A CROSS-SECTIONAL STUDY ASSESSING THE ASSOCIATION BETWEEN ONLINE RATINGS AND STRUCTURAL AND QUALITY OF CARE MEASURES FROM TWO GERMAN PHYSICIAN RATING WEBSITES

Adelhardt T1, Emmert M2, Sander U2, Wambach V2, Lindenthal J2, FAU-Erlangen-Nuremberg, Nuremberg, Germany, 2Friedrich-Alexander University Erlangen-Nürnberg, Nuremberg, Germany, 3Hochschule Hannover, Hannover, Germany, 4QuE, Nuremberg, Germany

PHP179 G11 RELATIONSHIP BETWEEN THE PROVISION OF INJECTION SERVICES IN AMBULATORY PHYSICIAN OFFICES AND PRESCRIBING INJECTABLE MEDICINES IN IRAN

Yousefi N1, Rashidian A2, Soleymani P3, Tehran University of Medical Sciences, Tehran, Iran, 2Food and Drug Organization, Tehran, Iran

PHP180 G12 THE CLINICAL AND ECONOMIC BURDEN OF MEDICATION ERRORS IN THE CANADIAN ACUTE CARE SETTING: A REVIEW OF PUBLISHED STUDIES

Baginska E1, Becton Dickenson, Mississauga, ON, Canada

PHP181 G13 U.S. PAYER EXPECTATIONS FOR REIMBURSEMENT OF BIOSIMILARS

Malik AN1, Keeping K, Fletcher-Louis M2, Decision Resources Group, London, UK

PHP182 G14 UNDERSTANDING LOCAL COMMISSIONING DECISIONS ON NEW PHARMACOTHERAPIES IN THE UK

Singh S1, Purchase J, Pope Woodhead and Associates Ltd., St Ives, UK

PHP183 G15 THE GERMAN AMNOG DRUG REIMBURSEMENT PROCESS: FACTORS ASSOCIATED WITH GBA-DECISIONS ABOUT THE ADDITIONAL BENEFIT

Mueller S1, Brandt S2, Wilke T2, IPAM, Wismar, Germany, 2Ingress Health, Wismar, Germany

PHP184 G16 OVERVIEW OF NUB PROCESS FOR IN-PATIENT DRUGS AND DEVICES IN GERMAN

Aggarwal S1, Kumar S2, Topaloglu H1, NOVEL Health Strategies, Chevy Chase, MD, USA, 2GLOBAL ACCESS Monitor, Bethesda, MD, USA

PHP185 G17 REIMBURSEMENT OF ORPHAN AND EXPENSIVE DRUGS IN THE NETHERLANDS: EXPLORATION OF ESSENTIAL CRITERIA IN THE DECISION MAKING PROCESS

Tariq L1, Frederix GW, Roberts RW, van Bakel P, Belitser SV, van Bakel P, Raaijmakers JA, Purchase J, Pope Woodhead and Associates Ltd., St Ives, UK

PHP186 G18 PERFORMANCE OF DRG-BASED REIMBURSEMENT POLICY IN NATIONAL HEALTH INSURANCE: EIGHT YEARS' EXPERIENCES

Kim J1, Yim E2, Bae H1, Seoul National University, Seoul, South Korea, 2Daegu Health College, Daegu, South Korea

PHP187 G19 IMPACT OF ESSENTIAL HEALTH BENEFIT BENCHMARK PLANS ON US MARKET ACCESS

Aggarwal S1, Topaloglu H1, Kumar S2, NOVEL Health Strategies, Chevy Chase, MD, USA, 2GLOBAL ACCESS Monitor, Bethesda, MD, USA

PHP188 G20 A SIMULATION ANALYSIS USING THE ORANGE PRICE REFERENCE TOOL

Zah V1, Stoykova B1, Walzer S1, Thompson S2, ZRx Outcomes Research, Mississauga, ON, Canada, 2Daichi Sankyo, Gerrards Cross, UK, 3MarS Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany, 4ZRx Outcomes Research, Berlin, Germany

PHP189 G21 ULTRA ORPHAN AND CANCER DRUG PRICING TRENDS IN THE US AND THE UK

Aggarwal S1, Topaloglu H1, Kumar S2, NOVEL Health Strategies, Chevy Chase, MD, USA, 2GLOBAL ACCESS Monitor, Bethesda, MD, USA

PHP190 G22 DISCOUNT DISTRIBUTION ANALYSIS OF ORIGINAL MEDICINES WHICH HAS NO GENERICS IN TURKEY

Tuna E1, Yenilmez FB1, Atikeler K1, Kockaya G1, Hacettepe University, Ankara, Turkey, 2Health Economics and Policy Association, ANKARA, Turkey
PHP191 G23 IMPACT OF ASSESSMENTS OF NEW MEDICINES BY THE SMC IN ENGLAND  
   Furniss J, Panciera D, Roibu C, GIK NOP Ltd, Melton Mowbray, UK, GIK UK Ltd, London, UK

PHP192 G24 REGULATIONS OF THE GERMAN DRUG MARKET  
   Friedmann B, Schwarz R, Freiberg M, Wilskiche J, Meyer H, Quintiles Commercial, Mannheim, Germany

PHP193 G25 A SYSTEMATIC COMPARISON OF IQWIG RECOMMENDATIONS AND G-BA DECISIONS IN THE AMNOG PROCESS IN GERMANY  
   Vollmer L, Dröschel D, Fröhlich N, de Paz B, Walser S, MArs Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany, NF, Bremen, Germany, PRIORITIS Market Access, Paris, France

PHP194 G26 PHARMACOECONOMIC GUIDELINE FOR POSITIVE DRUG LIST APPLICATION PURPOSES IMPLEMENTED IN BULGARIA  
   Savova A, Stoimenova A, Manova M, Zidarova B, Petrova G, Danchev N, Medical University Sofia, Faculty of Pharmacy, Sofia, Bulgaria, National Council of prices and reimbursement of medicinal products, Sofia, Bulgaria

PHP195 G27 DIFFERENCES BETWEEN THE EFFICACY OF BIOSIMILARS AND ORIGINATORS - ANALYSIS AND IMPLICATIONS FOR THE COST-EFFECTIVENESS-ANALYSIS-FROM A PAYERS PERSPECTIVE  
   Bierbaum M, Haffer A, Bierbaum ME, HS Aalen, Nürnberg, Germany, FAU Erlangen-Nürnberg, Nürnberg, Germany, BERSERCON, Nürnberg, Germany

PHP196 G28 INFLUENCE OF PATIENT-REPORTED OUTCOMES (PRO) ON MARKET ACCESS DECISIONS IN MARKETS WITH CENTRALIZED HEALTHCARE SYSTEMS  
   Hogue S, Brogan AP, DeMuro C, Barrett A, D’Allessio D, Bal V, RTI Health Solutions, Research Triangle Park, NC, USA, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PHP197 G29 STREAMLINING THE ACCESS DECISION PROCESS FOR GERMAN PATIENTS TO RECEIVE REIMBURSED TREATMENTS IN ANOTHER EUROPEAN UNION MEMBER STATE  

PHP198 G30 NUB STATUS – AN ANALYSIS COMPARING RESULTS OF 2015 VS. 2014 - LEADING THERAPEUTIC AREAS CONFIRMED  
   Freiberg M, Friedmann B, Schalk E, Schwarz R, Quintiles Commercial, Mannheim, Germany

PHP199 G31 ARE VACCINATIONS REALLY DIFFERENT TO PHARMACEUTICALS WITH RESPECT TO MARKET ACCESS IN GERMANY?  
   Droeschel D, Vollmer L, Krone FA, Walser S, MArs Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany, State University Baden-Wuerttemberg, Loerrach, Germany

PHP200 G32 A COMPARISON OF ON-PATENT MEDICINE PRICES USING AN EKS METHOD  
   Davey P, Illuminate Health Consulting, Chatswood, Australia

PHP201 G33 ASSESSING THE POTENTIAL FOR TIERED PRICING OF HIGH PRICED THERAPIES WITHIN ARGENTINA, COLUMBIA, MEXICO, INDONESIA, AND THAILAND  
   Napiecek D, Shah S, Ramesh V, Market Access Solutions LLC, Raritan, NJ, USA

PHP202 H1 QUALITATIVE AND QUANTITATIVE ANALYSIS OF THE SCOTTISH MEDICINES CONSORTIUM (SMC) ADVICE  

PHP203 H2 ATC1 GROUP DISCOUNT DISTRIBUTION ANALYSIS OF ORIGINAL MEDICINES WHICH HAS NO GENERIC IN TURKEY  
   Atikeler K, Yenilmaz FB, Tuna E, Kockaya G, Hacettepe University, Ankara, Turkey, Health Economics and Policy Association, ANKARA, Turkey

PHP204 H3 IMPACT OF HEALTHCARE REFORMS ON PRICING AND REIMBURSEMENT IN TURKEY  
   Atikeler K, Ozcelikay G, Hacettepe University, Ankara, Turkey, Ankara University, Ankara, Turkey

PHP205 H4 CRITICAL ANALYSIS OF PRICING AND REIMBURSEMENT PROCESS ON THE BASIS OF NEW INTRODUCED PHARMACOECONOMIC GUIDELINES IN BULGARIA  
   Benisheva - Dimitrova TV, Christoff GC, Stoyanova R, Medical University - Sofia, Sofia, Bulgaria, Bulgarian Association of Drug Information, Sofia, Bulgaria

PHP206 H5 HOW DOES THE ADDITIONAL BENEFIT EXTENT OF ORPHAN DRUGS IMPACT PRICE NEGOTIATIONS IN THE GERMAN OUTPATIENT SECTOR?  
   Freiberg M, Schwarz R, Fath F, Quintiles Commercial, Mannheim, Germany

PHP207 H6 QUANTITATIVE ASSESSMENT OF CANADIAN PROVINCIAL PUBLIC FUNDING DECISIONS FOR ONCOLOGY DRUGS FOLLOWING PCORI ECONOMIC EVALUATIONS FOR 2013 AND 2014  

PHP208 H7 VALUE JUDGMENT OF HEALTH INTERVENTIONS FROM DIFFERENT PERSPECTIVES: ARGUMENTS AND CRITERIA  
   Vermeulen KM, Selivanova A, Krabbe PF, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

PHP209 H8 FDA BREAKTHROUGH MEDICINES; HAVE THEY CAUSED BREAKTHROUGH HEADACHES FOR HTA
**HEALTH CARE USE & POLICY STUDIES - Health Care Research & Education**

**PHP221 H20** MEASURING HEALTH CARE PERFORMANCE ON EQUITY: A FRAMEWORK USING NATIONAL ADMINISTRATIVE DATA FROM 2004/5 TO 2011/12  
Ali S, University of York, York, UK

**PHP222 H21** METHODOLOGICAL GAPS IN THE ASSESSMENT OF THE UTILITY AND BURDEN OF RISK MINIMISATION INTERVENTIONS  
Bergamasco A1, Thurin N2, Saib M3, Yousif A4, Moride Y5, YolaRx Consultants, Paris, France, 2Université de Bordeaux, Bordeaux, France, 3University of Montreal, Montreal, QC, Canada, 4YolaRx Consultants, Montreal, QC, Canada, 5Faculty of Pharmacy, Université de Montréal, Montreal, QC, Canada

**PHP223 H22** IS ASSIGNMENT OF FINANCIAL VALUE STIMULATING FRENCH RESEARCHERS OF PARIS ACADEMIC HOSPITALS TO PUBLISH IN INTERNATIONAL JOURNALS? RESULTS OF THE DIAZEPAM SURVEY  
Duracinsky M1, Baudoin L1, Lalanne C2, Descamps A1, Pellet C3, Peretz F3, Chassany O1, Assistance Publique-Hopitaux de Paris, Paris, France, 2Université Paris-Diderot, Sorbonne Paris Cité, Paris, France, 3Abelia Science, Saint Georges sur Baulche, France

**PHP224 H23** QUALITY ANALYSIS OF PHARMACEUTICALS EVALUATION AND APPLICATION LITERATURE IN CHINA DURING 2009-2013  
Wu H, Guizhou Medical University, Guiyang, China

**PHP225 H24** GLOBAL PUBLICATION TRENDS IN MEDICAL NUTRITION HEALTH ECONOMICS  
Naberhuis JK1, Bell JD2, Goeses S3, Nuijten M1, University of Illinois at Urbana-Champaign, Urbana, IL, USA, 2Abbott Nutrition, Columbus, OH, USA, 3Ars Accessus Medica, Jisp, The Netherlands

**PHP226 H25** EVALUATION STUDY ON EQUALIZATION OF BASIC MEDICAL AND HEALTH SERVICES IN CHINA  
Liu J1, Wu J2, Zhu B3, Mao Y4, Xi'an Jiaotong University, Xi'an, China, 2Xi'an Jiaotong University, Xi'an, China
PHP227 H26 A SYSTEMATIC LITERATURE REVIEW TO ASSESS THE IMPACT OF SOCIAL NETWORKS ON HEALTHCARE IN INDIA
Patel P, Nair SR, Jha D, Pagada A, Jamdade V, Basa P, Capita India Pvt. Ltd., Mumbai, India

PHP228 H27 CHALLENGES AND BENEFITS OF CONDUCTING VALUE OF INFORMATION ANALYSIS FROM THE PERSPECTIVE OF INDUSTRY: A SIMULATION STUDY
Mohseninejad L1, Aballéa S2, Toumi M3, ’Creativ-Ceutical, Rotterdam, The Netherlands, ’Creativ-Ceutical, Paris, France, *University of Marseille, Marseille, France

PHP229 H28 ETHICAL REQUIREMENTS FOR THE CONDUCT OF DRUG UTILISATION STUDIES INVOLVING AD HOC DATA COLLECTION: AN INTERNATIONAL CROSS-SECTIONAL SURVEY
Bergamasco A1, Yousif A2, Tremblay C3, Thurin N4, Moride Y5, YolaRx Consultants, Paris, France, YolaRx Consultants, Montreal, QC, Canada, 1University of Montreal, Montreal, QC, Canada, 4University of Bordeaux, Bordeaux, France, 5Faculty of Pharmacy, Université de Montréal, Montreal, QC, Canada

PHP230 H29 A PICTURE OF PRIVATE HEALTH INSURANCE POLICYHOLDERS IN ITALY
Turchetti G, Cannizzo S, Lorenzoni V, Scuola Superiore Sant'Anna, Pisa, Italy

PHP231 H30 BUILDING A BRIDGE BETWEEN CLINICAL EVIDENCE RESEARCH AND PATIENT PREFERENCE RESEARCH
Broekhuizen H1, Ijzerman MJ2, Hauber AB2, Groothuis-Oudshoorn CG1, University of Twente, Enschede, The Netherlands, 2RTI Health Solutions, Research Triangle Park, NC, USA

PHP232 H31 A LITERATURE STUDY ABOUT UTILIZATION OF ORIENTAL MEDICAL SERVICES
Lim SM, Korea National Rehabilitation Research Institute, Seoul, South Korea

PHP233 H32 AN ECONOMIC ANALYSIS OF INFORMAL CARE PROVISION IN IRELAND
Murphy A, Walsh E, University College Cork, Cork, Ireland

PHP234 H33 THE SURVEY OF PHYSICIANS’ SATISFACTION OF IMPLEMENTING INTERVENTIONS FOR CHANGING PRESCRIBING BEHAVIOR TOWARD RATIONAL MEDICINE USE-2014
Shahriari F1, Rashidian A2, Soleymani F3, Food and Drug Organization, Tehran, Iran, 2Tehran University of Medical Sciences, Tehran, Iran

PHP235 I1 TRENDS IN HOSPITAL STANDARIZED MORTALITY RATIOS IN JAPAN
Shinjo D1, Fushimi K2, The University of Tokyo Hospital, Tokyo, Japan, 2Tokyo Medical and Dental University Graduate School of Medicine, bunkyo-ku, Japan

PHP236 I2 SURVEY OF THE HUNGARIAN PHYSIOTHERAPISTS’ MIGRATION AND CAREER CHANGING BEHAVIOUR
Pónusz R1, Kovács D1, Varga A1, Hock M1, Raposa B1, Boncz I2, Endrei D3, University of Pécs, Pécs, Hungary, 2University of Pécs, Pécs, Hungary

PHP237 I3 GENDER DIFFERENCES IN PHYSICAL ACTIVITY OF HUNGARIAN ADULTS: AN OBSERVATORY SURVEY
Makai A, Füge K, Breitenbach Z, Prémusz V, Járomi M1, Boncz I2, Lampek K, Figler M, University of Pécs, Pécs, Hungary

PHP238 I4 TAILORING SPONSOR-PAYER ENGAGEMENT TO FACILITATE EFFECTIVE AND FAIR PATIENT ACCESS
Purchase JL, Lyons EJ, Singh S, Pope Woodhead and Associates Ltd., St Ives, UK

PHP239 I5 EXAMINATION OF THE EFFECT OF CLINICAL PRACTICES AMONG NURSING STUDENTS
Szunomár S1, Pakai A2, Szebeni-Kovács G1, Boncz I1, Fullér N1, Müller Á1, Füge K1, Oláh A1, University of Pécs, Pécs, Hungary, 2University of Pécs, Zalaegerszeg, Hungary

HEALTH CARE USE & POLICY STUDIES - Health Technology Assessment Programs

PHP240 I6 ARE MEDICINES GRAANTED WITH A CONDITIONAL APPROVAL BY THE EUROPEAN MEDICINES AGENCY GAINING POSITIVE ASSESSMENT BY PAYERS IN FRANCE, GERMANY AND THE UNITED KINGDOM?
Desjardins C, Conti CC, GfK, London, UK

PHP241 I7 A HANDBOOK AND A TOOLKIT FOR HOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENT
Sanprietru-Colom L1, Lach K1, Escolar I2, Sroka S1, Soto M1, Cicchetti A1, Fure B2, Kahveci R1, Kidholm K2, Kidvet R2, Pastemack I1, Rossenmoller M1, Wesserf subnet J2, Wild C3, Hospital Clinic Barcelona, Barcelona, Spain, 2Catholic University of Sacred Heart, Rome, Italy, 3NOKC, Oslo, Norway, 4Ankara Numune Training and Research Hospital, Ankara, Turkey, 5CIMT - Center for Innovative Medical Technologies, Odense C, Denmark, 6University of Tartu, Tartu, Estonia, 7University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 8IESE Business School, Barcelona, Spain, 9CHUV | Lausanne university hospital, Lausanne, Switzerland, 10Ludwig Boltzmann Institute for Health Technology Assessment, Vienna, Austria

PHP242 I8 THE CEESP ECONOMIC EVALUATION: CAN CLINICAL EFFICACY AND COST-EFFECTIVENESS CO-EXIST IN FRANCE
Gambari J1, Beckerman R2, CBPartners, New York, NY, USA, 2Maple Health Group, LLC, New York, NY, USA

PHP243 I9 CONSUMER INTEREST IN ADOPTING AN ELECTRONIC HEALTH RECORD (EHR) MOBILE APPLICATION BASED ON THE RISK THAT IDENTIFIABLE INFORMATION IS LEAKED
Wasserman D, Claey S, Radley C, Tomaszewski K, KJT Group, Inc., Honeoye Falls, NY, USA

PHP244 I10 AN ANALYSIS OF GERMAN G-BA ADDED BENEFIT ASSESSMENT DECISIONS USING THE WORLD HEALTH ORGANIZATION DALY FRAMEWORK
Loftus BM, Gustavsen G, Gaebler JA, Health Advances, Weston, MA, USA
ROMANIA'S NEW HTA SYSTEM: WHAT PROGRESS HAVE INNOVATIVE DRUGS MADE UNDER THE POINTS-BASED SYSTEM SO FAR?

Melick B, iHIS, London, UK

DIRECT EVIDENCE VERSUS LACK OF DIRECT EVIDENCE AND THE IMPACT ON HTA ACCEPTANCE


HEALTH TECHNOLOGY ASSESSMENT ARCHETYPE: IMPLICATION ON LAUNCH PLANNING AND EVIDENCE SYNTHESIS

Mazumder D1, Kapoor A1, Gwatkin N2, Medeiros C3, Optum Global Solutions, Noida, India, 2Geni Biopharma, Hampshire, UK, 3Optum Life Sciences, Minneapolis, MN, USA

EVALUATING THE SAFETY IMPACT OF LIGHT EMITTING DIODE (LED) GUIDED DRUG PICKING IN AN OUTPATIENT PHARMACY

Wong JK1, Shek PY2, Tan MC2, Chen LL2, Wong JA2, Gunawan YZ2, Ong YS2, Temasek Polytechnic, Singapore, Singapore, Singapore General Hospital, Singapore, Singapore

EVIDENCE REVIEW GROUP (ERG) CRITIQUE OF SYSTEMATIC REVIEWS (SR) SUBMITTED TO NICE AS PART OF SINGLE TECHNOLOGY APPRAISALS (STA) OR MULTIPLE TECHNOLOGY APPRAISALS (MTA) IN THE LAST THREE YEARS

Srivastava K, Rajora P, Gupta S, Bisen R, BresMed Health Solutions, Panjim, India

EVOLUTION & INFLUENCE OF HTA IN EMERGING MARKETS

Yong C, Jiang Y, Sun D, Duttagupta S, CBPartners, New York, NY, USA

ASSESSMENT OF CONSUMER LIKELIHOOD TO ADOPT AN ELECTRONIC HEALTH RECORD (EHR) MOBILE APPLICATION AND THE IMPACT OF PERCEIVED RISK OF PRIVACY LEAKS

Claeys C, Tomaszewski K, Radley C, Wasserman D, KJT Group, Inc., Honeoye Falls, NY, USA

PREVALENCE AND INCIDENCE ESTIMATIONS IN GERMAN AMNOG APPLICATIONS – THE ROLE OF REAL-WORLD EVIDENCE (RWE)

Altevers J, Borchert K, Mittendorf T, Braun S, Xcenda GmbH, Hannover, Germany

THE CHALLENGES OF CARRYING OUT AN INDIRECT COMPARISON WITH SINGLE-ARM STUDIES

Langham S, Pooley N, Madrigal AM, PHMR Ltd, London, UK

NICE DECISION MAKING: TO APPEAL OR NOT TO APPEAL?

Vlachaki I, Murphy D, Hirst A, WG Access Ltd, London, UK

BIOSIMILARS: ACCESSING THE UK MARKET

Das P, Boehringer Ingelheim UK, Bracknell, UK

COMPARISON BETWEEN HTA REPORTS IN VENETO AND EMILIA ROMAGNA: DRUGS ASSESSMENT DECISION CRITERIA AND PRIORITIES

Bruno GM1, Valentino MC1, Oselin M2, Colombo GL2, Di Matteo S1, S.A.V.E. Studi - Health Economics & Outcomes Research, Milan, Italy, 2University of Pavia, Milan, Italy

COMPARISON OF ECONOMIC EVALUATION BETWEEN THREE MAJOR HTA AGENCIES. IS THERE A FRENCH TOUCH?

Levy P1, de Paz B1, Gugliand G1, Porte F1, Carion PL1, Minacori R1, Popot C1, Bendebba L1, Kossi Dédé S1, Peirone V2, Renard C3, Vorimore A1, Université Paris-Dauphine, Paris, France, 2PRIORITIS Market Access, Paris, France

THE USE OF MOBILE HEALTH TECHNOLOGY IN PROMOTING INFANT VACCINE ACCEPTANCE – A HEALTH TECHNOLOGY ASSESSMENT

Ananthakrishnan A1, Shankar M1, Chahar A2, Kachroo K2, Ameel M2, Sharma J2, Vsn M3, Dang A3, HTA Fellow, New Delhi, India, 2WHO Collaborating Centre for Priority Medical Devices & Health Technology Policy, NHSRC, New Delhi, India, 3Marksman Healthcare Solutions LLP (HEOR and RWE Consulting), Navi Mumbai, India

VARIABILITY IN CLINICAL COMPARATORS AND STANDARDS OF CARE: CONSEQUENCES FOR PAN-EUROPEAN RELATIVE EFFICACY

Jaksa A, Ho Y, Context Matters, New York, NY, USA

DOES CONDITIONAL MARKETING AUTHORISATION INFLUENCE MARKET ACCESS IN FRANCE, ENGLAND, AND GERMANY?

Kaaniche A1, Troubat A1, Sherwood A2, IMS, PARIS, France, 2 IMS Health, La Défense, France

IMPLEMENTING THE FULL ECONOMIC EVALUATIONS OF MEDICINES IN THE HTA PROGRAMMES IN CATALONIA: FIRST STEPS AND FUTURE PERSPECTIVES

Puig-Peiró R1, Mora-Ripoll R1, Gilabard-Perramon A2, CatSalut, Catalan Health Service, Barcelona, Spain, 2Government of Catalonia, Barcelona, Spain

ANALYSIS OF FOUR EARLY DIALOGUES (ED) AS PART OF THE SEED (SHAPING EUROPEAN EARLY DIALOGUES) PILOT: LESSONS Learnt AND WAY FORWARD. SANOFI'S PERSPECTIVE

Vidal A1, Prudhomme M1, Caprafi F2, Sanofi, CHILLY MAZARIN, France, 2Sanofi, Chilly-Mazarin, France

MANUFACTURERS' REACTIONS IN RESPONSE TO THE NEW REQUIREMENT FOR COST-EFFECTIVENESS IN FRANCE
Moïse P., Yocolly A., Quintiles, Levallois-Perret, France

**PHP264** I30 HEALTH TECHNOLOGY ASSESSMENT TOOLS FOR TECHNOLOGIES INCORPORATION INTO PUBLIC HEALTH SYSTEM
Pereira VC, Salomon F, Souza A, Santos VC, Petramale C, Department of Management and Incorporation of Health Technology, National Committee for Health Technology Incorporation (CONITEC), Brazilian Ministry of Health, Brasilia, Brazil

**PHP265** I31 A RETROSPECTIVE ANALYSIS OF TIME TO MARKET ACCESS AND THE REGIONAL IMPACT OF SPANISH ‘PLACE IN THERAPY’ REPORTS

**PHP266** I32 TRENDS IN NON-SUBMISSIONS IN THE UK
Murphy D, Vlahaki I, Guy H, NG Access Ltd, London, UK

**PHP267** I33 INNOVATION RANKING IN FRANCE AND ITALY: DIFFERENCES AND THEIR IMPACT ON PRICING AND REIMBURSEMENT PROCESSES
Solaman DA, Chandler T, Wright A, PHMR Ltd, London, UK

**PHP268** J1 ORGANIZATIONAL MODELS OF HOSPITAL BASED HTA: EMPIRICAL EVIDENCE FROM ADHOPHTA EUROPEAN PROJECT
Cicchetti A¹, Marchetti M², Iacopino V³, D’Amico G⁴, Sampietro-Colom L⁵, ¹Catholic University of Sacred Heart, Rome, Italy, ²Technology and Clinical Engineering Assessment Unit, A. Gemelli General Hospital, Catholic University of the Sacred Heart, Rome, Italy, ³Catholic University of the Sacred Heart, Rome, Italy, ⁴Catholic University of The Sacred Heart, Rome, Italy, ⁵Hospital Clinic Barcelona, Barcelona, Spain

**PHP269** J2 CURRENT PERCEPTION OF UPCOMING COST-EFFECTIVENESS REQUIREMENTS IN JAPAN: A SURVEY ON THE PERSPECTIVE OF PHARMACEUTICAL INDUSTRY
Kim HR, Sugimoto T, Kamei I, The University of Tokyo, Graduate School of Public Policy, Tokyo, Japan

**PHP270** J3 MAKING COLLABORATIVE RELATIVE EFFECTIVENESS ASSESSMENTS RELEVANT: EXPERIENCE OF 4 EUNETHA PILOTS ACROSS PHARMACEUTICALS AND MEDICAL DEVICES
Griffin A¹, Hemels M², Velleca M³, Duchesne I⁴, Holy C⁵, Johnson & Johnson, Buckinghamshire, UK, ²Janssen-Cilag A/S, Birkered, Denmark, ³Johnson & Johnson Medical SpA, Pomezia, Italy, ⁴Janssen EMEA, Beerse, Belgium, ⁵Acclarent Inc, Menlo Park, CA, USA

**PHP271** J4 EUNETHA TOOLS AND METHODS – FACILITATING UPTAKE BY TRAINING ACTIVITIES
Saterdal I¹, Chalon P², Klemp M³, ¹Norwegian Knowledge Centre for the Health Services, Oslo, Norway, ²Belgian Health Care Knowledge Centre, Brussels, Norway

**PHP272** J5 IDENTIFYING PRACTICAL GAPS TO COMPLY WITH COST-EFFECTIVENESS GUIDELINE IN SELECTING COMPARATORS IN SOUTH KOREA
Kang H¹, Lee H², Cho H³, Kim SY⁴, ¹Yonsei University, Incheon, South Korea, ²Korea University, Seoul, South Korea

**PHP273** J6 STEPS TOWARDS INTRODUCING A SYSTEM OF HEALTH TECHNOLOGIES ASSESSMENT IN UKRAINE
Melynyk Y, Lisichysynhyna O, State Expert Center of the Ministry of Health of Ukraine, Kyiv, Ukraine

**PHP274** J7 INCREASING TRANSPARENCY AND THE PATIENT VOICE IN HTA OF NEW MEDICINES
Lee A¹, Jones J², Brown A¹, Macfarlane K¹, Fox JG², ¹Healthcare Improvement Scotland, Glasgow, UK, ²Greater Glasgow Health Board, Glasgow, UK

**PHP275** J8 SHAPING EUROPEAN EARLY DIALOGUES: THE SEED PROJECT
Harousseau J¹, Pavlovic M², Mouas H³, Meyer F⁴, ¹French National Authority for Health (HAS), Saint-Denis La Plaine, France, ²Hauté Autorité de Santé (HAS), Paris, France, ³French National Authority for Health (HAS), Paris, France

**PHP276** J9 THE CUMULATIVE ANALYSIS OF CHECKLIST QUESTIONNAIRES FILLED OUT BY THE HUNGARIAN HTA OFFICE
Nemeth B, Csordas A, Papp E, National Institute of Pharmacy and Nutrition, Budapest, Hungary

**PHP277** J10 ASSESSING THE COST-EFFECTIVENESS OF THERAPIES IN THE THIRD QUADRANT ON THE COST-EFFECTIVENESS PLANE
Nemeth B, Eder B, National Institute of Pharmacy and Nutrition, Budapest, Hungary

**PHP278** J11 EUNETHA MEMBERS: WHAT ARE THEIR ROLES WITHIN THE NATIONAL SETTING?
Diekmann S¹, Krüger LJ², Warren DS³, Goetttsch W⁴, ¹The National Healthcare Institute (ZIN), Diemen, The Netherlands, ²National Healthcare Institute (ZIN), Diemen, The Netherlands

**PHP279** J12 POTENTIAL SOCIETAL VALUE OF BIOSIMILARS ADOPTION: THE EXAMPLE OF UK
Mendoza C¹, Ionescu D², Radieri G¹, Rémuzat C², Lee D², Toumi M³, ¹Sandoz International GmbH, Holzkirchen, Germany, ²Carnaby-Ceutical, Paris, France, ³Aix-Marseille University, Marseille, France

**HEALTH CARE USE & POLICY STUDIES - Patient Registries & Post-Marketing Studies**

**PHP280** J13 THE EU PATIENT REGISTRY LANDSCAPE: SURVEY OF REGISTRY PROFILES THROUGH PARENT JA RESEARCH AND FRAMEWORK
Pristas J¹, Doupi P², Karanikas H³, Brkic M¹, Plese B¹, Zaletel M², Magajne M³, Zuriaga Llorens O⁴, López-Briones C⁵, ¹Croatian Institute of Public Health, Zagreb, Croatia, ²National Institute for Health and Welfare (THL), Helsinki,
**PIN73 N27**  
**BROAD ACCESS TO TREATMENT IS COST-EFFECTIVE FOR PATIENTS WITH CHRONIC HEPATITIS C IN ENGLAND**  

**PIN74 N28**  
**COST-UTILITY ANALYSIS OF DOLUTEGRAVIR/ABACAVIR/LAMIVUDINE (DTG/ABC/3TC) AS A SINGLE TABLET TREATMENT OF NAIVE HIV INFECTED PATIENTS**  
Parrondo J, Moreno S, Losa JE, Berenguer J, Martinez-Sesmero JM, Grasset E, Cenoz-Gomis S, GSK - Spain, Madrid, Spain, Hospital Ramón y Cajal, Madrid, Spain, Hospital Universitario Fundación Alcorcón (HUFA), Alcorcón - Madrid, Spain, Hospital General Universitario Gregorio Marañón, Madrid, Spain, Complexo hospitalario de Toledo, Toledo, Spain, ViV HealthCare, Madrid, Spain

**PIN75 N29**  
**COST-EFFECTIVENESS OF LEDIPASVIR/SOFOSBUVIR FOR THE TREATMENT OF GENOTYPE 1 OR 4 CHRONIC HEPATITIS C IN ENGLAND AND WALES**  

**PIN76 N30**  
**TESTING FOR NSSA RESISTANCE IN ORDER TO OPTIMIZE ANTIVIRAL THERAPY WITH SIMEPREVIR AND SOFOSBUVIR 12 WEEKS APPEARS COST-EFFECTIVE IN NON-CIRRHOTIC GENOTYPE 1 HEPATITIS C VIRUS TREATMENT EXPERIENCED PATIENTS**  

**PIN77 N31**  
**ECONOMIC EVALUATIONS IN INFECTIOUS DISEASE: WHICH INFECTIONS, WHAT SETTINGS AND WHAT TYPE OF ECONOMIC EVALUATIONS WERE REPORTED IN PAPERS PUBLISHED IN 2014?**  
Martin A, Crystallise Ltd., London, UK

**PIN78 N32**  
**PHARMACOEPIDEMIOLOGIC MODELING OF TREATMENT HIV-INFECTED PATIENTS WITH RILPIVIRINE/ TENOFOVIR/ EMTRICITABIN (SINGLE TABLET REGIMEN) IN RUSSIA**  
Yaquidina R, Kulikov A, Babyi V, I. M. Sechenov First Moscow State Medical University, Moscow, Russia

**PIN79 N33**  
**THE EPIDEMIOLOGICAL AND COST BURDEN OF HERPES ZOSTER (HZ) AND POST-HERPETIC NEURALGIA (PHN) IN THE UK**  

**PIN80 O1**  
**PUBLIC HEALTH AND ECONOMIC BENEFITS OF QUADRIVALENT INFLUENZA VACCINE IN PANAMA**  
Jamotte A, Caicedo Navas AG, Macabo B, Lopez JG, Moreno B, Franco D, Garcia LN, Isaza de Molto Y, Creativ-Ceutical, Paris, France, Sanofi Pasteur, Bogota, Colombia, Sanofi Pasteur, Lyon, France, Sanofi Pasteur, Mexico City, Mexico, Gorgas Memorial Institute for Health Studies, Panama City, Panama, Panama Ministry of Health, Panama City, Panama

**PIN81 O2**  
**PUBLIC HEALTH AND ECONOMIC BENEFITS OF QUADRIVALENT INFLUENZA VACCINE IN COLOMBIA**  
Jamotte A, Caicedo Navas AG, Macabo B, Lopez JG, Romero M, Marrugo R, Alfonso Quiñones PA, Creativ-Ceutical, Paris, France, Sanofi Pasteur, Bogota, Colombia, Sanofi Pasteur, Lyon, France, Sanofi Pasteur, Mexico City, Mexico, Salutia Foundation, Bogotá, Colombia

**INFECTION - Patient-Reported Outcomes & Patient Preference Studies**

**PIN82 O3**  
**ADHERENCE TO ANTIRETROVIRAL THERAPY AMONG PATIENTS LOST-TO-FOLLOW UP: A CASE OF AN HIV CLINIC IN A PRIVATE-FOR-PROFIT HEALTH FACILITY IN KAMPALA, UGANDA**  
Kayanga F, Anguzu R, Makerere University School of Public Health, Kampala, Uganda

**PIN83 O4**  
**EXPLORING ATTITUDES AND PERCEPTIONS OF PATIENTS AND STAFF TOWARDS A FEE FOR SERVICE “AFTER HOURS” CLINIC SUPPLEMENTING FREE HIV SERVICES IN UGANDA: A QUALITATIVE STUDY**  
Adelline T, King R, Schlech WF, Faridah M, Kakaire T, Rosalind Parkes-Ratanshi P, Infectious Diseases Institute, College of Health Sciences Makerere University, Kampala, Uganda, University of California, San Francisco, San Francisco, CA, USA, Dalhousie University, Nova Scotia, NS, Canada

**PIN84 O5**  
**HEALTH STATE UTILITIES OF RISKS ASSOCIATED WITH ANTIRETROVIRAL TREATMENT FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV)**  
Matza LS, Chung KC, Kim KJ, Paulus T, Davies EW, Stewart KD, McComsey GA, Fordyce M, Evidera, Bethesda, MD, USA, Gilead Sciences, Inc, Foster City, CA, USA, University of Georgia, Athens, GA, USA, Evidera, London, UK, Case Western Reserve University, Cleveland, OH, USA

**PIN85 O6**  
**DISUTILITIES ASSOCIATED WITH CENTRAL NERVOUS SYSTEM (CNS) SIDE EFFECTS OF ANTIRETROVIRAL THERAPY (ART) IN HIV**  

**PIN86 O7**  
**KNOWLEDGE, ATTITUDE AND PERCEPTION OF POLIO (POLIOMYELITIS) AMONG GENERAL PUBLIC IN PAKISTAN**  
Iqbal MS, Iqbal MW, Bahari MB, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan, Department of Clinical Pharmacy, Faculty of Pharmacy, MAHSA University, Selangor, Malaysia, Faculty of Law,
PIN87 08  EFFECT OF PHARMACIST INTERVENTIONS AND PATIENT REPORTED OUTCOMES ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY COUNSELING IN INDIAN HIV POSITIVE PATIENTS: A PROSPECTIVE STUDY
Rajesh R1, Ansar H2, Sudha VS3, Varma DM3, MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES, MANIPAL UNIVERSITY, MANIPAL, India, 1MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES, MANIPAL, India, 2Kasturba Medical College, MANIPAL, India

PIN88 09  MULTIPLE PILL REGIMENS, SINGLE TABLET REGIMENS AND HIV+ PATIENTS QUALITY OF LIFE: EVIDENCE FROM THE STRAQ STUDY
Foglia E1, Maggiolo F2, Quirino T3, Bonfanti P4, Scolari F1, Garagiosa E1, Ferrario L1, Bernasconi D5, Croce D5, LIUC University, Castellanza, Italy, 1Papa Giovanni 23th Hospital Authority, Bergamo, Italy, 2Ospedale di Circolo Hospital Authority, Busto Arsizio, Italy, 3Alessandro Manzoni Hospital Authority, Lecco, Italy, 4University of the Witwatersrand, Johannesburg, South Africa

PIN89 010  ASSESSMENT OF HIV-RELATED QUALITY OF LIFE IN A REPRESENTATIVE SAMPLE OF FRENCH PATIENTS USING MULTIVARIATE MULTI-STATISTICAL MODELS
Lalanne C1, Randrianomanana M1, Carriere PM2, Dray-Spira R3, Chassany O4, Duracinsky M5, University Paris-Diderot, Sorbonne Paris Cité, Paris, France, 1INSERM, Marseille, France, 2University, Paris, France

PIN90 011  PSYCHOMETRIC VALIDATION OF THE NEW INTERNATIONAL QUESTIONNAIRE TO ASSESS HEALTH-RELATED QUALITY OF LIFE (HRQOL) SPECIFIC TO VIRAL HEPATITIS C: PROQOL-HCV
Duracinsky M1, Armstrong A2, Hermann S3, Lalanne C1, Galano E4, Da Silva MH5, Carriere PM5, Chassany O4, University Paris-Diderot, Sorbonne Paris Cité, Paris, France, 1Australian Institute of Family Studies, Melbourne, Australia, 2Murdoch University, Murdoch, Australia, 3Centro de Referência e Treinamento DST/Aids, Sao Paulo, Brazil, 4INSERM, Marseille, France

PIN91 012  THE CONCEPTUAL FRAMEWORK OF QUALITY OF LIFE IN HIV AND HCV
Dara AF1, Préau M2, Rojas Castro D3, Auger I1, Baumann L1, Ilona J3, Huntingdon B3, Da Silva MH4, Morel S5, Chassany O4, Duracinsky M1, University Paris-Diderot, Sorbonne Paris Cité, Paris, France, 1Université Lumière Lyon 2, Bron, France, 2AIDES; Pantin, France, 3The University of Sydney, Sydney, Australia, 4University of Sydney NSW 2006, Sydney, Australia, 5Centro de Referência e Treinamento DST/Aids, Sao Paulo, Brazil

PIN92 013  QUALITY OF LIFE AMONG HIV PATIENTS: RESULTS FROM THE IANUA CLINICAL TRIAL
Ameri M1, Cassola G2, Cenderrello G3, Di biagio A4, Giacomoni M5, Giannini B5, Mazzarelli G6, Merlano C7, Montefiori M1, Orcamo P2, Setti M3, Viscoli C4, University of Genova, Genoa, Italy, 1EO Ospedali Galliera, Genoa, Italy, 2Genova University, Genoa, Italy, 3Genoa University, Genoa, Italy, 4Liguria Region, Genova, Italy

PIN93 014  HIV PATIENT PREFERENCES FOR SIMPLIFIED TREATMENT REGIMENS
Orme ME1, Miners A2, Perard R3, Alfred S3, Rogatto F3, Reilly G3, ICERA Consulting Ltd, Swindon, UK, 2London School of Hygiene & Tropical Medicine, London, UK, 3Gilead Sciences Europe Ltd, Uxbridge, UK

INFECTION - Health Care Use & Policy Studies

PIN94 015  INDISCRIMINATE PRESCRIPTION OF ANTIBIOTICS AND AN URGENT NEED OF LEGISLATION- A SURVEY FROM PAKISTAN
Wagas M1, Hussain T2, Abdul Wali Khan University, Mardan, Pakistan, 1National University of Sciences and Technology, Islamabad, Pakistan

PIN95 016  A SYSTEMATIC REVIEW OF HERPES ZOSTER VACCINE ACCEPTANCE
Damm O, Witte J, Greiner W, School of Public Health, Bielefeld University, Bielefeld, Germany

PIN96 017  REAL-WORLD HEPATITIS C TREATMENT STRATEGIES IN DENMARK
Jaibert J1, Pisini M2, van Sanden S3, Nalpas C4, Bakshi S5, Duchesne I6, Amzal B7, LASER Analytica, New York, NY, USA, 1Janssen EMEA, Beerse, Belgium, 2Janssen Pharmaceuticals, Paris, France, 3Janssen Pharmaceuticals, London, UK

PIN97 018  TREATMENT PATTERNS AND CHARACTERISTICS OF MEDICARE BENEFICIARIES WITH HIV RELATED CACHEXIA
Neone J1, Blanchette CM2, Van Doren BA3, Zacherle E1, Arthur S1, Roy D5, University of North Carolina at Charlotte, Charlotte, NC, USA, 2Precision For Medicine, New York, NY, USA, 3University of North Carolina, Charlotte, Charlotte, NC, USA

PIN98 019  ASSESSING THE COST-EFFECTIVENESS OF ANTIRETROVIRAL TREATMENTS IN HIV: AN INDIVIDUAL PATIENT SIMULATION APPROACH
Kiff C1, Fenwick E2, Parker C4, Hawkins NS1, Perard R3, ICON Health Economics and Epidemiology, Oxford, UK, 1Gilead Sciences Europe Ltd, Uxbridge, UK

PIN99 020  THE IMPACT OF SOCIETAL VIEWS ON MARKET ACCESS- CASE STUDIES FOR UTILIZATION OF HPV VACCINES IN CERVICAL CANCER AND PREP HIV PREVENTIVE THERAPY
Staples O1, Sanyal S2, Khatura N3, Mishra A2, Kumar A1, ZS Associates, London, UK, 2ZS Associates, New Delhi, India

PIN100 021  TRENDS OF HPV VACCINE UPTAKE, COMPLETION, AND ADHERENCE IN THE UNITED STATES: 2006-2011
Lee H, Lin H, Indiana University, Bloomington, IN, USA

PIN101 01  STEERING VACCINES THROUGH THE UK SYSTEM - WHAT FACTORS INFLUENCE THE LIKELIHOOD OF
A DECISION OPTIONS APPROACH TO ANTIBIOTIC R&D INVESTMENT

Supontam A1, Zhang D2, Burrell E1, Nwankwo C3, Merck & Co., Inc., North Wales, PA, USA, 2Merck & Co., Inc., West Point, PA, USA, 3Merck & Co., Inc., Kenilworth, NJ, USA

DECONTAMINATION AND INFECTION CONTROL OF NURSING TOOLS AND PATIENT ENVIRONMENT REGARDING NOSOCOMIAL INFECTIONS

Oláh A1, Lukačics A1, Müller A1, Boncz I1, Fullér N1, Stromájer-Rácz T1, Gelencsér E1, Szabó-Kovács G1, University of Pécs, Pécs, Hungary, 2University of Pécs, Kaposvár, Hungary

DESCRIPTIVE ANALYSIS OF DRUG UTILIZATION AMONG CHRONIC HEPATITIS C VIRUS (CHC) PATIENTS IN THE US COMMERCIALLY INSURED POPULATION

Puenpatom A1, Zhang D2, Burrell E1, Nwankwo C3, Merck & Co., Inc., North Wales, PA, USA, 2Merck & Co., Inc., West Point, PA, USA, 3Merck & Co., Inc., Kenilworth, NJ, USA

CHARACTERISTICS AND DRUG UTILIZATION AMONG TREATED CHRONIC HEPATITIS C VIRUS (CHC) PATIENTS WITH AND WITHOUT CHRONIC KIDNEY DISEASE (CKD) IN THE US

Puenpatom A1, Zhang D2, Burrell E1, Nwankwo C3, Merck & Co., Inc., North Wales, PA, USA, 2Merck & Co., Inc., West Point, PA, USA, 3Merck & Co., Inc., Kenilworth, NJ, USA

ADHERENCE OF HIV PATIENTS SWITCHING TO EMTRICITABINA+TENOFOVIR DISPROXIL+RILPIVIRIN. REAL WORLD EVIDENCE FROM ITALIAN ADMINISTRATIVE DATABASES

Degli Esposti L1, Sangiorgi D1, Buda S1, Crovato E1, Maggiolo F1, Antinori A1, Angaran G1, Lazzarin A2, Clicon S.r.l., Ravenna, Italy, 2Az. Osp. Papa Giovanni XXII, Bergamo, Italy, 3National Institute for Infectious Diseases, Rome, Italy, 4University of Bari, Policlinic Hospital, Bari, Italy, 5University Vita-Salute San Raffaele, Milan, Italy

MINIMUM INDICATORS TO EVALUATE MANAGEMENT AND CLINICAL RESULTS IN INSTITUTIONS ASSISTING PATIENTS LIVING WITH HIV IN COLOMBIA

Acuña L1, Sanzchiz P2, Alvis LF2, Soler L3, Cuanta de Alto Costo, Bogotá, Colombia, 2Cuanta de Alto Costo, Bogota, Colombia, 3Cuanta de alto costo, bogota, Colombia

HOW MUCH IS SPENT IN VACCINES ACROSS WESTERN EUROPE COUNTRIES?

Baron-Papillon F1, Ethgen O2, Cornier M3, Sanofi Pasteur MSD, Lyon, France, 2University of Liege, Liege, Belgium

RELIABILITY OF MANUFACTURERS' BUDGET IMPACT ESTIMATES FOR CHRONIC HCV GT1 DRUGS IN POLAND

Iwanczuk T1, Zawodnik S1, Tatare T1, Sliwczynski A1, Brzozowska M2, Agency for Health Technology Assessment and Tariff System in Poland (AOTMiT), Warsaw, Poland, 2Medical University of Lodz, Lodz, Poland

THE COST OF VACCINATION THROUGHOUT LIFE: A PAN-EUROPEAN PERSPECTIVE

Cornier M1, Ethgen O2, Baron-Papillon F3, Sanofi Pasteur MSD, Lyon, France, 2University of Liege, Liege, Belgium

WILLINGNESS TO PAY FOR INNOVATIVE DRUGS: ANTI-HCV TREATMENT FROM THE ITALIAN NATIONAL HEALTH SYSTEM PERSPECTIVE

Mennini FS1, Marcellusi A1, Viti R1, Andreoni M2, Faculty of Economics, Centre for Economic and International Studies (CEIS)-Economic Evaluation and HTA (EEHTA), University of Rome, Rome, Italy, 2University of Rome, Rome, Italy

ARE VACCINES GETTING A FAIR DEAL? HEALTH TECHNOLOGY ASSESSMENT OF VACCINES ACROSS EUROPE

Wei C, Jarrett J, Ovcinnikova O, Bending MW, Mapi, London, UK

NATIONAL SURVEY OF BEHAVIOR, ATTITUDES AND PRACTICE OF GENERAL PRACTITIONERS AND VARIOUS SPECIALISTS CONCERNING ANTIMICROBIAL USE AND RESISTANCE IN RESPIRATORY TRACT INFECTIONS

Babeli R1, Slezakova Z2, Szydlowski S3, St. Elizabeth University of Health and Social Work, BRATISLAVA, Slovak Republic, 2Educational Section, Ministry of Health, BRATISLAVA, Slovak Republic, 3University of Scranton, Scranton, PA, USA

IDENTIFYING RESEARCH GAPS IN ANTIMICROBIAL RESISTANCE (AMR): LITERATURE REVIEW, POTENTIAL RESEARCH QUESTIONS AND STUDY DESIGNS

Silveira DS, Leite BF, Alves Md, Brazilian Ministry of Health, Brasilia, Brazil

ANALYSIS OF HIV – INFECTION SITUATION IN KAZAKHSTAN

Mauyenova D1, Karp L1, Turgambayeva A1, Kulov D2, Zhakipbekova V1, Rakhimzhanova F3, Astana Medical University, Astana, Kazakhstan, 2Karaganda State Medical University, Karaganda, Kazakhstan, 3Semey Medical University, Semey, Kazakhstan

DO PNEUMOCOCCAL CONJUGATE VACCINES REPRESENT GOOD VALUE FOR MONEY IN A LOWER-MIDDLE INCOME COUNTRY? A COST-UTILITY ANALYSIS IN THE PHILIPPINES

Haasis MA1, Ceria JA1, Kulpeng W2, Teerawattananon Y2, Alejandra MM3, Department of Health Philippines, Manila, Philippines, 2Ministry of Public Health Thailand, Bangkok, Thailand, 3University of the Philippines Manila, Manila, Philippines

SCORING AND MEASUREMENT PROPERTIES OF A TOOL TO ASSESS PRIMARY CARE PHYSICIANS' ENGAGEMENT IN AND PERCEIVED BARRIERS TO VACCINATION: THE 'DETERMINANT OF INTENTIONS OF VACCINATION' (DIVA©) QUESTIONNAIRE

Siliwczynski A1, Cornier M2, Ethgen O3, Papillon F4, Ovcinnikova O, Bending MW, Mapi, London, UK
PDB1 A1  RISK OF NEW-ONSET DIABETES ASSOCIATED WITH CONCOMITANT ANTIDEPRESSANT, INHALED CORTICOSTEROIDS, AND STATIN USE AMONG MEDICAID BENEFICIARIES WITH COPD
Ajmera MR1, Sambamoorthi U2, RTI Health Solutions, RTP, NC, USA, 3West Virginia University, Morgantown, WV, USA

PDB2 A2  THE ASSOCIATION OF WAIST CIRCUMFERENCE AND MICROVASCULAR COMPLICATIONS IN DIABETIC PATIENTS IN AN ASIAN POPULATION
Azmi S1, Feisul Mi1, Abdat A1, Goh A1, Abdul Aziz SH1, Azmi Burhani Consulting, Petaling Jaya, Malaysia, 2Ministry of Health, Malaysia, Putrajaya, Malaysia

PDB3 A3  RELATIONSHIP BETWEEN GLYCAEMIC BURDEN AND MICRO- AND MACROVASCULAR COMPLICATIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A REAL-WORLD STUDY IN THE PHARMO DATABASE NETWORK
Overbeek J1, van Wijngaarden R1, Diels J1, Schubert A1, Straatman H1, Besson H1, Steyerberg EW1, Hemels M1, Nijpels G1, Herings R1, PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 2Janssen Research & Development, Beerse, Belgium, 3Janssen-Cilag Poland, Warsaw, Poland, 4Erasmus MC, Rotterdam, The Netherlands, 5Janssen-Cilag A/S, Birkerød, Denmark, 6EMGO Institute, VU Medical Centre, Amsterdam, The Netherlands

PDB4 A4  EXENATIDE ONCE WEEKLY PLUS METFORMIN FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS: A NETWORK META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS
Kayaniyil S1, Lozano-Ortega G2, Bennett H3, Johnsson K4, Shaunik A5, Grandy S6, Kartman B7, ICON plc, Toronto, ON, Canada, 1ICON, Vancouver, BC, Canada, 2AstraZeneca, Mölndal, Sweden, 3AstraZeneca, Gaithersburg, MD, USA, 4AstraZeneca Pharmaceuticals, LP, Gaithersburg, MD, USA

PDB5 A5  NETWORK META-ANALYSIS (NMA) TO ASSESS RELATIVE EFFICACY MEASURED AS PERCENTAGE OF PATIENTS TREATED TO HBA1C TARGET WITH CANAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) INADEQUATELY CONTROLLED ON METFORMIN AND SULPHONYLUREA (MET+SU)
Taieb V1, Pacou M1, Schroeder M2, Schubert A3, Nielsen AT4, Amaris, London, UK, 2Amaris, Paris, France, 3Janssen UK, High Wycombe, UK, 4Janssen-Cilag Poland, Warsaw, Poland, 5Janssen-Cilag A/S, Birkerød, Denmark, 6Janssen Global Services, LLC, Raritan, NJ, USA

PDB6 A6  A NETWORK META-ANALYSIS (NMA) TO ASSESS THE LONGER-TERM RELATIVE EFFICACY OF CANAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON METFORMIN
Taieb V1, Pacou M1, Schroeder M2, Nielsen AT3, Schubert A4, Neslusan C5, Amaris, London, UK, 2Amaris, Paris, France, 3Janssen UK, High Wycombe, UK, 4Janssen-Cilag A/S, Birkerød, Denmark, 5Janssen-Cilag Poland, Warsaw, Poland, 6Janssen Global Services, LLC, Raritan, NJ, USA

PDB7 A7  BAYESIAN NETWORK META-ANALYSIS (NMA) TO ASSESS THE RELATIVE EFFICACY OF CANAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) INADEQUATELY CONTROLLED WITH INSULIN
Taieb V1, Pacou M1, Schroeder M2, Nielsen AT3, Schubert A4, Neslusan C5, Amaris, London, UK, 2Amaris, Paris, France, 3Janssen UK, High Wycombe, UK, 4Janssen-Cilag A/S, Birkerød, Denmark, 5Janssen-Cilag Poland, Warsaw, Poland, 6Janssen Global Services, LLC, Raritan, NJ, USA, 7Janssen-Cilag Poland, Warsaw, Poland

PDB8 A8  ACHIEVEMENT OF GLYCAEMIC TARGETS WITH CANAGLIFLOZIN IN TRIPLE THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
Diels J1, Schubert A2, Hamilton G3, Canovatchel W4, 1Janssen Research & Development, Beerse, Belgium, 2Janssen-Cilag Poland, Warsaw, Poland, 3Janssen-Cilag Ltd, High Wycombe, UK, 4Janssen Global Services, LLC, Raritan, NJ, USA

PDB9 A9  LIRAGLUTIDE VS OTHER DAILY GLP-1 ANALOGUES IN PEOPLE WITH TYPE 2 DIABETES: A NETWORK META-ANALYSIS
Lorenzi M1, Ploug UJ2, Vega G3, Jansen JP4, Redwood Outcomes, San Francisco, CA, USA, 2Novo Nordisk A/S, Seborg, Denmark, 3Novo Nordisk Ltd., Gareth, UK

PDB10 A10  INDIRECT COMPARISON TO EVALUATE THE EFFICACY AND SAFETY OF Dipeptidyl Peptidase-4 Inhibitors (DPP4I) AND SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS (SGLT2I) ADDED TO INSULIN THERAPY IN TYPE 2 DIABETES
Yoon J1, Min SH, Hahn S, Cho YM, Seoul National University College of Medicine, Seoul, South Korea

PDB11 A11  A MULTIVARIATE SAFETY AND EFFICACY ANALYSIS OF PRESCRIBING INFORMATION FOR NEXT GENERATION SGLT-2 INHIBITORS IN TYPE 2 DIABETES TREATMENT
Taylor D1, Martin S, Coolbaugh N, Sjostedt P, Institute for Evidence Based Medicine, New Hope, PA, USA

PDB12 A12  "EFFECTIVENESS AND SAFETY BARIATRIC SURGERY VS. CLINICAL TREATMENT IN CONTROL OF LEVELS GLYCEMIC AND REMISSION DIABETES MELLITUS TYPE II IN PATIENTS OBESE"
Zanghelinif1, Buehler AM2, Pereira Td3, Universidade Federal de Pernambuco, Recife, Brazil, 1Hospital Alemão Oswaldo Cruz, São Paulo, Brazil

PDB13 A13  A CROSS-SECTIONAL STUDY ON INSULIN TREATMENTS AND GLYCEMIC CONTROL IN TYPE 2 DIABETES IN
FRANCE, ITALY, GERMANY, UK AND SPAIN
Phan T1, Boutilmy E2, Coulombel N2,3Novo Nordisk Health Care AG, Zürich, Switzerland, 2IMS Health, Boulogne-Billancourt, France

PDB14 A14 PATTERNS OF PHARMACOLOGICAL TREATMENT IN TYPE 2 DIABETES IN FRANCE IN 2013
Simon D1, Dallongeville J2, Charbonnel B3, Bureau H4, Detournay B5, Leproust S6, Levy-Bachelot L7, Gourmelen J8,1Pitié Hospital, Paris, France, 2Pasteur Institute, Lille, France, 3University of Nantes, Nantes, France, 4Cemka-Eval, Bourg La Reine, France, 5Cemka-Eval, Bourg-la-Reine, France, 6MSD France, COURBEVOIE, France, 7UMS 011 - Insem - UVSQ, Villejuif, France

PDB15 A15 PRESCRIPTION PATTERNS OF ANTIDIABETIC TREATMENT IN THE ELDERLY. RESULTS FROM SOUTHERN ITALY
Valentina Orlando V1, Francesca Guerriero F2, Putignano Daria D1, Valeria Marina Monetti V3, Michele Giuseppe Tari M4, Giuseppina Farina G5, Maddalena Illario M6, Guido Iaccarino G7, Menditto E1, University of Naples Federico II, Naples, Italy, 2Caserta LHU, Caserat, Italy, 3University of Naples Federico II, Naples, Ivory Coast, 4University of Salerno, Italy, Baronissi, Italy

PDB16 A16 CARdiovascular outcomes of Antidiabetic therapy - results of a literature search
Greiner R1, Eheberg D, Paulus G, Batscheider A, IMS Health, Munich, Germany

PDB17 A17 FACTORS ASSOCIATED WITH 2TDM TREATMENT CHOICE ACROSS EUROPE
Overbeek JA1, Heintjes EM1, Hall GC2, Lapi F3, Prieto Alhambra D4, Bezemer ID1, 1PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 2Grimsdyke House, London, UK, 3Health Search, Italian College of General Practitioners and Primary Care., Firenze, Italy, 4IDIAP Jordi Gol, Barcelona, Spain

PDB18 A18 TRENDS IN PREVALENCE AND INCIDENCE RATES OF TYPE 2 DIABETES MELLITUS IN MEDICARE POPULATION
Xie L1, Wang Y1, Tan H1, Ogbomo A1, Baser O2, Yuce H3, STATInMED Research, Ann Arbor, MI, USA, 2STATinMED Research, Columbia University, New York, NY, USA, 3New York City College of Technology-CUNY / STATinMED Research, New York, NY, USA

PDB19 A19 IMPACT OF SOCIOECONOMIC STATUS ON THE PREVALENCE OF COMPLICATIONS IN TYPE 2 DIABETES IN INDIAN POPULATION: A SYSTEMATIC REVIEW
Esam H1, Mothe RK, Vsn M, Likhar N, Dang A, MarksMan Healthcare Solutions LLP (HEOR and RWE Consulting), Navi Mumbai, India

PDB20 A20 THE ASSOCIATION OF WAIST CIRCUMFERENCE WITH GLYCAEMIC CONTROL IN DIABETIC PATIENTS IN AN ASIAN POPULATION
Azmi S1, Feisul Mi1, Abdat A1, Goh A1, Abdul Aziz SH1, Azmi Burhani Consulting, Petaling Jaya, Malaysia, 2Ministry of Health, Malaysia, Putrajaya, Malaysia

PDB21 A21 FACTORS ASSOCIATED WITH THE RISK OF DIABETES-RELATED EVENTS: A RETROSPECTIVE ANALYSIS
Mueller S1, Wilke T2, Groth A1, Fuchs A2, Seitz L3, Kienhoefer J4, Maywald U3, Lundershagen R5, Wehling M1, 1IPAM, Wismar, Germany, 2Ingress Health, Wismar, Germany, 3AOK PLUS, Dresden, Germany, 4Novo Nordisk Pharma GmbH, Mainz, Germany, 5AOK Plus, Dresden, Germany, 6Diabetes Centre Erfurt/Bad Berka, Erfurt, Germany, 7Clinical Pharmacology, Mannheim/Center for Gerontopharmacology, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany

PDB22 A22 RISK OF FRACTURE IN TYPE 2 DIABETES MELLITUS PATIENTS: META-ANALYSIS OF OBSERVATIONAL STUDIES
Shah C1, Shah R2, Kinra G3, Singuru S1, Naidu M4, Dang A2, MarksMan Healthcare Solutions LLP (HEOR and RWE Consulting), Navi Mumbai, India, 2S.J.M. College of Pharmacy, Chitradurga, India

PDB23 A23 HETEROGENEITY IN THE DEFINITION OF DRUG INDUCED HYPOGLYCEMIA IN CLINICAL TRIALS: A REVIEW
Balijepalli C1, Sarwar E2, Druys E2, Siliman G3, Toor K4, Joffreys M1, Thorlund K5, 1Simon Fraser University, Vancouver, BC, Canada, 2University of British Columbia, Vancouver, BC, Canada, 3Redwood Outcomes, Vancouver, BC, Canada

DIABETES/ENDOCRINE DISORDERS - Cost Studies

PDB24 A24 BUDGET IMPACT ANALYSIS OF LONG-ACTING INSULIN ANALOGUES IN THE PERSPECTIVE OF BRAZILIAN PUBLIC HEALTH SYSTEM
Laranjeira FO1, Silva EN, Pereira MG, University of Brasilia, Brasilia / DF, Brazil

PDB25 A25 THE NHS EXPENDITURE MANAGING SEVERE HYPOGLYCEMIA EPISODES IN TYPE 2 DIABETIC PATIENTS IN PORTUGAL
Laires PA1, Conceição J1, Araújo F2, Dores J3, Silva C4, Radican L5, Nogueira AM1, 1Merck Sharp & Dohme, Oeiras, Portugal, 2Hospital Beatriz Angela, Loures, Portugal, 3Hospital Santo António, Porto, Portugal, 4Eurotrials, Scientific Consultants, Lisbon, Portugal, 5Merck Sharp & Dohme Corp., Rahway, NJ, USA

PDB26 A26 COSTS FOR DIABETIC PATIENTS RECEIVING Dipeptidyl Peptidase-4 (DPP-4) INHIBITORS IN US MEDICARE AND COMMERCIAL INSURANCE PLANS
Rascati KL1, Worley K1, Everhart D1, Meah Y1, 1The University of Texas at Austin, College of Pharmacy, Austin, TX, USA, 2CHI, Humana, Inc., Louisville, KY, USA, 3Humana Inc., Louisville, KY, USA

PDB27 A27 IMPACT OF NURSE-LED TELECOACHING ON THE ANNUAL HEALTHCARE UTILIZATION AND COSTS IN
PDB43 B10 COST OF ACHIEVING COMBINED IMPROVEMENTS IN HBA1C AND WEIGHT WITHOUT HYPOGLYCAEMIA OVER 4 YEARS IN A POST-HOC ANALYSIS OF DAPA GLIFLOZIN + MET VS GLIPIZIDE + MET
Johansen P1, Mukherjee J2, Sörstadius E3, Sternhufvud C4, 5The Swedish Institute for Health Economics (IHE), Lund, Sweden, 6Bristol Myers Squibb, Wallingford, CT, USA, 7AstraZeneca, Mölndal, Sweden

PDB44 B11 RELATIONSHIP BETWEEN SPENDING ON DIABETES DRUGS AND OCCURRENCE OF RISKS ASSOCIATED WITH TYPE 2 DIABETES IN ENGLISH GENERAL PRACTICES
Spain VA, Murphy EM, Beaumont A, Cogora, London, UK

PDB45 B12 COST OF MEDICATION NONADHERENCE IN PATIENTS WITH DIABETES MELLITUS
Nadendla R, Chalapathia Institute of Pharamaceutical Sciences, Guntur, India

PDB46 B13 DIRECT COST AND MEDICATION USAGE IN ELDERLY TYPE 2 DIABETIC PATIENTS UNDER HOSPITALIZATION AMONG INSURED URBAN POPULATION IN CHINA
Liu Q1, Liu M1, Chu Y2, Li Z2, WANG D2, 1Beijing Brainpower Pharma Consulting Co. Ltd, Beijing, China, 2Boehringer Ingelheim (China) Investment Co., Ltd., Beijing, China

PDB47 B14 DIRECT COST AND MEDICATION USAGE AMONG INSURED TYPE 2 DIABETES PATIENTS WITH CHRONIC KIDNEY DISEASE UNDER HOSPITALIZATION IN BEIJING AND TIANJIN, CHINA
Liu Q1, Liu M1, Chu Y2, Li Z2, WANG D2, 1Beijing Brainpower Pharma Consulting Co. Ltd, Beijing, China, 2Boehringer Ingelheim (China) Investment Co., Ltd., Beijing, China

PDB48 B15 ASSOCIATION BETWEEN WEIGHT CHANGE, DIABETES-RELATED HEALTHCARE COSTS, AND HBA1C AMONG PATIENTS WITH TYPE 2 DIABETES
Mukherjee J1, Sternhufvud C2, Smith N3, Bell K4, Stott-Miller M5, 6Johnston S6, 7Bristol Myers Squibb, Wallingford, CT, USA, 8AstraZeneca, Mölndal, Sweden, 9Bristol Myers Squibb, Lawrenceville, NJ, USA, 10AstraZeneca, Fort Washington, PA, USA, 11Truven Health Analytics, Cambridge, MA, USA, 12Truven Health Analytics, Bethesda, MD, USA

PDB49 B16 ECONOMIC BURDEN OF TYPE 2 DIABETES MELLITUS TREATMENT STRATEGIES: A COST CONSEQUENCE ANALYSIS OF SITAGLIPTIN VS SULFONYLUREAS IN LOMBARDY REGION
Genovese S1, Torre E2, Baccetti F3, 1IRCCS Multimedica, Milan, Italy, 2Endocrinologia, Diabetologia e Malattie metaboliche ASL 3 Genovese, Genova, Italy, 3SD Diabetologia e Malattie Metaboliche ASL 1 Massa Carrara, Massa, Italy

PDB50 B17 COST-EFFECTIVENESS ANALYSIS OF EXENATIDE ONCE-WEEKLY VERSUS DULAGLUTIDE, LIRA GLUTIDE AND LIXISENATIDE FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS: AN ANALYSIS FROM THE UK NHS PERSPECTIVE
Charokpou M1, Chuang L2, Verhegen B1, Gibson D3, Grundy S2, 4Kartman BB, 5Pharmerit International, Rotterdam, The Netherlands, 6AstraZeneca, Luton, UK, 7Astrazeneca Pharmaceuticals, LP, Gaithersburg, MD, USA, 8AstraZeneca, Mölndal, Sweden

PDB51 B18 THE COST-EFFECTIVENESS (CE) OF INTRAVITREAL AFLIBERCEPT (IVT-AFL) IN THE TREATMENT OF DIABETIC MACULAR EDEMA (DME) IN TURKEY
Deger C1, Ozdemir O2, Eldem B1, Unlu N2, Alp MN3, Saatci AO4, Ozmert E1, Altintas AK2, Sermet F1, Erdal E1, Sar C1, Asan S1, Sumer F3, Parali E1, Ozel O1, 2Bayer Turk Kimya San. Ltd. Sti., Istanbul, Turkey, 3Yorum Consulting Ltd., Istanbul, Turkey, 4Hacettepe University Faculty of Medicine, Ankara, Turkey, 5Ankara Training & Research Hospital, Ankara, Turkey, 6Ankara Numune Training & Research Hospital, Ankara, Turkey, 7Ankara Ulucanlar Eye Training & Research Hospital, Ankara, Turkey

PDB53 B19 THE LONG-TERM COST-EFFECTIVENESS OF TWICE-DAILY EXENATIDE WITH INSULIN GLARGINE VERSUS ONCE-DAILY LIRA GLUTIDE WITH INSULIN DETEMIR IN ADULT PATIENTS WITH TYPE 2 DIABETES IN RUSSIA
Krysanov I1, Tiapkina M2, 1Postgraduate Medical Institute, Moscow National University of Food Production, Moscow, Russia, 2I.M. Sechenov First Moscow State Medical University, Moscow, Russia

PDB54 B20 EVALUATING THE COST-EFFECTIVENESS OF GLP-1 RECEPTOR AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES IN THE UK
Ashley D1, Vega G1, Hunt B2, Valentine WJ1, 1Novo Nordisk Ltd., Gatwick, UK, 2Ossian Health Economics and Communications, Basel, Switzerland

PDB55 B21 COST-EFFECTIVENESS OF DAPA GLIFLOZIN AS ADD-ON TO METFORMIN FOR THE TREATMENT OF TYPE 2 DIABETES IN GREECE
Tzanetakos C1, Tentoulouris N2, Kourlaba G3, Maniadakis N1, 1National School of Public Health, Athens, Greece, 2Athen's University Medical School, Athens, Greece, 3Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO). Athens, Greece

PDB56 B22 COST-EFFECTIVENESS OF DULAGLUTIDE 1.5MG ONCE WEEKLY FOR THE TREATMENT OF PATIENTS WITH TYPE TWO DIABETES MELLITUS IN SWEDEN

PDB57 B23 DAPA GLIFLOZIN VERSUS A Dipeptidyl Peptidase 4 Inhibitor (DPP4) BOTH ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM): IMPACT ON HEALTH, QUALITY OF LIFE AND COSTS IN THE TURKISH CLINICAL SETTING

A SYSTEMATIC REVIEW OF COST-EFFECTIVENESS MODELS IN TYPE 1 DIABETES MELLITUS
Henriksson M¹, Jindal R², Sternhufvud C³, Sörstadius E⁴, Bergenheim K⁵, Willis M⁶, Linköping University, Linköping, Sweden, ²Paraxel International, Chandigarh, India, ³AstraZeneca, Malmö, Sweden, ⁴The Swedish Institute for Health Economics, Lund, Sweden

THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) 10MG AND EMPAGLIFLOZIN (EMPA) 25MG IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) AS MONOTHERAPY IN THE UNITED KINGDOM
Schroeder M¹, Johansen P², Willis M³, Neslusan C⁴, Janssen UK, High Wycombe, UK, ²The Swedish Institute for Health Economics, Lund, Sweden, ³Janssen Global Services, LLC, Raritan, NJ, USA

COST-EFFECTIVENESS ANALYSIS OF GESTATIONAL DIABETES MELLITUS SCREENING IN URBAN CHINESE SETTING
Zhang L¹, Chen W¹, Wang Y¹, Ma R¹, Du M¹, Xu X¹, ¹Fudan University, Shanghai, China, ²1st Affiliated Hospital of Kunming Medical University, Kunming, China, ³Shanghai General Hospital, Shanghai, China

COST OF REACHING DEFINED HBA1C TARGET USING CANAGLIFLOZIN COMPARED TO DAPAGLIFLOZIN AS ADD-ON TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN THE UNITED ARAB EMIRATES (UAE)
Schubert A¹, Nielsen AT², El Khoury A³, Kamal A², Taieb V², Janssen-Cilag Poland, Warsaw, Poland, ²Janssen-Cilag AS, Birkered, Denmark, ³Janssen-Cilag, Dubai, United Arab Emirates, ⁴Amaris, London, UK

COST-EFFECTIVENESS ANALYSIS OF VILDAGLIPTIN VS. GLIMEPIRIDE AS ADD-ON TO METFORMIN IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS IN GREECE
Kousoulakou H¹, Kalogeropoulou M², Panetti E³, ¹University of Peloponnese, Corinth, Greece, ²Novartis Hellas, Metamorfosis, Greece

COST-EFFECTIVENESS OF SITAGLIPTIN COMPARED TO SULPHONYLUREA AS AN ADD-ON TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES IN GREECE
Athanasakis K¹, Zhuo J¹, Chen J¹, Boubouchairepouloù N¹, Tarantilis F¹, Papageorgiou M¹, Retsa P², Brandtmüller A³, Tunceli K³, Karokis A³, Kyriopoulos J¹, National School of Public Health, Athens, Greece, ³Merck & Co., Inc., North Wales, PA 19454-2505, PA, USA, ⁴MSD Greece, Athens, Greece, ⁵MSD, Health Outcomes & Customer Solutions, MER, Budapest, Hungary, ⁶Merck & Co., Inc., North Wales, PA, USA

ECONOMIC EVALUATION OF SAXAGLIPTIN IN COMBINATION WITH METFORMIN VERSUS SITAGLIPTIN OR VILDAGLIPTIN IN COMBINATION WITH METFORMIN IN PATIENTS WITH TYPE 2 DIABETES IN RUSSIA
Krysanov I¹, Tiapkina M², ¹Postgraduate Medical Institute, Moscow National University of Food Production, Moscow, Russia, ²M. Sechenov First Moscow State Medical University, Moscow, Russia

ECONOMIC EVALUATION OF SECOND LINE ORAL ANTIDiABETICS FOR TYPE 2 DIABETES IN COLOMBIA
Quitian H¹, Aschner P¹, Muñoz O¹, Iragorn N¹, Girón D¹, Gomez-Restrepo C², Rosselli D², ¹Pontificia Universidad Javeriana, Bogota, Colombia, ²Pontificia Universidad Javeriana, Bogotá, Colombia

COST-EFFECTIVENESS ANALYSIS OF EXENATIDE TWICE DAILY (BID) VERSUS INSULIN GLARGINE ONCE DAILY (QD) AS ADD-ON THERAPY IN CHINESE PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY ORAL THERAPIES
Deng J¹, Gu S¹, Shao H², Dong H², Zhao Y², Shi L³, ¹Johns Hopkins Bloomberg School of Public Health, Baltimore, LA, USA, ²Zhejiang University School of Medicine, Hangzhou, China, ³Tulane University, New Orleans, LA, USA, ⁴Zhejiang University, Hangzhou, China, ⁵Xavier University of Louisiana, New Orleans, LA, USA

COST ANALYSIS OF THE DIABETIC TREATMENT IN ITALY: THE ROLE OF VILDAGLIPTIN VS. OTHER THERAPEUTIC OPTIONS IN PATIENTS WITH TYPE 2 DIABETES WITH RENAL INSUFFICIENCY
Torre E¹, Colombo GL², Bruno GM³, Valentino MC³, Di Matteo S², ¹Diabetologia e Malattie Metaboliche U.O. Genova-Ponente, Serra Ricco (GE), Italy, ²University of Pavia, Milan, Italy, ³S.A.V.E. Studi - Health Economics & Outcomes Research, Milan, Italy

COST-EFFECTIVENESS OF INCREASING THE INFLUENZA VACCINATION RATE IN ADULTS WITH TYPE 2 DIABETES IN TURKEY
Macabeo B¹, Akin L¹, Caliskan Z², Altinel S², Satman I³, Sanofi Pasteur, Lyon, France, ²Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Hacettepe University, Ankara, Turkey, ⁴Sanofi Pasteur, Istanbul, Turkey, ⁵Istanbul University Istanbul Medical Faculty, Istanbul, Turkey

COST-UTILITY ANALYSIS OF INSULIN ANALOGUES COMPARED WITH MULTIPLE DAILY INJECTIONS OF HUMAN INSULIN FOR THE TREATMENT OF 15 YEARS OLD OR OLDER PATIENTS WITH TYPE 1 DIABETES MELLITUS IN COLOMBIA
Rosselli D¹, Quitian H², Gomez AM³, Garcia Peña AA³, Arciniegas J³, Iragorrí N³, Mantilla B³, ¹Gomez-Restrepo C³, ²Pontificia Universidad Javeriana, Bogotá, Colombia, ³Pontificia Universidad Javeriana, Bogotá, Colombia

COST-EFFECTIVENESS OF PASIRETOTIDE LONG-ACTING IN A TREATMENT OF ACROMEGALY IN FINLAND. ECONOMIC EVALUATION BASED ON FINNISH AURIA BIOBANK DATA ON HEALTH CARE RESOURCE UTILIZATION

PDB58 B24

PDB59 B25

PDB60 B26

PDB61 B27

PDB62 B28

PDB63 B29

PDB64 B30

PDB65 B31

PDB66 B32

PDB67 B33

PDB68 C1

PDB69 C2

PDB70 C3
PDB71 C4 ECONOMICS ANALYSIS OF DAPAGLIFLOZIN COMPARE TO SULFONYLUREA IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN SPAIN: COST OF ACHIEVING COMPOSITE ENDPOINTS
Capel M, Cordero L, AstraZeneca, Madrid, Spain

PDB72 C5 COST-MINIMIZATION ANALYSIS (CMA) OF CANAGLIFLOZIN COMPARED TO GLIMEPIRIDE AND SITAGLIPTIN AS DUAL THERAPY IN COMBINATION WITH METFORMIN
Ravasio R1, Pisarra P2, Comaschi M3, Health Publishing & Services, Milano, Italy, 2Janssen Italy, Cologno Monzese MI, Italy, 3Diabetologia, Endocrinologia, Medicina Interna, ICLAS, GVM Care & Research, Rapallo, Genova, Italy

PDB73 C6 HEALTH UTILITIES ASSOCIATED WITH HYPglycemic EVENTS IN TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS RECEIVING BASAL-BOLUS INSULIN THERAPY
Ionova T1, Nikitina T1, Kurbatova K2, National Pirogov Medical Surgical Center, Moscow, Russia, 2National Center for Quality of Life Research, Saint-Petersburg, Russia

PDB74 C7 COST-EFFECTIVENESS OF RAPID-ACTING ANALOG INSULIN FOR TYPE 1 DIABETES IN THE UK SETTING
Saunders R1, Boye KS2, van Brunt K2, Pollock RF1, Valentine WJ3, Ossian Health Economics and Communications GmbH, Basel, Switzerland, 2Eli Lilly and Company, Indianapolis, IN, USA, 3Eli Lilly & Company, Windlesham, UK, 4Ossian Health Economics and Communications, Basel, Switzerland

PDB75 C8 ECONOMIC EVALUATION OF THE ONE-STEP SCHEME COMPARED WITH TWO-STEPS FOR SCREENING AND DIAGNOSIS OF GESTATIONAL DIABETES IN COLOMBIA
Quitian H, Acosta A, Martinez RA, Bohorquez A, Cajamarca J, Amado L, Gomez-Restrepo C, Rosselli D, Pontificia Universidad Javeriana, Bogota, Colombia, 2Pontificia Universidade Javeriana, Bogotá, Colombia

PDB76 C9 UNDERSTANDING THE INTER-RELATIONSHIP BETWEEN IMPROVED GLYCAEMIC CONTROL, HYPOGLYCAEMIA AND WEIGHT CHANGE WITHIN A TYPE 1 DIABETIC POPULATION
Bennett H, Bergenheim K, McEwan P, Health Economics and Outcomes Research Ltd, Cardiff, UK, 2AstraZeneca, Mölndal, Sweden

PDB77 C10 THE ROLE OF SELECTIVE INHIBITORS OF SODIUM-Glucose CO-CONVEYOR TYPE 2 IN REDUCING OF VASCULAR A çift effects
Meshkov DO, Khabriev RU, Bezmelnitsyna LY, Berseneva EA, Cherkasov SN, National Research Institution for Public Health, Moscow, Russia

PDB78 C11 THE COST OF NON-SEVERE HYPOGLYCAEMIA IN EUROPE
Chubb B1, Tikkkanen C2, Novo Nordisk Healthcare AG, Gatwick, UK, 2Novo Nordisk Healthcare AG, Copenhagen, Denmark

DIABETES/ENDOCRINE DISORDERS - Patient-Reported Outcomes & Patient Preference Studies

PDB79 C12 IMPACT OF A TELEPHONIC OUTREACH PROGRAM ON MEDICATION ADHERENCE IN MEDICARE ADVANTAGE PRESCRIPTION DRUG (MAPD) PLAN BENEFICIARIES
Park H, Adeyemi A, Roane T, University of Florida, Gainesville, FL, USA

PDB80 C13 IMPACT OF ADHERENCE TO ORAL ANTIDIABETICS ON ALL-CAUSE MORTALITY: A POPULATION BASED STUDY
Simard P1, Presse N1, Roy L2, Dorais M3, White-Guay B4, Râkel A4, Perreault S4, 1Université de Montréal, Montreal, QC, Canada, 2Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada, 3StatSciences Inc, ND Ile-Perrot, QC, Canada

PDB81 C14 BASAL INSULIN PERSISTENCE, ASSOCIATED FACTORS, AND OUTCOMES AFTER INITIATION AMONG PEOPLE WITH TYPE 2 DIABETES MELLITUS IN JAPAN
Hadjijyanianni I1, Desai U1, Ivanova JI2, Kirson NY3, Enloe CJ4, Cummings AG5, Birnbaum HG6, Suzuki SJ7, Duan R8, Raijouu A9, Cao D10, Perez-Nieves M11, 1Lilly Deutschland GmbH, Bad Homburg, Germany, 2Analysis Group, Inc., Boston, MA, USA, 3Analysis Group, Inc., New York, NY, USA, 4Eli Lilly Japan KK, Kobe, Japan, 5Eli Lilly and Company, Indianapolis, IN, USA, 6Eli Lilly and Company Limited, Windlesham, Surrey, UK

PDB82 C15 ADHERENCE AND PERSISTENCE IN PATIENTS INITIATING TREATMENT WITH INJECTABLE THERAPIES FOR TYPE 2 DIABETES MELLITUS (T2DM) IN SPAIN
Sicas-Mainar A1, Navarro R2, Ruiz L3, Morano R4, 1Badalona Serveis Assistencials, Badalona. Barcelona, Spain, 2Hospital German Trias i Pujol, Badalona, Barcelona, Spain, 3GlaxoSmithKline, Madrid, Spain

PDB83 C16 MEDICATION ADHERENCE AND SATISFACTION WITH TREATMENT IN PATIENTS WITH DIABETES MELLITUS RECEIVING ORAL COMBINATION THERAPY: DATA OF A REAL-WORLD STUDY
Ionova T1, Nikitina T1, Rodionova A2, Kurbatova K3, 1National Pirogov Medical Surgical Center, Moscow, Russia, 2Multinational Center for Quality of Life Research, Saint-Petersburg, Russia

PDB84 C17 ADHERENCE TO INITIATED BASAL INSULIN ANALOG TREATMENT IN TYPE 1 AND 2 DIABETES
Westerbacca J, Mihailov H, Valle T, Jaaskelainen S, Kaukua J, 1Sanofi Finland, Helsinki, Finland, 2University of Eastern Finland, Kuopio, Finland, 3Mehiläinen Diabetes Clinic, Helsinki, Finland

PDB85 C18 POTENTIAL BARRIERS TO INSULIN INTENSIFICATION AMONG PATIENTS WITH TYPE 2 DIABETES: THE PATIENT PERSPECTIVE IN GERMANY
Hohl J, Kurki S, Miettinen T, Snicker K, AT Medical Affairs Consulting Oy (Medaffcon), Espoo, Finland, 2Auria Biobank, Turku University Hospital and University of Turku, Turku, Finland, 3Novartis Finland Oy, Espoo, Finland
Bøgelund M, Vega-Hernandez G, Seitz L, Cel M, Incentive, Holte, Denmark, Novo Nordisk Ltd., Gatwick, UK, Novo Nordisk Pharma GmbH, Mainz, Germany

**PDB86 C19** BARRIERS TO INTENSIFICATION OF INSULIN TREATMENT IN PATIENTS WITH TYPE 2 DIABETES IN THE NETHERLANDS: ASSESSING PATIENT PREFERENCES AND BEHAVIOURS

Bøgelund M, Vega-Hernandez G, Lopes S, Schaper N, Incentive, Holte, Denmark, Novo Nordisk Ltd., Gatwick, UK, Novo Nordisk Health Care AG, Copenhagen, Denmark, Maastricht University Hospital, Maastricht, The Netherlands

**PDB87 C20** PATIENT PERSPECTIVE ON CONVENIENCE AND INTENSIFICATION OF INSULIN TREATMENT IN TYPE 2 DIABETES IN ITALY


**PDB88 C21** ASSOCIATION BETWEEN KNOWLEDGE AND MEDICATION ADHERENCE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN PAKISTAN

Nazir SU, Hassali MA, Saleem F, Bashir S, Aljadhey H, School of Pharmaceutical Sciences, Penang, Malaysia, Universiti Sains Malaysia (USM), Pulau Pinang, Malaysia, Universiti Sains Malaysia, Penang, Malaysia, University of Sargodha, Sargodha, Pakistan, King Saud University, Riyadh, Saudi Arabia

**PDB89 C22** DOES TREATMENT ADHERENCE CORRELATES WITH HEALTH-RELATED QUALITY OF LIFE: FINDINGS FROM A CROSS SECTIONAL ANALYSIS OF TYPE 2 DIABETES MELLITUS PATIENTS IN PAKISTAN

Nazir SU, Hassali MA, Saleem F, Bashir S, Aljadhey H, School of Pharmaceutical Sciences, Penang, Malaysia, Universiti Sains Malaysia (USM), Pulau Pinang, Malaysia, Universiti Sains Malaysia, Penang, Malaysia, University of Sargodha, Sargodha, Pakistan, King Saud University, Riyadh, Saudi Arabia

**PDB90 C23** EXPERIENCES OF ITALIAN PATIENTS WITH DIABETES: AN ANALYSIS OF THE EU PI EMER DIABETES STUDY

Xenakis J, McBride M, Garfield S, GfK, Wayland, MA, USA, GfK, East Hanover, MA, USA, GfK Custom Research, Wayland, MA, USA

**PDB91 C24** SYSTEMATIC LITERATURE REVIEW OF STATE HEALTH UTILITIES FOR ADULTS WITH TYPE 1 DIABETES

Smith-Palmer J, Boye KS, Bae J, Norrbacka K, Hunt B, Valentine WJ, Ossian Health Economics and Communications, Basel, Switzerland, Eli Lilly and Company, Indianapolis, IN, USA, Eli Lilly Finland, Helsinki, Finland, Ossian Health Economics and Communications GmbH, Basel, Switzerland

**PDB92 C25** ASSESSMENT OF UNMET HEALTHCARE NEEDS IN DIABETIC PATIENTS IN BULGARIA

Yordanova S, Petrova G, Gerenova J, Orbetzova M, Kamenov Z, Medical University, Sofia, Bulgaria, Medical University - Sofia, Sofia, Bulgaria, Trakia University, Stara Zagora, Bulgaria, Medical University, Plovdiv, Bulgaria

**PDB93 C26** EVALUATING DIABETES PATIENTS’ PREFERENCES FOR PROFILES OF GLP-1 TREATMENTS IN THE UNITED KINGDOM: A DISCRETE CHOICE EXPERIMENT

Gelhorn HL, Poon JL, Davies EW, Paczkowski R, Curtis SE, Boye KS, Evidera, Bethesda, MD, USA, Evidera, London, UK, Eli Lilly and Company, Indianapolis, IN, USA

**PDB94 C27** PATIENT PREFERENCES FOR ATTRIBUTES OF TYPE 2 DIABETES MELLITUS (T2DM) TREATMENTS IN SPAIN

Mansfield CA, Sikirica M, Pugh A, Poulos C, Martin AA, Ruiz Moran L, Morano Larragueta R, RTI Health Solutions, Research Triangle Park, NC, USA, GlaxoSmithKline, King of Prussia, PA, USA, GlaxoSmithKline, Uxbridge, UK, GlaxoSmithKline, Madrid, Spain

**PDB95 C28** IDEGLIRA IMPROVES HEALTH UTILITY COMPARED WITH INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE

Freemantle N, Lingvay I, Kongsoe JH, Abrahamsen T, Bjormer JB, University College London, London, UK, UT Southwestern Medical Center, Dallas, TX, USA, Novo Nordisk A/S, Bagsvaerd, Denmark, Novo Nordisk A/S, Seborg, Denmark, University of Copenhagen, Copenhagen, Denmark

**PDB96 C29** CROSS-SECTIONAL SURVEY STUDY TO UNDERSTAND BEHAVIOURS, THOUGHTS AND PERCEPTIONS OF MEALTIME INSULIN USAGE IN PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES


**PDB97 C30** PATIENT-REPORTED FREQUENCY AND BURDEN OF HYPOGLYCAEMIA FOR INSULIN-TREATED DIABETES PATIENTS IN 5 CITIES OF CHINA: A CROSS-SECTION STUDY

Li H, Ruan Z, Guan XD, Nie XY, Xie XH, Xie XX, Zhao YL, Sun FY, Shi LW, School of Pharmaceutical Sciences, Peking University, Beijing, China, Novonordisk(China) Pharmaceuticals Co., Ltd., Beijing, China, International Research Center of Medical Administration, Peking University, Beijing, China

**PDB98 C31** A PILOT STUDY MEASURING KNOWLEDGE AND ATTITUDES TOWARDS DIABETES MELLITUS IN KEDAH, MALAYSIA

Saleem F, Hassali MA, Verma AK, Aljadhey H, Universiti Sains Malaysia (USM), Pulau Pinang, Malaysia, School of Pharmaceutical Sciences, Penang, Malaysia, King Saud University, Riyadh, Saudi Arabia

**PDB99 C32** A NOVEL TOOL TO MEASURE THE SUBJECTIVE BURDEN OF ACUTE POST-PRANDIAL HYPERGLYCAEMIA (PPHG)

Kosmas CE, Lloyd A, Kragh N, Nikolajsen A, Heller S, ICON plc., Oxford, UK, Novo Nordisk A/S, Søborg, Denmark, University of Sheffield, Sheffield, UK
PDB100 C33 BENEFITS AND RISKS OF VILDAGLIPTIN/METFORMIN VERSUS SULPHONYLUREAS/METFORMIN COMBINATION THERAPY IN TYPE 2 DIABETES MELLITUS (T2DM) FROM PATIENT'S PERSPECTIVE: REAL-WORLD DATA

Ionova T1, Nikitina T2, Kurbatova K2, Rodionova A2, National Pirogov Medical Surgical Center, Moscow, Russia, 1Multinational Center for Quality of Life Research, Saint-Petersburg, Russia

PDB101 D1 DIAREG - DIABETES REGISTER INCLUDING PATIENT REPORTED OUTCOMES

Hahn M, Götzte H, Busch S, Astrazeneca GmBH, Wedel, Germany

PDB102 D2 RASCH ANALYSIS IN THE DEVELOPMENT OF A SPECIFIC HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE FOR HYPOGLYCEMIC EVENTS IN DIABETIC PATIENTS: THE QOLHYPO QUESTIONNAIRE

Balana M1, Artola Menendez S2, Jansa i Morato M2, Lopez de la Torre Casares M2, Orozco Beltran D2, Fuster E2, Novartis Farmaceutica S.A., Barcelona, Spain, 1Centro de Salud Jose Marva, Madrid, Spain, 2Hospital Clinic, Barcelona, Spain, 1Hospital Virgen de las Nieves, Granada, Spain, 2Centro de Salud Cabo Huertas, Alicante, Spain

PDB103 D3 TRANSLATION AND VALIDATION OF THE POLISH DIABETIC FOOT ULCER SCALE - SHORT FORM (DFS-SF)

Sobol E1, Macioch T1, Krakowiecki A2, Mrozikiewicz-Rakowska B2, Kasprzick M1, Hermanowski TR1, 1Medical University of Warsaw, Warsaw, Warsaw, Poland, 2PODS Wound Healing Clinic, Warsaw, Warsaw, Poland

PDB104 D4 ASSESSMENT OF HEALTH RELATED QUALITY OF LIFE (HRQL) USING EQ-5D IN TYPE 2 DIABETES MELLITUS PATIENTS IN A UNIVERSITY TEACHING HOSPITAL

Vohra Y1, Patidar V1, Alexander A1, Nair S1, Thunga G1, Bhat S2, Acharya R2, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India, 1Kasturba Medical College, Udupi, Karnataka, India

PDB105 D5 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ADRENAL INSUFFICIENCY RECEIVING PLENADREN COMPARED WITH IMMEDIATE-RELEASE HYDROCORTISONE

Bergthorsdottir R1, Nilsson AG2, Gillberg P3, Ekman B2, Wahlberg J1, Sahlgrenska University Hospital, Gothenburg, Sweden, 1Shire, Danderyd, Sweden, 2Linckoping University, Linkoping, Sweden

PDB106 D6 A CROSS-SECTIONAL ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE AMONG TYPE 2 DIABETIC PATIENTS IN PAKISTAN

Nazir SU1, Hassali MA2, Saleem F3, Bashir S4, Aljadhey H5, School of Pharmaceutical Sciences, Penang, Malaysia, 1Universiti Sains Malaysia (USM), Pulau Pinang, Malaysia, 2Universiti Sains Malaysia, Penang, Malaysia, 3University of Sargodha, Sargodha, Pakistan, 4King Saud University, Riyadh, Saudi Arabia

PDB107 D7 HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH DIABETIC FOOT ULCERATION – OBSERVATIONAL STUDY IN POLAND

Macioch T1, Sobol E1, Mrozikiewicz-Rakowska B1, Krakowiecki A1, Hermanowski TR1, 1Medical University of Warsaw, Warsaw, Warsaw, Poland, 2PODS Wound Healing Clinic, Warsaw, Warsaw, Poland

PDB108 D8 QUANTIFYING THE SHORT-TERM IMPACT OF CHANGES IN HBA1C, WEIGHT AND INSULIN REGIMEN ON HEALTH RELATED QUALITY-OF-LIFE

Evans M1, Riddershälte M2, Jensen HH2, Begeldun M2, Jensen MM3, Ericsson Å4, Jendle J1, 1University Hospital Linköping, Linköping, Sweden, 2Podd Linköping, Sweden, 3University of Linköping, Linköping, Sweden

PDB109 D9 WILLINGNESS TO PAY FOR ONE QUALITY ADJUSTED LIFE YEARS IN PATIENTS WITH DIABETES

Moradi N1, Rashidian A2, Rasekh hR3, Mohammadi T4, Alamdari S5, oliaei Manesh A6, shahid beheshti university of medical science, tehran, Iran, 1tehran university of medical science, tehran, Iran, 2Shahid Beheshti University of Medical Sciences, Tehran, Iran, 3allameh Tabatabai University, tehran, Iran, 4Shahid Beheshti university of Medical Sciences, tehran, Iran, 5Ministry of Health and Medical Education, tehran, Iran

PDB110 D10 MOBILE PHONE USE AND WILLINGNESS TO PAY FOR SMS FOR DIABETES IN BANGLADESH

Shariful Islam SM, Ludwig-Maximilians-Universität (LMU), Munich, Germany, Munich, Germany

PDB111 D11 WILLINGNESS TO PAY FOR QUALITY-ADJUSTED LIFE YEARS IN PATIENTS WITH DIABETE

Moradi N1, Rashidian A2, shahid beheshti university of medical science, tehran, Iran, 1tehran university of medical science, tehran, Iran

DIABETES/ENDOCRINE DISORDERS - Health Care Use & Policy Studies

PDB112 D12 USING THE TRANSTHEORETICAL MODEL TO ENHANCE SELF-MANAGEMENT ACTIVITIES IN TYPE 2 DIABETIC PATIENTS: A SYSTEMATIC REVIEW

Mohamed Ibrahim M1, Arafat Y2, Awaisu A3, College of Pharmacy, Qatar University, Doha, Qatar, 2Qatar University, Doha, Qatar

PDB113 D13 INTENSIFICATION OF BASAL INSULIN TREATMENT AMONG PATIENTS WITH DIABETES MELLITUS TYPE 2 IN THE NETHERLANDS

Overbeek J1, Houben E2, Kring S2, Sommer J2, Penning-van Beest F1, van der Heijden A2, Nijpels G3, Herings R3, 1PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 2Novo Nordisk Scandinavia AB, Copenhagen, Denmark, 3Novo Nordisk B.V, Alphen a/d Rijn, The Netherlands, 4EMGO Institute, VU Medical Centre, Amsterdam, The Netherlands

PDB114 D14 EFFICIENCY OF A PERSONALIZED CARE MODEL IN DIABETES AS AN EXAMPLE OF CHRONIC DISEASE WITH INFORMATION AND COMMUNICATIONS TECHNOLOGY SUPPORT
HOW TO DETERMINE THE TARGET POPULATION IN EARLY BENEFIT ASSESSMENTS IN GERMANY? THE CASE OF DIABETES MELLITUS TYPE 2
Schwalm A1, Mostardt S1, Ten Thoren C1, Zhou M1, Gerber-Grote AU2, IQWiG, Cologne, Germany, 2Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany

TRIO H’S (HYPERGLYCEMIA, HYPERTENSION, HYPERLIPIDEMIA): UNDIAGNOSED MODIFIABLE RISK FACTORS IN MALAYSIA RURAL COMMUNITY
Lee Y1, Lee L, Hong L, Welluppillai V, Kamarudin A, Pfizer Malaysia, Kuala Lumpur, Malaysia

TELEMEDICINE COMPARED WITH STANDARD CARE IN TYPE 2 DIABETES MELLITUS. A RANDOMIZED CONTROLLED PROJECT IN AN OUTPATIENT CLINIC
Rasmussen oW, Kolding Hospital, Kolding, Denmark

EFFECT OF PATIENT-EDUCATION ON HEALTH-RELATED QUALITY OF LIFE OF DIABETIC FOOT ULCER PATIENTS IN A TERTIARYCARE HOSPITAL
Miraj SS1, Roy RT1, Unnikrishnan M1, K V1, Rodrigues GS2, Mukhopadhyay C2, Manipal College of Pharmaceutical Sciences, Manipal, India, 2Kasturba Medical College, Manipal, India

BLOOD GLUCOSE TEST RESULT FROM EMPLOYEES AT HEALTH CLINIC OF SONGINO KHAIRKHAN DISTRICT
Lundee O, Batchuluun D, Galbat M, Mongolian National University of Medical, ulaanbaatar, Mongolia

IMPORTANCE OF HYPOGLYCEMIA BARRIER ON THE TREATMENT OF DIABETES MELLITUS (DM) – SURVEY WITH TURKISH PHYSICIANS
Malhan S1, Emral R2, Guler S2, Baskent University, Ankara, Turkey, 2Ankara University, Ankara, Turkey, 3Hitit University, Corum, Turkey

AN ANALYSIS OF DIABETIC MEDICINE UTILIZATION IN TURKEY
Kilicaslan H1, Kockaya G2, Uludag O1, Abacioglu N1, Gazi University, Ankara, Turkey, 2Health Economics and Policy Association, Ankara, Turkey

CLINICIAN-REPORTED INSIGHTS OF INSULIN DEGLUDEC USE IN GERMANY AND FOUR SUPPORTING EUROPEAN COUNTRIES
Seitz L1, Lopes S2, Vandebrouck T2, Parekh WA3, Canty E2, Robinson A2, Ohlson L1, Novo Nordisk Pharma GmbH, Mainz, Germany, 2Novo Nordisk Health Care AG, Copenhagen, Denmark, 3Novo Nordisk Health Care AG, Brussels, Belgium, 4Novo Nordisk Health Care AG, Gatwick, UK, 5Adelphi Values, Bollington, UK, 6Salford Royal Hospital, Greater Manchester, UK, 7Capio Lundby Närşjukhus, Gothenburg, Sweden

CURRENT CLINICAL PRACTICE CORRESPONDENCE WITH TREATMENT GUIDELINES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Chandran A1, Parisi M2, Saltiel-Berzin R1, Bonafede MM2, Becton Dickinson, Franklin Lakes, NJ, USA, 2Truven Health Analytics, Cambridge, MA, USA

QUALITY OF CARE FOR PATIENTS WITH DIABETES MELLITUS (DM) IN CANADA: FINDINGS FROM A NATIONAL POPULATION-BASED SURVEY
Szabo SM1, Balijepalli C, Cheung A, Johnston KM, Redwood Outcomes, Vancouver, BC, Canada

SYSTEMATIC REVIEW OF ESOMEPRAZOLE FOR THE TREATMENT OF GASTROESOPHALGEAL REFLUX DISEASE
Wójcik P1, Chudziak D1, Macioch T1, Niewada M2, HealthQuest, Warsaw, Poland, 2Medical University of Warsaw, Warsaw, Poland

EFFECTS OF NUTRITIONAL SUPPLEMENT USAGE ON MORTALITY IN PATIENT UNDERWENT ABDOMINAL RESECTION SURGERY FOR NON-ONCOLOGICAL CONDITIONS
Gulkan S1, Berktas M2, Tezcan ES1, Dogukan MN1, Ozcan O1, Koksal I1, Social Security Institute, Ankara, Turkey, 2Yeditepe University, Istanbul, Turkey

HEALTHCARE PATHWAYS AND BURDEN OF DISEASE OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES (IBD)
Martini N1, Cinconze E2, Calabria S3, Esposito I1, De Rosa M1, Accademia Nazionale di Medicina, Roma, Italy, 2CINECA Interuniversity Consortium, Casalecchio di Reno, Italy, 3CORE, Collaborative Outcome Research, Bologna, Italy
PGI6 E13 INTRODUCTION OF NEW COMBINATION THERAPY FOR TREATMENT OF EXPERIENCED HCV GT1 PATIENTS: BUDGET IMPACT ANALYSIS, THE CROATIAN PERSPECTIVE
Mance D1, Mance D2, Vitezic D3, 1University of Rijeka, School of Medicine, Rijeka, Croatia, 2University of Rijeka, Faculty of Economics, Rijeka, Croatia, 3University of Rijeka, School of Medicine and University Hospital Centre Rijeka, Rijeka, Croatia

PGI7 E14 OPTIMAL TREATMENT OF CHRON'S DISEASE WITH BIOLOGICALS IN A WESTERN BALKAN COUNTRY: ESTIMATES OF COST/UTILITY BY MARKOV MODEL AND BUDGET IMPACT ANALYSIS
Jankovic S1, Djakovic L2, Susic R3, Kostic M4, 1Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia and Montenegro, 2Association of patients with Chron's disease and ulcerative colitis, Belgrade, Serbia and Montenegro, 3University of Kragujevac, Kragujevac, Serbia and Montenegro

PGI8 E15 IS NICE TOO OPTIMISTIC ABOUT SAVINGS FROM FAECAL CALPROTECTIN TESTING?
McFarlane M1, Chambers S1, Dhaliwal A1, Lee B2, Sung E3, Nwokolo C4, Waugh N5, Arasaradnam R6, 1UHCW, Coventry, UK, 2Warwick Hospital, Warwick, UK, 3George Eliot Hospital, Nuneaton, UK, 4University of Warwick, Coventry, UK

PGI9 E16 COST ANALYSIS OF PROTON PUMP INHIBITORS IN THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE IN UKRAINE
Iakovlieva L1, Gerasymova O, Mishchenko O, Bezditko N, Kyrchensko O, Kuznetsov I, National University of Pharmacy, Kharkiv, Ukraine

PGI10 E17 STRENGTHS AND WEAKNESSES OF CURRENT CLINICAL AND ECONOMIC EVIDENCE FOR THE COMPARISON OF LAPAROSCOPIC VERSUS OPEN REPAIR OF INCISIONAL HERNIA
Hargreaves JA, Covidien (UK) Commercial Ltd, now part of Medtronic, Whiteley, Fareham, UK

PGI11 F1 PHARMACOECONOMICS ANALYSIS OF DIFFERENT STRATEGIES OF REPLACEMENT THERAPY IN RUSSIAN PATIENTS WITH PANCREATIC EXOCRINE INSUFFICIENCY
Ryazhennov VV1, Maximkin SA2, 1M. Sechenov First Moscow State Medical University, Moscow, Russia, 2Center for strategic research in healthcare, Moscow, Russia

PGI12 F2 ECONOMIC BURDEN AND QUALITY OF LIFE OF MODERATE-TO-SEVERE IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN GERMANY: RESULTS FROM THE IBIS-C STUDY
Layer P1, Andresen V1, Diemert S2, Mackinnon J3, Bertsch J4, Fortea J5, Tack J6, Israelitic Hospital, Hamburg, Germany, 2Almirall S.A, Barcelona, Spain, 3TFS Develop S.L, Barcelona, Spain, 4University Hospital Gasthuisberg, Leuven, Belgium

PGI13 F3 COSTS OF INFLAMMATORY BOWEL DISEASE (CROHN’S DISEASE AND ULCERATIVE COLITIS) IN SERBIA
Kostic M1, Djakovic L2, Susic R3, Jankovic S4, 1Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia and Montenegro, 2UKUKS, Belgrade, Serbia and Montenegro, 3Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia and Montenegro

PGI14 F4 REAL-WORLD MEDICAL COSTS OF ANTIVIRAL THERAPY AMONG PATIENTS WITH CHRONIC HCV INFECTION AND ADVANCED HEPATIC FIBROSIS
Maan R1, Zaim G2, van der Meer A3, Feld J4, Wedemeyer H5, Dufour J6, Lammert F7, Mans M8, Zeuzem S9, Hansen B10, Janssen H11, Veldt B12, de Knecht R13, Uyl-de Groot C14, Erasmus MC University Medical Center, Rotterdam, The Netherlands, 2Erasmus University, Rotterdam, The Netherlands, 3Toronto Western and General Hospital, University Health Network, Toronto, ON, Canada, 4Medical School Hannover, Hannover, Germany, 5University of Bern, Bern, Switzerland, 6Saarland University Medical Center, Homburg, Germany, 7Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt, Germany

PGI15 F5 ECONOMIC BURDEN IN STUDIES PUBLISHED IN 2014: WHAT TYPE OF GASTROINTESTINAL DISORDERS, INTERVENTIONS AND OUTCOMES HAVE BEEN MOST COMMONLY ASSESSED?
Martin A, Crystallise Ltd., London, UK

PGI16 F6 PERSISTENCE OF REMISSION AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE AFTER ADALIMUMAB THERAPY IS STOPPED: ECONOMIC IMPLICATIONS
Borras Blasco J1, Cortes X, Fernandez S, Moles J, Castera M, Hospital Sagunto, Sagunto, Spain

PGI17 F7 EVALUATION OF COST OF MANAGING HEPATITIS C IN GREECE ACROSS ALL DISEASE STAGES AND THE POTENTIAL VALUE OF SIMPREVIR TRIPLE REGIMEN AS A TREATMENT OPTION IN THE EARLY STAGES
Geitona M1, Koussoulakou H2, Lathouris A3, 1University of Peloponnese, Corinth, Greece, 2Janssen-Cilag Pharmaceutical SACI, Pefki, Greece

PGI18 F8 THE COST-EFFECTIVENESS OF REFERRING PATIENTS WITH IRRITABLE BOWEL SYNDROME TO A GASTROENTEROLOGIST IN THE UK
Canavan C4, 1Card T1, West J2, Moayyedi P3, 1University of Nottingham, Nottingham, UK, 2McMaster University, Hamilton, ON, Canada

PGI19 F9 MODELING THE COST-EFFECTIVENESS OF ILAPRAZOLE VS. OMPERAZOLE FOR THE TREATMENT OF NEWLY DIAGNOSED DUODENAL ULCER PATIENTS IN CHINA
Lu Y1, Xu GX2, Lu WQ3, Liu Z4, Song Ri5, Xue J6, 1Shanghai Centennial Scientific Co., Ltd, Shanghai, China, 2Livzon Pharmaceutical Group Inc., Shenzhen, China, 3China Pharmaceutical Innovation and Research Development Association, Beijing, China, 4Sun Yat-Sen University, Guangzhou, China

PGI20 F10 COST-EFFECTIVENESS OF ESOMEPRAZOLE COMPARED WITH OTHER PPIS CURRENTLY REIMBURSED IN
POLAND IN THE TREATMENT OF GERD
Wójcik P1, Chudziak D1, Macioch T1, Niewada M2,1HealthQuest, Warsaw, Poland, 2Medical University of Warsaw, Warsaw, Poland

PGI21 F11 EVALUATION OF THE COST EFFECTIVENESS OF RIFAXIMIN-á 550MG IN THE REDUCTION OF RECURRENTNESS OF OVERT HEPATIC ENCEPHALOPATHY IN SWEDEN
Poole CD1, Berni E2, Conway P3, Radwan A4, Currie C J4,1Cardiff University, Cardiff, UK, 2Pharmatelligence, Cardiff, UK, 3Norgine Ltd, Harefield, UK, 4Norgine Ltd, Uxbridge, UK

PGI22 F12 ECONOMIC ASSESSMENT OF ELTROMBOPAG IN THE TREATMENT OF THROMBOCYTOPENIA IN ITALY
Romano R1, Ruggeri M2, Coretti S1, Giannini EG2, Sacchini D1, Annicchiarico BE3, Marchetti M4, Rodeghiero F5, Lidonnici D6,1ALTEMS, Università Cattolica del Sacro Cuore (UCSC), Postgraduate School of Health Economics and Management, Rome, Italy, 2San Martino University Hospital – National Cancer Research Institute, University of Genoa, Genoa, Italy, 3Institute of Bioethics, Università Cattolica del Sacro Cuore, Rome, Italy, 4Internal Medicine and Gastroenterology Unit, “A. Gemelli” General Hospital, Università Cattolica del Sacro Cuore, Rome, Italy, 5Technology and Clinical Engineering Assessment Unit, “A. Gemelli” General Hospital, Catholic University of the Sacred Heart, Rome, Italy, 6Cell Therapy and Haematology Department, San Bortolo Hospital, Vicenza, Italy, 1MA Provider, Milano, Italy

PGI23 F13 STUDY ON COST-EFFECTIVENESS ANALYSIS FOR ULCERATIVE COLITIS TREATMENT: A SYSTEMATIC REVIEW OF LITERATURE FROM 2004-2014
Yamabe K1, Hiroi S1, Inoue S4, Kobayashi M1,1Takeda Pharmaceutical Company Ltd., Tokyo, Japan, 2CRECON Medical Assessment Inc., Tokyo, Japan

PGI24 F14 EVALUATING THE COST-EFFECTIVENESS OF PROLONGED-RELEASE TACROLIMUS RELATIVE TO IMMEDIATE-RELEASE TACROLIMUS IN LIVER TRANSPLANT PATIENTS BASED ON DATA FROM ROUTINE CLINICAL PRACTICE
Muduma G1, Odeyemi IA1, Pollock RF2,1Astellas Pharma Europe Ltd, Chertsey, UK, 2Ossian Health Economics and Communications GmbH, Basel, Switzerland

PGI25 F15 COST EFFECTIVENESS OF RIFAXIMIN-á 550MG IN THE REDUCTION OF RECURRENTNESS OF OVERT HEPATIC ENCEPHALOPATHY IN UNITED KINGDOM
Berni E1, Poole CD2, Conway P3, Radwan A4, Currie C J4,1Pharmatelligence, Cardiff, UK, 2Cardiff University, Cardiff, UK, 3Norgine Ltd, Harefield, UK, 4Norgine Ltd, Uxbridge, UK

PGI26 F16 COST-EFFECTIVENESS OF EVEROLIMUS IN LIVER TRANSPLANTATION
Mendes LR1, Haddad L, D'albuquerque LA, Sao Paulo University, Sao Paulo, Brazil

PGI27 F17 EARLIER DETECTION AND TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE: AN ECONOMIC EVALUATION TO APPRAISE AN INNOVATIVE DIAGNOSTIC PATHWAY TO DETECT AND INTERVENE WHERE THERE ARE KNOWN RISK FACTORS
Tanajewski L1, Harris R5, Harman D5, Guha N6, Gkountouras G7, Berdunov V8, Elliott RA9, University of Nottingham, Nottingham, UK, 2Nottingham University Hospitals Trust and University of Nottingham, Nottingham, UK

PGI28 G1 COST-EFFECTIVENESS OF SIMEPREVIR VS. TELAPREVIR FOR THE TRIPLE THERAPY OF HEPATITIS C IN KAZAKHSTAN
Bektur C1, Nurgozhin T1, Abdulkhakimova D2,1Nazarbayev University, National Laboratory Astana, Astana, Kazakhstan, 2Nazarbayev University, School of Science and Technology, Astana, Kazakhstan

PGI29 G2 ECONOMIC EVALUATIONS OF TREATMENTS FOR INFLAMMATORY BOWEL DISEASES
Lachaine J1, Miron A, Nait Ladjemil D, University of Montreal, Montreal, QC, Canada

PGI30 G3 SHOULD SOFOBUVIR-BASED ALL-ORAL TREATMENT BE CONSIDERED IN ELDERLY CHRONIC HEPATITIS C PATIENTS?
Cortesi PA1, Ciacci A1, Belleri G2, Rota M2, Rota M1, Conti S1, Mantovani LG1, Annoni G2, Strazzabosco M2,1University of Milano-Bicocca, Monza, Italy, 2University of Milan-Bicocca, Monza, Italy, Monza, Italy, 3University of Milan-Bicocca, Monza, Italy, 4University of Milan - Bicocca, Monza, Italy, 5Yale University School of Medicine, New Haven, CT, USA

PGI31 G4 KEY DRIVERS OF COST EFFECTIVENESS IN CROHN'S DISEASE
Sly Le1, Worbes-Cereo M2, Cranmer H3, Thompson G4, Almond C5,1BresMed, Sheffield, UK, 2Janssen-Cilag UK, High Wycombe, UK

PGI32 G5 MODELING THE COST-EFFECTIVENESS OF THE ALL ORAL, DIRECT-ACTING ANTIVIRAL REGIMEN DACLATASVIR PLUS SOFOBUVIR IN PATIENTS CO-INFECTED WITH HEPATITIS C VIRUS (HCV) AND HIV

PGI33 G6 COST-EFFECTIVENESS AND COST-UTILITY OF HOME-BASED HYPNOTHERAPY USING COMPACT DISC VERSUS INDIVIDUAL HYPNOTHERAPY BY A THERAPIST FOR PEDIATRIC IRRITABLE BOWEL SYNDROME AND FUNCTIONAL ABDOMINAL PAIN (SYNDROME)
van Barrevelde M1, Rutten J2, Vlieger A2, Frankenhuis C3, George E4, Groeneweg M5, Norbruis O6, Tjon a Ten W7, van Wering H1, Merkus M1, Benninga M2, Dijkstraaf M8,1Academic Medical Centre, Amsterdam, The Netherlands, 2Emma Children’s Hospital Academic Medical Centre, Amsterdam, The Netherlands, 3St. Antonius Hospital, Nieuwegein, The Netherlands, 4Medical Centre Alkmaar, Alkmaar, The Netherlands, 5Maasstad Hospital, Rotterdam, The Netherlands
ECONOMIC EVALUATION OF FECAL MICROBIOTA TRANSPLANTATION FOR THE TREATMENT OF RECURRENT CLOSTRIDIUM DIFFICILE INFECTION IN AUSTRALIA
Merlo G1, Graves N1, Connelly L1,1 Queensland University of Technology, Brisbane, Australia, 2 University of Queensland, Brisbane, Australia

EVALUATION OF THE COST EFFECTIVENESS OF RIFAXIMIN-â IN THE REDUCTION OF RECURRENCE OF OVER HEPATIC ENCEPHALOPATHY IN BELGIUM
Bemt E1, Connolly M1, Conroy P2, Radwan A3, Currie CJ1, Pharmatelligence, Cardiff, UK, 2 University of Groningen, Groningen, The Netherlands, 3 Norgine Ltd, Harefield, UK, 4 Norgine Ltd, Uxbridge, UK, 5 Cardiff University, Cardiff, UK

ECONOMIC EVALUATION OF INFliximAB FOR TREATMENT OF REFRACTORY ULCERATIVE COLITIS IN IRAN: COST-EFFECTIVENESS ANALYSIS
Moradi N1, Tofighi S2, Zanganeh M4, akbari Sari A2, Zarei L1,1 shahid beheshti university of medical science, tehran, Iran, 2 Baghiatallah University of Medical Sciences, tehran, Iran, 3 Ministry of Health and Medical Education, tehran, Iran, 4 tehran university of medical science, tehran, Iran

A COST-UTILITY ANALYSIS OF PROLONGED-RELEASE TACROLIMUS RELATIVE TO IMMEDIATE-RELEASE TACROLIMUS AND CICLOSPORIN IN LIVER TRANSPLANT RECIPIENTS IN THE UK
Muduma G1, Odeyemi IA1, Pollock RF2,1 Asterlas Pharma Europe Ltd, Chertsey, UK, 2 Ossian Health Economics and Communications GmbH, Basel, Switzerland

EVALUATION OF THE COST EFFECTIVENESS AND SOCIETAL IMPACT OF RIFAXIMIN-â 550MG IN THE REDUCTION OF RECURRENCE OF OVER HEPATIC ENCEPHALOPATHY IN THE NETHERLANDS
Whitehouse JT1, Bemt E1, Conroy P3, Radwan A3, Henrar R3, Currie CJ1, Norgine, Uxbridge, UK, 2 Pharmatelligence, Cardiff, UK, 3 Norgine Ltd, Harefield, UK, 4 Norgine Ltd, Uxbridge, UK, 5 Norgine B.V, Amsterdamer, The Netherlands, 6 Cardiff University, Cardiff, UK

A COST-UTILITY ANALYSIS OF DIFFERENT ORAL ANTIVIRAL MEDICATIONS IN PATIENTS WITH CHRONIC HEPATITIS B IN IRAN: AN ECONOMIC MICRO-SIMULATION DECISION MODEL
Keshavarz K1, Nikfar S2,3 Shiraz University of Medical Sciences, Shiraz, Iran, 4 Tehran University of Medical Sciences, Tehran, Iran

GASTROINTESTINAL DISORDERS - Patient-Reported Outcomes & Patient Preference Studies

PATIENTS' PERCEPTION OF ADHERENCE TO THERAPY IN ULCERATIVE COLITIS: RESULTS OF A SURVEY TO SPECIALIZED CENTERS
Castiglione E1, Colombo GL2, Valentino MC3, Di Matteo S1, Bruno GM2, Università Degli Studi di Napoli Federico II, Napoli, Italy, 2 University of Pavia, Milan, Italy, 3 S.A.V.E. Studi - Health Economics & Outcomes Research, Milan, Italy

HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN POLAND (APPLICATION OF THE EQ-5D AND SELF-ASSESSMENT OF HEALTH STATE)
Petryszyn P1, Zachariasz A1, Ekk-Cierniaikowski P2, Well M3, Wroclaw Medical University, Wroclaw, Poland, 2 Warsaw School of Economics, Warsaw, Poland, 3 Wroclaw University of Economics, Wroclaw, Poland

COMPOUND ATTRIBUTES FOR SIDE EFFECT IN DISCRETE CHOICE EXPERIMENTS: RISK OR SEVERITY - WHAT IS MORE IMPORTANT TO HEPATITIS C PATIENTS?
Mühlbacher AC1, Bethge S, Sadler A, Hochschule Neubrandenburg, Neubrandenburg, Germany

HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WHO HAVE UNDERGONE COLECTOMY FOR ULCERATIVE COLITIS: IMPACTS OF COMPLICATIONS POST-SURGERY
Kosmas CE1, Kerr C2, Marsh SE3, Gentile B1, Doll HA1, Finney-Hayward T3,1 ICON plc, Oxford, UK, 2 Formerly ICON plc, Oxford, UK, 3 AbbVie Ltd, Maidenhead, UK

SYSTEMATIC LITERATURE REVIEW OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS RECEIVING PARENTERAL NUTRITION
Neves C1, Chapman A1, Burden S1, Lal S1, MacCulloch A1, BresMed, Sheffield, UK, 2 University of Manchester, Manchester, UK, 3 Salford Royal Foundation Trust, Salford, UK, 4 Shire, Basingstoke, UK

TRANSLATABILITY ASSESSMENT AND LINGUISTIC VALIDATION OF THE PATIENT-REPORTED OUTCOME INSTRUMENT FOR IRRI TABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D PRO)
Popielnicki A1, Arbuckle R1, Banderas B2, Delgado-Herrera L1, Gagnais I1, Lasch K3, Nishida A4, Zeiher B5, Zentner S6, TransPerfect, Boston, MA, USA, 2 Adelphi Values Ltd., Bollington, UK, 3 Adelphi Values, Boston, MA, USA, 4 Astellas Pharma Global Development, Northbrook, IL, USA, 5 Pharmerit International, Newton, MA, USA, 6 Astellas Pharma Inc, Tokyo, Japan

DEVELOPMENT OF A VALIDATED QUESTIONNAIRE EVALUATING THE BURDEN OF THE HAEMORRHOIDAL DISEASE AND ANAL FISSURE (HEMO-FISS)
Bord C1, Pillant H1, Favreau-Weitzer C4, Sénéjouxs A4, Soudan D2, Arredondo Bisonò T5, Zikl A6, Berdeaux G6, Abramowitsch L1, Polyclinique Saint Roch, Montpellier, France, 2 Private, Paris, France, 3 Hospital Bagatelle, Talence, France, 4 Centre hospitalier privé de saint grégoire, Saint grégoire, France, 5 Pierre Fabre, Boulogne-Billancourt, France, 6 Pierre Fabre, Boulogne Billancourt, France, 7 Hospital Bichat, Paris, France

NUTRITIONAL ASPECTS AND DISINFORMATION IN LIVER DISEASE: A QUESTIONNAIRE-BASED SURVEY IN
ITALIAN PATIENTS

PG148 G21 HEALTH-RELATED QUALITY OF LIFE, WORK PRODUCTIVITY, AND DAILY ACTIVITY AMONG A SAMPLE OF COMMERCIALLY INSURED PATIENTS WITH IRRETABLE BOWEL SYMROME WITH CONSTIPATION OR CHRONIC CONSTIPATION IN THE UNITED STATES

PG149 G22 MODELS OF THE IMPACT OF MAJOR LIVER DISEASES ON EQ-5D VISUAL ANALOGUE SCALE AND UTILITY-INDEX: CONVERGENCES AND DIVERGENCES
Conti S, Cortesi PA, Scalone L, Strazzabosco M, Cesana G, Mantovani LG, 1University of Milano - Bicocca, Monza, Italy, 2University of Milano-Bicocca, Monza, Italy

PG150 G23 LIFE QUALITY OF YOUNG ADULT PATIENTS WITH INFAMMABLE BOWEL DISEASE

PG151 G24 THE DEMOGRAPHIC ASPECTS OF UKRAINIAN CHRONIC HEPATITIS C PATIENTS AND THE TREATMENT INITIATION FROM A PHYSICIAN'S & PATIENT'S POINT OF VIEW. FIRST INTERIM ANALYSIS OF TURKISH DATA FROM MOSAIC STUDY (AN INTERNATIONAL MULTICENTER PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE THE EPIDEMIOLOGY, HUMANISTIC AND ECONOMIC OUTCOMES OF TREATMENT FOR CHRONIC HEPATITIS C VIRUS)
Koksal I, Aladag M, Koklu S, Sezgin O, Karadeniz Tech University, Trabzon, Turkey, 2Inonu University, Malatya, Turkey, 3Hacettepe University, Ankara, Turkey, 4Mersin University, Mersin, Turkey

GASTROINTESTINAL DISORDERS - Health Care Use & Policy Studies

PG152 G25 DIAGNOSIS AND MANAGEMENT OF MONTAGE-TO-SEVERE IRRETABLE BOWEL SYMROME WITH CONSTIPATION (IBS-C) IN 10 YEARS: RESULTS FROM THE IBIS-C STUDY
Layer P, Andresen V, Dieter M, Mackinnon J, Bertsch J, Fortea J, Tack J, Israeliic Hospital, Hamburg, Germany, 2Almirall S.A, Barcelona, Spain, 3TFS Develop S.L, Barcelona, Spain, 4University Hospital Gasthuisberg, Leuven, Belgium

PG153 G26 CLINICAL CHARACTERISTICS AND PATTERNS OF CARE AMONG PATIENTS WITH GENOTYPE 1 (G1) HEPATITIS C VIRUS IN EUROPE (EU)

PG154 G27 PROTON PUMP INHIBITORS IN ITALY: IT'S TIME TO MAKE A (POLICY) CHANGE
Lidonnici D, Lanati EP, 3Pharma Consulting Boutique Sagl, Lugano, Switzerland, 4MA Provider Srl, Milano, Italy

PG155 G28 ASSESSING THE RATIONALITY OF COSTS OF DRUG TREATMENT OF NONALCOHOLIC STEATOHEPATITIS IN THE HOSPITAL OF UKRAINE
Iakovleva L, Tkachova O, Mishchenko O, Gerasymova O, Zavadska I, Lyashenko N, National University of Pharmacy, Kharkiv, Ukraine

PG156 G29 THE BURDEN OF MODERATE-TO-SEVERE IRRETABLE BOWEL SYMROME WITH CONSTIPATION (IBS-C) IN FRANCE: A COMPARISON WITH THE EUROPET RESULTS FROM THE IBIS-C OBSERVATIONAL STUDY
Coffin B, Follet M, Mackinnon J, Bertsch J, Fortea J, Tack J, Louis-Mourier Hospital, Colombes, France, 2Almirall SAS, Paris, France, 3TFS Develop S.L, Barcelona, Spain, 4Almirall S.A, Barcelona, Spain, 5University Hospital Gasthuisberg, Leuven, Belgium

PG157 G30 MEDICAL RESOURSE UTILISATION OF AUSTRALIAN PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C: A RETROSPECTIVE OBSERVATIONAL STUDY
McElroy H, Roberts S, Thompson A, Angus P, McKenna SJ, Warren E, Musgrave S, Covance (Asia) Pte Ltd, Singapore, Singapore, 2The Alfred Hospital, Melbourne, Australia, 3St. Vincent's Hospital Melbourne, Fitzroy, Australia, 4Austin Hospital, Heidelberg, Australia, 5Covance Pty Ltd, North Ryde, Australia, 6HERA Consulting Australia Pty Ltd, Balmain, Australia, 7AbbVie, Mascot, Australia

PG158 G31 HEALTH TECHNOLOGY ASSESSMENT IN CHRONIC HEPATITIS C: ASSESSMENT OF DECISION LANDSCAPE AND MANUFACTURER INPUTS IN SIX AGENCIES
Mazumder D, Kapoor A, Gwatkin N, Medeiros C, Optum Global Solutions, Noida, India, 2Geni Biopharma, Hampshire, UK, 3Optum Life Sciences, Minneapolis, MN, USA

PG159 G32 COMPARISON OF REGULATORY LABELS AND HTA DECISIONS FOR CHRONIC HEPATITIS-C THERAPIES
Banderjee P, Kapoor A, Mazumder D, Gwatkin N, Medeiros C, Optum Global Solutions, Noida, India, 2Geni Biopharma, Hampshire, UK, 3Optum Life Sciences, Minneapolis, MN, USA

PG160 G33 TRENDS IN HEALTH TECHNOLOGY ASSESSMENT DECISIONS ACROSS THE GLOBE: A FOCUS ON HEPATITIS C
Clark RS, Meyer KL, Bramley TJ, Xcenda, Palm Harbor, FL, USA

PG161 H1 BIOLOGICS IN ULCERATIVE COLITIS (UC): TREATMENT GUIDELINES AND HEALTH TECHNOLOGY
ASSESSMENTS (HTA)
Khan S, Zimovetz E, Healey P, Copley-Merriman K, RTI Health Solutions, Research Triangle Park, NC, USA, RTI Health Solutions, Manchester, UK, Pfizer Inc, Groton, CT, USA

PGI62 H2 DOSE ESCALATION AMONG ULCERATIVE COLITIS PATIENTS TREATED WITH ADAJLUMAB IN SWEDEN

PGI63 H3 EFFECTS OF FINANCIAL INCENTIVES FOR SAVING DRUG EXPENDITURES ON PHYSICIAN PRESCRIPTION BEHAVIORS
Park S, Han E, Korea Institute for Health and Social Affairs, Sejong, South Korea, Yonsei University, Incheon, South Korea

MUSCULAR-SKELETAL DISORDERS - Clinical Outcomes Studies

PMS1 H4 THE EFFECT OF POSITIONING THE LOWER EXTREMITIES ON POSTOPERATIVE BLEEDING AFTER TOTAL KNEE REPLACEMENT

PMS2 H5 RHEUMATOID ARTHRITIS AND ISCHEMIC HEART DISEASE IN PATIENTS FROM BLUMENAU - BRAZIL
Nobre M, Gomes R, Heart Institute (InCor) São Paulo University, São Paulo, Brazil, FURB - University of Blumenau, São Paulo, Brazil

PMS3 H6 INCREASED RISK OF OSTEOPOROSIS IN DEPRESSED PATIENTS: A REAL WORLD DATA STUDY CONDUCTED IN ITALY
Heimann F, Moretti R, Pegoraro V, Cataldo N, IMS Health Information Solutions Medical Research S.r.l, Milan, Italy

PMS4 H7 APPLYING WEIGHTED CUMULATIVE EXPOSURE MODELS TO PATTERNS OF NONSPECIFIC SYMPTOM CONSULTATIONS FOR EARLY DIAGNOSIS: A PRIMARY CARE DATABASE STUDY OF KNEE PAIN AND OSTEOARTHRITIS

PMS5 H8 CLINICAL EFFECTIVENESS OF BISPHOSPHONATES FOR PREVENTION OF FRACTURE RISKS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
Sanderson J, University of Sheffield, Sheffield, UK

PMS6 H9 COMPLIANCE WITH ALLOPURINOL AMONG HYPERTENSIVE PATIENTS WITH GOUT DIAGNOSIS AND THE RELATIONSHIP TO ONSET OF END-STAGE RENAL DISEASE
Perreaud S, Nuevo J, Baumgartner S, Morlock R, Université de Montréal, Montreal, QC, Canada, Astrazeneca, Spain, Ardea Biosciences, San Diego, CA, USA

PMS7 H10 REDUCTION IN C-REACTIVE PROTEIN WITH BIOLOGIC DRUGS IN RHEUMATOID ARTHRITIS AND Spondylitis Patients in German Rheumatologist Practices
Gossen N, Kostev K, IMS Health, Frankfurt am Main, Germany

PMS8 H11 CLINICAL EVALUATION OF AMRITADI GUGGULU AND MANDOORA BHASMA IN OSTEOARTHRITIS PATIENTS
Acharya S, Singh R, Nagappa AN, Mateti UV, PG Dept. of Kayachikitsa, Manipal Institute of Ayurveda Medical Sciences, Manipal, India, Dept. of Pharmacy Management, MCOPS, Manipal University, Manipal, India

PMS9 H12 THE EFFECT OF SZIGETVÁR THERMAL WATER ON QUALITY OF LIFE OF PATIENTS WITH RHEUMATIC DISEASES

PMS10 H13 EFFICACY OF SURGICAL VS. NON-SURGICAL TREATMENT OF CARPAL TUNNEL SYNDROME (CTS): A SYSTEMATIC REVIEW
Goyal R, Kaneria J, Rai MK, Singh R, Rana P, Tata Consultancy Services, Mumbai, India

PMS11 H14 USING ACTIVE TECHNIQUES TO HANDLE CHRONIC LOW BACK PAIN CAUSED BY SEVERAL WORK

PMS12 H15 EFFECTIVENESS OF ALLOPURINOL IN ACHIEVING AND SUSTAINING TARGET SERUM URATE: AN ANALYSIS OF A NATIONAL INTEGRATED U.S. HEALTHCARE SYSTEM
Singh Ja, Yang S, UAB SCHOOL OF MEDICINE, Birmingham, AL, USA

PMS13 H16 THE EFFICACY AND SAFETY OF ABATECEPT, ADAJLUMAB, ETANERCEPT AND TOCILIZUMAB ARE COMPARABLE IN POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS

PMS14 H17 A NETWORK METAANALYSIS COMPARING THE EFFICACY OF BIOLOGICS FOR THE TREATMENT OF EARLY RHEUMATOID ARTHRITIS
Bizzi E, Petrella L, Integlia D, Migliore A, San Pietro Fatebenefratelli Hsopital, rome, Italy, Sapienza University,
PMS15 H18 MIXED TREATMENT COMPARISON TO RANK ANTIRESORPTIVE AGENTS IN PREVENTING NEW NON VERTEBRAL FRACTURES IN POSTMENOPAUSAL OSTEOPOROSIS
Massafra U1, Integlia D2, Broccoli S3, Migliore A1, S.Pietro Fatebenefratelli Hospital, Rome, Italy, 2IsHEO, Rome, Italy

PMS16 H19 NEW POSSIBILITY FOR TESTING THE DYNAMIC STABILITY OF THE TRUNK AND LOWER EXTREMITIES
Steinhauz V1, Siö E1, Gombos G1, Bajsz V1, Tóth E2, Sömjén K3, Ács P4, Boncz I5, University of Pécs, Zalaegerszeg, Hungary, 2Budai Physiotherapy Clinic, Budapest, Hungary, 3Elisabet Hospital, Žirc, Hungary, 4University of Pécs, Pécs, Hungary

PMS17 H20 HEALTHCARE PATHWAYS AND BURDEN OF DISEASE OF PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS
Rossi E1, Catadella S1, Calabria S2, Rielli R3, Esposito i4, Martini N5, CINECA Interuniversity Consortium, Casalecchio di Reno, Italy, 2CORE, Collaborative Outcome Research, Bologna, Italy, 3Accademia di Mediina, Roma, Italy

PMS18 H21 CHARACTERIZATION OF OSTEOPOROSIS IN PORTUGAL - TREATMENT PATTERNS AND REASONS FOR UNDER-TREATMENT AND NON-PERSISTENCE WITH PHARMACOLOGICAL TREATMENTS
Rodrigues A1, Laires PA2, Gouveia N1, Eusébio M1, Canhão H1, Branco JC1, Sociedade Portuguesa de Reumatologia, Lisbon, Portugal, 2Merck Sharp & Dohme, Oeiras, Portugal, 3Faculdade de Medicina da Universidade de Lisboa, Lisbon

PMS19 H22 IDENTIFICATION OF OSTEOPOROSIS & CHRONIC INFLAMMATORY RHEUMATIC DISEASE IN FRENCH CLAIMS DATA
Belhassen M1, Levy-Bachelot L2, Laforest L1, Ginoux M1, van Ganse E1, University of Lyon, LYON, France, 2MSD France, COURBEVOIE, France

PMS20 H23 BASELINE CHARACTERISTICS OF RHEUMATOID ARTHRITIS PATIENTS STARTING CERTOLIZUMAB PEGOL THERAPY AND GLUCOCORTICOID PRESCRIPTION IN THE ECLAIR STUDY IN 2012–2013
Saraux A1, Filipo R1, Fagnani F2, Bru I1, Cukierman G2, Joubert J3, Czarlewski W4, Dunkel J5, Massol J6, Combe B7, CHU de la Câvaille-Blanche, Brest Cedex, France, 2Hôpital Roger Salengro, Lille, France, 3Cemka-Eval, Bourg-la-Reine, France, 4UCB Pharma, Colombes, France, 5UCB Pharma, Monheim, Germany, 6CHU de Besançon, Besançon, France, 7Hôpital Lapeyronie, Montpellier, France

PMS21 H24 RISK FACTORS FOR CORONARY ARTERY DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS
Nobre M1, Gomes R2, Heart Institute (InCor) São Paulo University, São Paulo, Brazil, 2FURB - University of Blumenau, São Paulo, Brazil

PMS22 H25 PREVALENCE, COMORBIDITIES AND BURDEN OF SEVERE SPONDYLOARTHRITIS IN FRANCE: ANALYSIS OF A NATIONAL PUBLIC HEALTH INSURANCE DATABASE IN 2012 IN FRANCE
Claudepierre P1, Breban M2, de Chalus T3, Joubert J4, Laurendeau C5, Gourmelen J6, Fagnani F7, CHU Henri Mondor Crétail, Crétail, France, 2CHU Amboise-Paré, Boulogne, France, 3UCB Pharma, Colombes, France, 4Cemka-Eval, Bourg La Reine, France, 5UMS 011 - Inserm - UVSQ, Villejuif, France

PMS23 H26 WINTERTIME SURGERY INCREASES THE RISK OF OSTEONECROSIS AFTER INTERNAL FIXATION OF FEMORAL NECK FRACTURE
Sebestyén A1, Gajdácsi J2, Boncz I3, Molics B4, Péter I5, Laczó A6, Juhász K1, National Health Insurance Fund Administration, Pécs, Hungary, 2National Health Insurance Fund Administration, Budapest, Hungary, 3University of Pécs, Pécs, Hungary, 4University of Pécs, Pécs, Hungary, 5Zsigmondy Vilmos SPA Hospital, Harkány, Hungary, 6National Healthcare Service Center, Pécs, Hungary

PMS24 H27 PREDICTORS OF 10-YEAR MORTALITY AFTER PRIMARY FEMORAL NECK FRACTURE IN ELDERLY PATIENTS
Juhász K1, Gajdácsi J2, Molics B1, Boncz I3, Sebestyén A1, National Health Insurance Fund Administration, Pécs, Hungary, 2National Health Insurance Fund Administration, Budapest, Hungary, 3University of Pécs, Pécs, Hungary, 4University of Pécs, Pécs, Hungary

PMS25 H28 RELATIONSHIP BETWEEN GPX1 PRO198LEU POLYMORPHISM AND SUSCEPTIBILITY OF KASHIN-BECK DISEASE
Xiong YM1, Zou XZ, Chen Q, Du XL, Liu JF, Institute of Endemic Diseases, Xi’an, China

PMS26 H29 THE RESEARCH ON THE INCIDENCE OF KASHIN-BECK DISEASE AND THE SELENIUM LEVEL IN CHILDREN OF XUNYI COUNTY
Chen Q1, Wang ZL2, Xiong YM3, Liu D4, Chen GX1, Key Laboratory of Trace Elements and Endemic Diseases, National Health and Family Planning Commission (Xi’an Jiaotong University), Xi’an, China, 2The fifth hospital of Xi’an, Xi’an, China

PMS27 H30 THE RESEARCH ON THE RELATIONSHIP BETWEEN THE OVARIAN FUNCTION DAMAGE WITH FLUOROSIS AND THE PROTECTIVE EFFECT OF SELENIUM
Chen Q1, Wang ZL2, Xiong YM3, Liu D4, Chen GX1, Key Laboratory of Trace Elements and Endemic Diseases, National Health and Family Planning Commission (Xi’an Jiaotong University), Xi’an, China, 2The fifth hospital of Xi’an, Xi’an, China
THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM
Ferreira CN, Santana CF, Dulcine M, Pfizer, São Paulo, Brazil

PMS29 H32 BUDGET IMPACT ANALYSIS OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS IN GREECE
Tzanetakos C¹, Vassilopoulos D², Kourlaba G³, Christou P³, Maniadakis N¹,¹ National School of Public Health, Athens, Greece, University of Athens Medical School, Hippokration General Hospital, Athens, Greece, ³Collaborative Center for Clinical Epidemiology and Outcomes Research (Cleo), Athens, Greece, ⁴UCB Pharma, Athens, Greece

PMS30 H33 BUDGET IMPACT ANALYSIS OF IMPLEMENTING TENDERS BETWEEN THE BRANDED INFliximab AND ITS BIOSIMILARS IN THE PUBLIC HOSPITALS OF PARIS
Bocquet F¹, Fusier I¹, Cordonnier A¹, Lechat P², Paubel P¹, AP-HP, AGEPS, Paris, France, ²COMEDIMS AP-HP, Paris, France

PMS31 I1 BUDGET IMPACT ANALYSIS OF AN ETANERCEPT BIOSIMILAR FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN EUROPE
Ruff L¹, Rezk MF², Uhlig T³, Gommers JW², Covance Inc., London, UK, ²Biogen International GmbH, Zug, Switzerland, ³Diakonhjemmet Hospital, Oslo, Norway

PMS32 I2 BUDGET IMPACT ANALYSIS OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS IN GREECE
Relakis I¹, Patrikios D², Kourlaba G³, Christou P³, Maniadakis N¹,¹ National School of Public Health, Athens, Greece, ²Metropolitan Hospital, Athens, Greece, ³Collaborative Center for Clinical Epidemiology and Outcomes Research (Cleo), Athens, Greece, ⁴UCB Pharma, Athens, Greece

PMS33 I3 BUDGET IMPACT ANALYSIS OF AN ETANERCEPT BIOSIMILAR FOR THE TREATMENT OF ALL LICENSED ETANERCEPT INDICATIONS FOR ADULTS IN EUROPE
Ruff L¹, Rezk MF², Uhlig T³, Gommers JW², Covance Inc., London, UK, ²Biogen International GmbH, Zug, Switzerland, ³Diakonhjemmet Hospital, Oslo, Norway

PMS34 I4 BUDGET IMPACT ANALYSIS OF TOCILIZUMAB VERSUS ADALIMUMAB AS A FIRST LINE (1L) MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IN GREECE
Argyriou A², Papageorgiou L², Kourlaba G³, Christou P³, Skrumpellas A², Caporis C², Roche Hellas, Athens, Greece, ²Roche (Hellas) S.A., Athens, Greece

PMS35 I5 ECONOMIC EVALUATION OF CHONDROITIN SULFATE AND NON-STEROIDAL ANTIINFLAMMATORY DRUGS FOR THE TREATMENT OF OSTEOARTHRITIS
Rubio-Terrés C, Rubio-Rodríguez D, Health Value, Madrid, Spain

PMS36 I6 EXTENDED-RELEASE OXYCODONE HYDROCHLORIDE (OXYCONTIN®) FOR PAIN MANAGEMENT IN PATIENTS UNDERGOING ARTHROPLASTY: A COST ANALYSIS FROM THE BRAZILIAN PUBLIC AND PRIVATE HEALTHCARE SYSTEMS PERSPECTIVES
Demange M¹, Saggia M², Naves A³, Haas L⁴, Fernandes RA⁵, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Asigma, Sao Paulo, Brazil, ³Mundipharma, São Paulo, Brazil, ⁴Sense Company, Rio de Janeiro, Brazil

PMS37 I7 THE COST BURDEN OF MONOCLONAL ANTIBODY THERAPY IN AN ATHENS GREECE TERTIARY HOSPITAL. A SEVEN YEAR COST COMPARISON ANALYSIS
Papandreuou V, Chatzidimitriou G, Vilacho M, Statopoulos P, Papadopoulou V, Evaggelismos Hospital, Athens, Greece

PMS38 I8 ECONOMIC EVALUATION OF TOCILIZUMAB MONOTHERAPY VS ADALIMUMAB MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN ITALY
Ravera S¹, Baticiotti A², Riva M³, Donati C¹, Sarzi-Puttini P², Roche Spa, Monza, Italy, ¹L. Sacco University Hospital, Milan, Italy, ²San Gerardo dei Tintori Hospital, Monza, Italy

PMS39 I9 ECONOMIC BURDEN OF CONTROLLED GOUT, UNCONTROLLED GOUT, AND GOUT EXACERBATED BY COMMON COMORBIDITIES: RESULTS FROM THE 2012-2013 NATIONAL HEALTH AND WELLNESS SURVEY
Morlock R¹, Flores NM², Annunziata K², Chapnick J³,Nuevo J³, Ardea Biosciences, San Diego, CA, USA, ²Kantar Health, Foster City, CA, USA, ³Kantar Health, Princeton, NJ, USA, ⁴Kantar Health, Horsham, PA, USA, ⁵Astrazeneca, Madrid, Spain

PMS40 I10 EFFECT OF PERSISTENCE OF BIOLOGIC THERAPY ON LONG TERM DIRECT HEALTHCARE COSTS OF PSORIATIC ARTHRITIS IN RUSSIAN PLAQUE PSORIASIS PATIENTS
Lee XY¹, Lelli F², Nuhoho S³, Bobro I³, Janssen-Cilag A/S, Birkerød, Denmark, ²Janssen-Cilag SpA, Cologno Monzese (MI), Italy, ³Janssen-Cilag, Moscow, Russia

PMS41 I11 THE IMPACT OF BIOLOGIC THERAPY VERSUS CONVENTIONAL TREATMENT ON THE COSTS OF ANKYLOSING SPONDYLITIS CHRONIC COMPLICATIONS UNDER THE PERSPECTIVE OF BRAZILIAN PRIVATE HEALTHCARE SYSTEM
Menezes FG¹, Chibana V², Tolentino AC², Reis FH², AbbVie Brazil, São Paulo, Brazil, ²Instituto de Cardiologia Aloysio de Castro, Rio de Janeiro, Brazil, ³AbbVie, São Paulo, Brazil

PMS42 I12 YEARS OF WORKING LIFE LOST CAUSED BY RHEUMATIC DISEASES IN PORTUGAL
Laires PA¹, Gouveia M², Canhão H³, Rodrigues A³, Gouveia N³, Eusébio M³, Branco JC³, Faculdade de Medicina da
PMS43 113 PATIENT CHARACTERISTICS AND DISEASE BURDEN OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AT INCREASED RISK OF FrACTURE IN GERMANY
Hadji P1, Schweikert B2, Ansgorze S3, Toth E4, Krankenhaus Nordwest, Frankfurt am Main, Germany, 2Mapi, Munich, Germany, 3Gesundheitsforen Leipzig GmbH, Munich, Germany, 4UCB Biopharma Sprl., Brussels, Belgium

PMS44 114 COST OF EARLY RETIREMENT CAUSED BY RHEUMATIC DISEASES IN PORTUGAL
Laires PA1, Gouveia M2, Canhão H3, Rodrigues A4, Gouveia N5, Eusébio M6, Branco JC7, 1Faculdade de Medicina da Universidade de Lisboa, Lisbon Academic Medical Center, Lisbon, Portugal, Lisbon, Portugal, 2Católica Lisbon School of Business and Economics, Lisbon, Portugal, 3Sociedade Portuguesa de Reumatologia, Lisbon, Portugal

PMS45 115 HEALTH CARE RESOURCE UTILIZATION AND DIRECT MEDICAL COST FOR PATIENTS WITH OSTEOPOROTIC FRACTURES IN TIANJIN, CHINA
Qu Y, Wu J, Tianjin University, Tianjin, China

PMS46 116 COSTS OF ABSENTEEISM IN ANKYLOSING SPONDYLITIS BASED ON REAL-LIFE DATA FROM POLAND’S SOCIAL INSURANCE INSTITUTION DATABASE IN 2013
Malinowski K, Kawalec P, Jagiellonian University Medical College Institute of Public Health, Krakow, Poland

PMS47 117 THE COST OF REHUMATOID DISEASES IN ITALY: ANALYSIS FROM AN ITALIAN ADMINISTRATIVE DATABASE
Furneri G1, Iannazzo S2, Berti V3, Fregonara Medic i4, Parisi S5, Fusaro E6, 1EBMA Consulting, Melegnano, Italy, 2SIHS Health Economics Consulting, Torino, Italy, 3CSI Piemonte, Torino, Italy, 4Regione Piemonte, Torino, Italy, 5Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy

PMS48 118 BURDEN OF SPINAL DISEASES: RESULTS FROM REGISTRER STUDY IN SWEDEN
Olafsson G1, Jonsson E2, Fritzell P3, Hägg O4, Borgström F5, 1Quantify Research, Stockholm, Sweden, 2Neuro-orthopedic clinic, Futurum Academy, Jönköping, Sweden, 3Spine Center Göteborg, Gothenburg, Sweden

PMS49 119 YEARS OF WORKING LIFE LOST CAUSED BY OSTEOARTHRITIS IN PORTUGAL
Laires PA1, Gouveia M2, Canhão H3, Rodrigues A4, Gouveia N5, Eusébio M6, Branco JC7, 1Faculdade de Medicina da Universidade de Lisboa, Lisbon Academic Medical Center, Lisbon, Portugal, Lisbon, Portugal, 2Católica Lisbon School of Business and Economics, Lisbon, Portugal, 3Sociedade Portuguesa de Reumatologia, Lisbon, Portugal

PMS50 120 PREDICTING THE FUTURE ECONOMIC BURDEN OF HIP FRACTURES IN NORWAY–THE IMPACT OF EPIDEMIOLOGICAL UNCERTAINTY
Hagen G, Norwegian University of Science and Technology, Trondheim, Norway

PMS51 121 THE ASSOCIATION BETWEEN DISEASE ACTIVITY AND INDIRECT COSTS OF ABSENTEEISM AND PRESENTEEISM GENERATED BY PATIENTS WITH ANKYLOSING SPONDYLITIS IN POLISH POPULATION
Kawalec P, Malinowski K, Jagiellonian University Medical College Institute of Public Health, Krakow, Poland

PMS52 122 EXPECTED LIFETIME NUMBERS, RISKS, AND BURDEN OF FRACTURES FOR 50-YEAR OLD CHINESE WOMEN
Jiang Y, Ni W, University of Southern California, Los Angeles, CA, USA

PMS53 123 EPIDEMIOLOGIC AND ECONOMIC BURDEN ATTRIBUTABLE TO FIRST SPINAL FUSION SURGERY: ANALYSIS FROM AN ADMINISTRATIVE DATABASE
Cozzolino P1, Cortesi PA2, Assietti R3, Cuzzocrea F4, Prestamburgo D5, Pluder M6, Mantovani LG7, Cesana G8, 1University of Milano-Bicocca, Monza, Italy, 2Ospedale Fatebenefratelli e Oftalmico, Milan, Italy, 3Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia, Italy, 4Civile Regional Hospital, Legnano, Italy, 5Fondazione I.R.C.C.S. “Ca’ Granda” Ospedale Maggiore Policlinico, Milan, Italy

PMS54 124 PERSISTENCE AND ECONOMIC IMPACT OF ETANERCEPT AND ADALIMUMAB DOSE REDUCTION IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHROPATHY AND ANKYLOSING SPONDYLITIS PATIENTS WITH AT LEAST 1 YEAR IN CLINICAL REMISSION: EXPERIENCE FROM 2 SPANISH TEACHING HOSPITALS DURING 5 YEARS OF FOLLOW-UP
J B1, Anton R2, Navarro Ruiz A3, Castera M4, Rd R5, A M6, 1Hospital de Sagunto, Sagunto, Spain, 2Hospital de Elx, Elx, Spain

PMS55 125 HOW PRICING AND REIMBURSEMENT POLICIES AFFECT THE BUDGET IMPACT OF THE TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS IN TURKEY
Tatar M1, Tuna E2, Oguzhan G3, Senturk A4, Sozeri B5, Aktya Ayaz N6, Turgay S7, Turanli M8, Makay B9, Demirkaya E10, Unsal E11, Kasapc观音 O12, Ozen S13, 1Hacettepe University, Ankara, Turkey, 2Polar Health Economics and Policy Consultancy, Ankara, Turkey, 319 Mayis University, Samsun, Turkey, 4Erciyes University Faculty of Medicine, Kayseri, Turkey, 5Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey, 6Novartis Pharma, Istanbul, Turkey, 7Dokuz Eylul University Hospital, Izmir, Turkey, 8Gülhane Military Medical Academy, Ankara, Turkey, 9Cerrahpaşa Medical Faculty, Istanbul University, Istanbul, Turkey

PMS56 126 A PILOT STUDY OF DIRECT COSTS FOR PATIENTS WITH RHEUMATOID ARTHRITIS IN BULGARIA
Marinov L1, Kamusheva B2, Mitov K3, Nikolova I4, Petrova G5, 1Medical University, Faculty of Pharmacy-Sofia, Sofia, Bulgaria, 2Medical University - Sofia, Sofia, Bulgaria

PMS57 127 COST-EFFECTIVENESS OF ABATEACETE COMPARED TO ADALIMUMAB IN ITALY BASED ON A HEAD-TO-HEAD OUTCOMES STUDY IN RHEUMATOID ARTHRITIS
Gaultney J1, Nappi C2, Benucci M3, Iannazzo S4, Sion K5, Alemao E6, Sabater J7, 1Mapi Group, Houten, The Netherlands, 2Bergamo University, Bergamo, Italy, 3University of Milano-Bicocca, Monza, Italy, 4Mapi Group, Barcelona, Spain
Netherlands, 9Bristol Myers Squibb S.r.l., Roma, Italy, 10Rheumatology Unit Hospital, Florence, Italy, 4SIHS Health Economics Consulting, Torino, Italy, 5Bristol-Myers Squibb, Princeton, NJ, USA, 6Bristol-Myers Squibb, Madrid, Spain

PMS59  I28  HEALTHCARE COSTS IN PSORIATIC ARTHRITIS PATIENTS NEWLY INITIATED ON APREMILAST OR BIOLOGIC THERAPIES
Kuznik A, Clancy Z, Celgene Corporation, Warren, NJ, USA

PMS60  I29  COST-UTILITY OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF AXIAL SPONDYLOARTHRITIS IN GREECE
Relakias I1, Patrikos D2, Kourtla G3, Christou P4, Maniadakis N5, 1National School of Public Health, Athens, Greece, 2Metropolitan Hospital, Athens, Greece, 3Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), Athens, Greece, 4UBC Pharma, Athens, Greece

PMS61  I30  THE USE OF REAL WORLD DATA TO BUILD ECONOMIC MODELS: A CASE STUDY OF OSTEOPOROSIS
Valentina Orlando V1, Silvia Coretti S2, Francesca Guerrero F3, Maria Claudia Punzo M4, Denise Fiorentino D5, Matteo Ruggeri M5, Enrica Menditto E1, 1University of Naples Federico II, Naples, Italy, 2Università Cattolica del Sacro Cuore, Rome, Italy

PMS62  I31  COST-EFFECTIVENESS OF APREMILAST IN PSORIATIC ARTHRITIS IN SCOTLAND

PMS63  I32  A REVIEW OF COST EFFECTIVENESS STUDIES OF RHEUMATOID ARTHRITIS (RA) INTERVENTIONS IN THE UK AND US
Ryder S1, Armstrong N2, Arjuni R3, Peterson S4, Riemsma R5, Ganguly R5, Alfonso R7, Kleijnen Systematic Reviews Ltd, York, UK, 1Kleijnen Systematic Reviews Ltd., York, UK, 2GSK, King of Prussia, PA, USA, 3Janssen, Horsham, PA, USA, 4GlaxoSmithKline, King of Prussia, PA, USA

PMS64  I33  COST-UTILITY ANALYSIS OF APREMILAST FOR THE TREATMENT OF PSORIATIC ARTHRITIS PATIENTS IN SPAIN
Gonzalez CM1, Almodóvar R2, Caloto T3, Echave M4, Elias I5, Tencer T6, Department of Rheumatology, Gregorio Marañón University Hospital, Madrid, Spain, 1Department of Rheumatology, Fundación de Alcorcón University Hospital, Madrid, Spain, 2Department of Health Economics, Celgene Corporation, Madrid, Spain, 3Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain, 4Celgene Corporation, Warren, NJ, USA

PMS65  I34  COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF AXIAL SPONDYLOARTHRITIS IN TURKEY
Caglayan B1, Firidin A2, Yildirim N3, Tatar M4, Essiz M5, 1UCB Pharma, Istanbul, Turkey, 2Polar Health Economics and Policy Consulting, Ankara, Turkey, 3Freelancer, Istanbul, Turkey

PMS66  I35  PHARMACOECONOMIC ANALYSIS OF DIFFERENT STRATEGIES OF MONOTHERAPY WITH BIOLOGIC THERAPIES IN RUSSIAN PATIENTS WITH RHEUMATOID ARTHRITIS
Ryazhnenov VV1, Gorokhova SG2, 1M. Sechenov First Moscow State Medical University, Moscow, Russia, 2Research Clinical Center of JSC Russian Railways, Moscow, Russia

PMS67  I36  BUDGET IMPACT ANALYSIS OF APREMILAST IN PATIENTS WITH PSORIATIC ARTHRITIS IN THE ITALIAN SETTING
Capri S1, Barbieri M2, Oskar B3, 1School of Economics and Management Cattaneo - LIUC University, Castellanza, Italy, 2Centre for Health Economics, University of York, York, UK, 3Celgene Corporation, Milan, Italy

PMS68  I37  BIOLOGICAL AGENTS FOR PATIENTS WITH RHEUMATOID ARTHRITIS WHO HAD FAILED TREATMENT WITH METHOTREXATE IN THE SPANISH CLINICAL SETTING: A COST-EFFECTIVENESS ANALYSIS
Sánchez R1, Restovic G2, Planellas L3, AbbVie, Madrid, Spain, 1IMS Health, Barcelona, Spain

PMS69  I38  BUDGET IMPACT ANALYSIS OF APREMILAST IN PATIENTS WITH PSORIATIC ARTHRITIS IN SPAIN
Almodóvar R1, Gonzalez CM2, Caloto T3, Elias I4, Oyagüez I5, Tencer T6, 1Department of Rheumatology, Fundación de Alcorcón University Hospital, Madrid, Spain, 2Department of Rheumatology, Gregorio Marañón University Hospital, Madrid, Spain, 3Department of Health Economics, Celgene Corporation, Madrid, Spain, 4Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain, 5Celgene Corporation, Warren, NJ, USA

PMS70  I39  COST-UTILITY ANALYSIS OF APREMILAST FOR THE TREATMENT OF PSORIATIC ARTHRITIS IN THE ITALIAN SETTING
Capri S1, Barbieri M2, Oskar B3, 1School of Economics and Management Cattaneo - LIUC University, Castellanza, Italy, 2Centre for Health Economics, University of York, York, UK, 3Celgene Corporation, Milan, Italy

PMS71  I40  COST-EFFECTIVENESS OF ZOLEDRONIC ACID VERSUS ALENDRONIC ACID IN THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL EGYPTIAN PATIENTS: DECISION ANALYSIS
Elmansy H1, Metry AB2, Eldessouki R3, Elsisi G4, 1Canadian international college, Cairo, Egypt, 2Accsight, Cairo, Egypt, 3Elfayom university, Cairo, Egypt, 4Central administration for pharmaceutical affairs, Cairo, Egypt

PMS72  I41  COST-EFFECTIVENESS ANALYSIS OF CANACINUMAB IN THE TREATMENT OF PATIENTS SUFFERING FROM SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS IN RUSSIAN FEDERATION
Yagudina R, Kulikov A, Poçuprina A.I.M. Sechenov First Moscow State Medical University, Moscow, Russia

PMS73  I42  ASSESSMENT OF TOFACITINIB FOR RHEUMATOID ARTHRITIS FROM THE PERSPECTIVE OF THE BRAZILIAN HEALTHCARE SYSTEM
**PMS74 J10** COST-UTILITY ANALYSIS OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS IN GREECE

Tzanetakis C1, Vassiliopoulos D2, Kouralba G3, Christou P4, Maniadakis N5, 1National School of Public Health, Athens, Greece, 2University of Athens Medical School, Hippokration General Hospital, Athens, Greece, 3Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), Athens, Greece, 4UCB Pharma, Athens, Greece

**PMS75 J11** Telerhabilitation after total knee replacement: Preliminary cost-effectiveness analysis of an innovative device

Fusco F1, Turchetti G2, 1Scuola Superiore Sant’Anna, Pisa, Italy, 2Scuola Superiore Sant’Anna, Pisa, Italy

**PMS76 J12** Economic evaluation of tocilizumab combination in the treatment of the patients with dmARD-IR rheumatoid arthritis in china

Chen W1, Xu X2, 1Fudan University, Shanghai, China, 2Shanghai Roche Pharmaceuticals Ltd., Shanghai, China

**PMS77 J13** THE EFFECTIVENESS AND COST-EFFECTIVENESS OF HYLAN G-F 20 IN OSTEOSTHRITIS OF THE KNEE

Kostyuk A1, Almadiyeva A2, Akanov A3, 1Kazakh Medical University for Continuing Education, Astana, Kazakhstan, 2Asta Medical University, Astana, Kazakhstan

**PMS78 J14** Relationship between pain, functional disability and health-related quality of life in patient with failed back surgery syndrome undergoing spinal cord stimulation: results from the precise study

Scalone L1, Zucco F2, Ciampichini R3, Lavano A4, Costantini A5, De Rose M6, Poli P7, Fortini G8, Demartini L9, De Simone E10, Menardo V11, Meglio M12, Mantovani LG13, 1University of Helsinki, Helsinki, Finland, 2Jyväskylä Central Hospital, Jyväskylä, Finland, 3South Karelia Medical Center, Joensuu JT14, 4Blom M15, 1University of Helsinki, Helsinki, Finland, 2Jyväskylä Central Hospital, Jyväskylä, Finland, 3South Karelia Central Hospital, Lappeenranta, Finland, 4Helsinki University Central Hospital, Helsinki, Finland, 5Tampere University Hospital, Tampere, Finland, 6Kainuu Central Hospital, Kajaani, Finland, 7Kanta-Häme Central Hospital, Hämeenlinna, Finland

**PMS79 J15** Controlling the cost spent on expensive biologic agents: An example of net monetary savings by dose optimisation of tumor necrosis factor inhibitors in rheumatoid arthritis patients

Kievit W1, van Herwaarden N2, van de Hoogen F3, Bijlma H4, van der Bent B5, van der Maas A6, den Broeder A7, Radboudumc, Nijmegen, The Netherlands, 2Sint Maartenskliniek, Nijmegen, The Netherlands, 3University of Stud Magna Grecia, Germaneto, Italy, 4Ospedale di Circolo e Fondazione Macchi di Varese, Varese, Italy, 5Istituto Scientifico di Pavia, Pavia, Italy, 6A.O.R.N. S.G. Moscati, Avelillo, Italy, 7Ospedale di Circolo e Fondazione Macchi di Varese, Varese, Italy, 8AO Ospedale di Circolo e Fondazione Macchi di Varese, Varese, Italy, 9University of Milano - Bicocca, Monza, Italy, 10Ospedale di Circolo e Fondazione Macchi di Varese, Varese, Italy

**PMS80 J16** Economic analysis of ustekinumab for psoriatic arthritis in russia

Einarson TR1, Bereza BG2, Bobro i2, Efremova E2, Lelli F3, 1University of Toronto, Toronto, ON, Canada, 2Janssen-Cilag, Moscow, Russia, 3Janssen-Cilag SpA, Cologna Monzese (MI), Italy

**PMS81 J17** Tocilizumab in methotrexate-naïve rheumatoid arthritis – a cost-utility model for slovakia

Chang S1, Sawyer L2, Dejonckheere F3, Grichova L4, Diamantopoulos A1, 1Symmetron Limited, Elstree, UK, 2F Hoffmann-La Roche Ltd, Basel, Switzerland, 3Roche Slovensko, s.r.o., Bratislava, Slovak Republic

**PMS82 J18** COST-EFFECTIVENESS OF PROTON PUMP INHIBITOR INITIATION AIMED TO PREVENT UPPER GASTROINTESTINAL TOXICITY IN PATIENTS USING LOW-DOSE ACETYLSALICYLIC ACID

Sluiter R1, Chau SH2, Kievit W1, Tuompo R3, van Herwaarden N4, Bijlsma H5, 1University of Helsinki, Helsinki, Finland, 2Jyväskylä Central Hospital, Jyväskylä, Finland, 3South Karelia Central Hospital, Lappeenranta, Finland, 4Helsinki University Central Hospital, Helsinki, Finland, 5Tampere University Hospital, Tampere, Finland, 6Kainuu Central Hospital, Kajaani, Finland, 7Kanta-Häme Central Hospital, Hämeenlinna, Finland

**PMS83 J19** COST-EFFECTIVENESS OF BIOLOGICS COMPARED TO CONVENTIONAL DISEASE-MODIFYING ANTIHUMATIC DRUGS FOR TREATMENT OF RHEUMATOID ARTHRITIS IN FINLAND

Joensuu JT1, Aaltonen KJ2, Aronen P3, Sokka T4, Puolakka K5, Tuompo R6, Korpela M7, Vasala M8, Ilva K9, Nordström D10, Blom M11, 1University of Helsinki, Helsinki, Finland, 2Jyväskylä Central Hospital, Jyväskylä, Finland, 3South Karelia Central Hospital, Lappeenranta, Finland, 4Helsinki University Central Hospital, Helsinki, Finland, 5Tampere University Hospital, Tampere, Finland, 6Kainuu Central Hospital, Kajaani, Finland, 7Kanta-Häme Central Hospital, Hämeenlinna, Finland

**PMS84 J20** COMPARATIVE EFFECTIVENESS AND COST-EFFECTIVENESS OF GENERIC ALENDRONATE, RISENDRONATE, DENOSUMAB AND ZOLENDRONIC ACID FOR SECONDARY PREVENTION OF FRAILTY FRACTURES - PERLIMINAY RESULTS

Hagen G1, Norwegian University of Science and Technology, Trondheim, Norway

**PMS85 J21** Telerhabilitation After Total Knee Replacement: Preliminary Cost-Utility Analysis of an Innovative Device

Fusco F1, Turchetti G2, 1Scuola Superiore Sant’Anna, Pisa, Italy, 2Scuola Superiore Sant’Anna, Pisa, Italy

**PMS86 J22** Cost-Utility Analysis of Potential Campylobacter Control Measures in the Food Chain of Indoor Broiler Chicken in the EU

Pitter JG1, Vokó Z2, Halmos A3, Józwiak A4, 1Syreon Research Institute, Budapest, Hungary, 2Eötvös Lóránd University, Faculty of Social Sciences, Budapest, Hungary, 3National Food Chain Safety Office, Budapest, Hungary
MUSCULAR-SKELETAL DISORDERS - Patient-Reported Outcomes & Patient Preference Studies

**PMS87** J23 THE IMPACT OF SPA THERAPY ON AMBULATORY HEALTH CARE EXPENSES OF OSTEOARTHRITIC PATIENTS: THE PRELIMINARY RESULTS OF ECOTHERM STUDY

**PMS88** J24 PRODUCTIVITY LOSS DUE TO LOW BACK PAIN: RESULTS FROM SWEDISH REGISTERS

**PMS89** J25 THE IMPACT OF ANTI-TNF (ETANERCEPT) THERAPY ON WORK PRODUCTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND PSORIASIS IN THE CZECH REPUBLIC
Mlcoh T, Jirickova J, Mandelikova M, Kruntoradova K, Dolezal T, Value Outcomes, Prague, Czech Republic

**PMS90** J26 DISPENSING FREQUENCY AMONG PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH RITUXIMAB IN ENGLAND
Tsoumani E, McCann E, Tham R, Yu E, MSD, Hoddesdon, UK, IMS Health, London, UK
PMS103 K6 PATIENTS’ PREFERENCES FOR RHEUMATOID ARTHRITIS TREATMENTS AND THEIR PARTICIPATION IN THE DECISION-MAKING PROCESS. A SYSTEMATIC REVIEW OF THE LITERATURE

Dilla T1, Rentero ML1, Comellas M1, Lizar L1, Sacristán JA1, Lilly, Alcobendas (Madrid), Spain, “Outcomes 10, Castellon, Spain

PMS104 K7 FACTORS ASSOCIATED WITH INADEQUATE PAIN RELIEF IN PATIENTS WITH PRIMARY KNEE OSTEOARTHRITIS IN PORTUGAL: AN ANALYSIS FROM THE SURVEY OF OSTEOARTHRITIS REAL WORLD THERAPIES (SORT)

Laires PA1, Lains J2, Miranda LC3, Cernadas R4, Veloso L5, Rajagopalan S6, Taylor S1, Silva JC7,1 Merck Sharp & Dohme, Oeiras, Portugal, 2Centro de Medicina e Reabilitação da Região Centro, Coimbra, Portugal, 3Instituto Português de Reumatologia, Lisbon, Portugal, 4ARS Norte, Oporto, Portugal, 5Eurotrials, Scientific Consultants, Lisbon, Portugal, 6Med Data Analytics, Inc., East Brunswick, NJ, USA, 1Merck Co., Rahway, NJ, USA, 8Garcia de Orta Hospital, Almada, Portugal

PMS105 K8 PATIENT REPORTED OUTCOME IN HEALTH SERVICES RESEARCH: A PROSPECTIVE STUDY OF ORTHOPEDIC SURGERY IN ROUTINE CARE IN SWITZERLAND

Eichler K1, Hess S1, Twerenbold C1, Grobet C2, Flury M3, Wieser S1, Audigé L1, Winterthur Institute of Health Economics, Zurich University of Applied Sciences, Winterthur, Switzerland, 2Schulthess Clinic, Zurich, Switzerland

PMS106 K9 VALIDATION OF THE ENGLISH VERSION OF THE FORGOTTEN JOINT SCORE - 12 IN PATIENTS UNDERGOING TOTAL KNEE OR HIP ARTHROPLASTY

Giesinger JM1, Loth FL1, Howie C2, Giesinger K2, Hamilton DF2, Medical University of Innsbruck, Innsbruck, Austria, 1University of Edinburgh, Edinburgh, UK, 2Kantonsspital Sankt Gallen, Sankt Gallen, Switzerland

PMS107 K10 PATIENT-REPORTED OUTCOMES IN STUDIES PUBLISHED IN 2014: WHICH TOOLS HAVE BEEN MOST COMMONLY USED IN STUDIES OF MUSCULOSKELETAL DISORDERS?

Martin A, Crystallise Ltd., London, UK

PMS108 K11 PRO CLAIMS IN FIBROMYALGIA: A REVIEW OF THE LABELS OF PRODUCTS APPROVED BY THE FDA AND THE EMA

Acquadro C1, Perret C1, Regnault A2, 1Mapi Research Trust, Lyon, France, 2Mapi, Lyon, France

PMS109 K12 UNDERSTANDING THE RELATIONSHIP BETWEEN HEALTH ASSESSMENT QUESTIONNAIRE-DISABILITY INDEX (HAQ-DI), PSORIASIS AREA SEVERITY INDEX (PASI), AND QUALITY OF LIFE (QOL) AND ITS INFLUENCE ON COST-EFFECTIVENESS IN PSORIATIC ARTHRITIS (PSA)

Gunda P1, Syeda SS1, Jugl SM2, Novartis Healthcare Pvt. Ltd., Hyderabad, India, 1Novartis Pharma AG, Basel, Switzerland

PMS110 K13 THE ASSOCIATION BETWEEN DISEASE ACTIVITY AND QUALITY OF LIFE AMONG PATIENTS WITH ANKYLOSING SPONDYLITIS IN POLISH POPULATION

Malinowski K, Kawalec P, Jagiellionian University Medical Collage Institute of Public Health, Krakow, Poland

PMS111 K14 AVOIDABLE BURDEN AND UNMET NEED ASSOCIATED WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS TREATMENT: A CROSS-SECTIONAL EUROPEAN STUDY IN THE REAL WORLD SETTING

Holbrook T1, Wood R2, Black C2, Hu X2, Kachroo S2, 1Adelphi Real World, Macclesfield, UK, 2Merck & Co. Inc, Rahway, NJ, USA

PMS112 K15 BURDEN OF RESIDUAL SKIN AND JOINT DISEASE IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH BIOLOGICS

Wood R1, Mutebi A2, Sawant RV3, Piercy J1, Harrison DJ1, 1Adelphi Real World, Macclesfield, UK, 2Amgen, Thousand Oaks, CA, CA, USA, 3University of Houston, Houston, TX, USA, 4Adelphi Real World, Bollington, UK, 5Amgen Inc., Thousand Oaks, CA, USA

PMS113 K16 ESTIMATING THE MONETARY VALUE OF RELIEF OF TENNIS ELBOW: A CONTINGENT VALUATION STUDY OF WILLINGNESS-TO-PAY

Pereira MJ1, Coombes BK1, Bisset LM2, Vicenzino B1, Connelly L1, 1University of Queensland, Brisbane, Australia, 2Griffith University, Gold Coast, Australia

PMS114 K17 CLINICAL RESPONSES IN JOINT AND SKIN OUTCOMES AND PATIENT-REPORTED OUTCOMES ARE ASSOCIATED WITH INCREASED PRODUCTIVITY IN THE WORKPLACE AND AT HOME IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH CERTOLIZUMAB PEGOL

Kavanaugh A1, Gladman D1, van der Heijde D1, Purcaro O1, Mease PJ1, 1University of California, San Diego School of Medicine, La Jolla, CA, USA, 2University of Toronto, Toronto, ON, Canada, 3Leiden University Medical Center, Leiden, The Netherlands, 4UCB Pharma, Brussels, Belgium, 5Swedish Medical Center and University of Washington, Seattle, WA, USA

PMS115 K18 CLINICAL RESPONSES AND IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES ARE ASSOCIATED WITH INCREASED PRODUCTIVITY IN THE WORKPLACE AND AT HOME IN AXIAL SPONDYLOARTHRITIS PATIENTS TREATED WITH CERTOLIZUMAB PEGOL

van der Heijde D1, Braun J2, Rudwaleit M2, Purcaro O2, Kavanaugh A2, 1Leiden University Medical Center, Leiden, The Netherlands, 2University Medical Center Hamburg-Eppendorf, Hamburg, Germany
### MUSCULAR-SKELETAL DISORDERS - Health Care Use & Policy Studies

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>PMS116 K19</td>
<td>Elderly Osteoporosis Suspects Without Diagnosis – Interim Data From a German Geriatric Practice</td>
<td>Schmidt T1, Brumme UM1, Kemerle S2, Zimmer K2, Amgen Gmbh, Munich, Germany, Leipzig, Germany</td>
<td>University of California, San Diego School of Medicine, La Jolla, CA, USA</td>
</tr>
<tr>
<td>PMS117 K20</td>
<td>Persistence to Therapy and the Associated Risk of Fractures with Antiosteoporotic Drugs</td>
<td>Valentina Orlando V1, Francesca Guerriero F1, Valeria Marina Monetti V2, Maria Claudia Punzo M1, Francesca Gimigliano F2, Giovanni Iolascon G2, Enrica Menditto E1, University of Naples Federico II, Naples, Italy, AORN Cardarelli, Naples, Italy, Second University of Naples, Naples, Italy</td>
<td></td>
</tr>
<tr>
<td>PMS118 K21</td>
<td>Access to Biologics for Rheumatoid Arthritis in the Public Sector of a Latam Country</td>
<td>Najun Dubos L1, Renati L2, Roche Argentina, Buenos Aires, Argentina, FASTA Mar Del Plata University, Mar Del Plata, Argentina</td>
<td></td>
</tr>
<tr>
<td>PMS119 K22</td>
<td>Access to Biological Therapies and Consumption Trends in Bosnia and Herzegovina</td>
<td>Catic T1, ISPOR Bosnia and Herzegovina Chapter, Sarajevo, Bosnia</td>
<td></td>
</tr>
<tr>
<td>PMS120 K23</td>
<td>An Assessment of the Impact of Biosimilars on Access to Biologics Based on Primary Research, System Dynamics Modelling, and War Gaming</td>
<td>Teale CW, Morrison S, Glover J, Charafi N, Rose J, GKF NOP Ltd, Melton Mowbray, UK</td>
<td></td>
</tr>
<tr>
<td>PMS121 K24</td>
<td>Adherence and Persistence to Allopurinol Among Hypertensive Patients with Gout</td>
<td>Perreault S1, Nuevo J2, Baumgartner S3, Morlock R1, Université de Montréal, Montreal, QC, Canada, Astrazeneca, Madrid, Spain, Ardea Biosciences, San Diego, CA, USA</td>
<td></td>
</tr>
<tr>
<td>PMS122 K25</td>
<td>Age-Rationing - Reality or Virtue? A Study in Autoimmune Disease</td>
<td>Schmidt J1, Larisch K, Gesundheitsforen Leipzig, München, Germany</td>
<td></td>
</tr>
<tr>
<td>PMS123 K26</td>
<td>Gender Differences in Medication Taking Behaviour: A Case of Osteoporosis</td>
<td>Valentina Orlando V1, Francesca Guerriero F1, Valeria Marina Monetti V2, Denise Fiorentino D1, Francesca Gimigliano F2, Giovanni Iolascon G2, Enrica Menditto E1, University of Naples Federico II, Naples, Italy, AORN Cardarelli, Naples, Italy, Second University of Naples, Naples, Italy</td>
<td></td>
</tr>
<tr>
<td>PMS124 K27</td>
<td>Number of Osteoporosis Patients with Pathological Fractures by Gender in Outpatient Care in the Light of Physiotherapy Care in Hungary</td>
<td>Molics B1, Endrei D1, Rátgéber L2, Gyrö M1, Sebestyén A2, Juhász R1, Elmer D1, Boncz I1, Péter I1, Juhász K2, Járomi M1, University of Pécs, Pécs, Hungary, Ratgeber Academia, Pécs, Hungary, National Health Insurance Fund Administration, Pécs, Hungary, Zsigmondy Vílmos SPA Hospital, Harkány, Hungary</td>
<td></td>
</tr>
<tr>
<td>PMS125 K28</td>
<td>Number of Osteoporosis Patients with Pathological Fractures by Months in Outpatient Care in the Light of Physiotherapy Care in Hungary</td>
<td>Járomi M1, Rátgéber L2, Endrei D1, Juhász K2, Hanzel A1, Gyrö M1, Juhász R1, Péter I1, Boncz I1, Molics B1, University of Pécs, Pécs, Hungary, Ratgeber Academia, Pécs, Hungary, National Health Insurance Fund Administration, Pécs, Hungary, Zsigmondy Vílmos SPA Hospital, Harkány, Hungary</td>
<td></td>
</tr>
<tr>
<td>PMS127 K30</td>
<td>Reliability of Manufacturers’ Budget Impact Estimates for Severe Rheumatoid Arthritis Drugs in Poland</td>
<td>Zawodnik S1, Tatara T1, Iwanczuk T1, Sliwczynski A2, Brzozowska M2, Agency for Health Technology Assessment and Tariff System in Poland (AOTMiT), Warsaw, Poland, Medical University of Lodz, Lodz, Poland</td>
<td></td>
</tr>
<tr>
<td>PMS128 K31</td>
<td>Prevention of Fragility Fractures in Osteoporotic Patients: Can the Secondary Therapy Help Contain Costs for Admissions? A Retrospective, Observational Case Control Study Based on ASL Pavia’s Administrative Databases</td>
<td>Ronco GL1, Mirosa D2, Silvia V2, Carlo C2, Emmonos S.A., Fenegro1, Italy, A.S.L. Pavia, Pavia, Italy</td>
<td></td>
</tr>
<tr>
<td>PMS129 K32</td>
<td>Join Progress a Efficiency Partnership Program on Knee Joint Replacement</td>
<td>Espallardo O1, Garcia R2, Torner P2, Diaz C2, Collilles C2, Caballeria C2, Simo I2, Auge A2, Bel X2, Solá M2, Rincon J2, Gomez R2, Lechuga F2, Zamora F2, Olivares M2, Garcia G2, Diaz C2, Hernando P2, Solá J2, Fernandez I2, Vega M1, Martinez V1, Johnson &amp; Johnson Medical, Madrid, Spain, H. Parc Taulí, Barcelona, Spain, H. Parc Taulí, Barcelonaq, Spain</td>
<td></td>
</tr>
<tr>
<td>PMS130 K33</td>
<td>Establishing the Value of Emerging Biosimilars</td>
<td>Bolger T1, Anwar S1, Lin A1, Sasikumar D2, Ethchberger J1, Venugopal A2, Smart A2, Cassese M2, Navigant Consulting Inc., London, UK, Navigant Consulting Inc., NY, NY, USA</td>
<td></td>
</tr>
<tr>
<td>PMS131 L1</td>
<td>Strategies Based on Evidence- To Rationalize the High Cost Drugs National List in the Dominican Republic</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
GRAND-4: THE GERMAN RETROSPECTIVE ANALYSIS ON PERSISTENCE IN WOMEN WITH OSTEOPOROSIS TREATED WITH BISPHOSPHONATES OR DENOSUMAB

Hadjii P1, Kyverntakis J2, Kann P3, Niedhart C4, Hofbauer L5, Schwarz H6, Kurth AA7, Thomasius F8, Schulte M9, Intorcia M10, Psachoulla E11, Schmid T12, Krankenhaus Nordwest, Frankfurt am Main, Germany, 2Dpt. of Obstetrics and Gynecology, Philipps-University of Marburg, Germany, Marburg, Germany, 3Dpt. of Gastroenterology, Endocrinology and Metabolism, Philipps-University of Marburg, Marburg, Germany, 4Orthopedic Practice, Heinsberg, Germany, 5University Hospital, Dresden, Germany, 6Orthopedic Practice, reudenstadt, Germany, 7THEMISTOCLES GLUCK Hospital GmbH, Ratingen, Germany, 8Orthopedic Practice, Bad Homburg, Germany, 9Amgen GmbH, Munich, Germany, 10Amgen (Europe) GmbH, Zug, Switzerland

SELF-REPORTED RHEUMATIC DISEASES AND EARLY RETIREMENT IN PORTUGAL

Laires PA1, Gouveia M1, Canhão H2, Rodrigues A3, Gouveia N4, Eusébio M5, Branco JC6, 1Faculdade de Medicina da Universidade de Lisboa, Lisbon Academic Medical Center, Lisbon, Portugal, Lisbon, Portugal, 2Católica Lisbon School of Business and Economics, Lisbon, Portugal, 3Sociedade Portuguesa de Reumatologia, Lisbon, Portugal

CHARACTERISTICS OF PATIENTS STARTING BIOLOGIC TREATMENTS FOR RHEUMATOID ARTHRITIS IN THE REAL WORLD: SYSTEMATIC REVIEW

Kilcher G1, Didden E, Hummel N, Egger M, University of Bern, Bern, Switzerland

EFFECTIVENESS OF A REFERRAL PROGRAM FOR EARLY ARTHRITIS DIAGNOSIS AT PRIMARY CARE CENTERS IN PORTUGAL - PRELIMINARY RESULTS FROM THE SIARA STUDY

Laires PA1, Dezorto R2, Mesquita R3, Fonseca JE4, Ceradins R5, Miranda LC6, Silva JC7, Costa L8, Nogueira AM9, Merck Sharp & Dohme, Oeiras, Portugal, 1Centro Hospitalar Lisboa Norte, EPE - Hospital Santa Maria, Lisbon, Portugal, 2ARS Norte, Oporto, Portugal, 3Instituto Português de Reumatologia, Lisbon, Portugal, 4Garcia de Orta Hospital, Almada, Portugal, 5Hospital São João (Centro Hospitalar de São João, EPE), Oporto, Portugal

A WEB-BASED SURVEY TO INVESTIGATE THE EXTENT OF AWARENESS AND UNDERSTANDING FOR BIOSIMILAR AMONG JAPANESE PHYSICIANS AND PHARMACISTS

Tanabe K1, Sugimoto N, Fujimoto Y, Pfizer Japan Inc, Tokyo, Japan

ASSESSMENT OF RISK SHARING AGREEMENTS (RSAS) IN SELECT GLOBAL MARKETS WITH SPECIFIC FOCUS ON ACTIVITIES SURROUNDING IMMUNOMODULATORS

Napięcik D1, Shah S, Ramesh V, Market Access Solutions LLC, Raritan, NJ, USA

ASSOCIATION OF ADVERSE EVENTS AND HEALTH SERVICE USAGE WITH TAPENadol PROLONGED-RELEASE TREATMENT COMPARED WITH MORPHINE CONTROLLED-RELEASE (CR) AND OXYCODONE CR: A UK PRIMARY CARE OBSERVATIONAL STUDY

Baxter G1, Morgan CL2, Jenkins-Jones S3, Currie CJ4, Schultewolter D5, Grüenthal, Stokenchurch, UK, 2Pharmatelligence, Cardiff, UK

CLINICAL AND ECONOMIC BURDEN OF PULMONARY EXCERBATIONS IN PATIENTS WITH CYSTIC FIBROSIS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION

O’Sullivan AK1, Signorovitch JE2, Fang A3, Wagener J4, Hodgkins P5, ‘Vertex Pharmaceuticals, Boston, MA, USA, 2Analysis Group, Inc., Boston, MA, USA, 3University of Colorado, Aurora, CO, USA

EFFICACY OF THE MICA ANTIBODY FOR TRANSPLANT PATIENTS

MO J, National Evidence-based Healthcare Collaborating Agency, SEOUL, South Korea

A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS OF CAPSAICIN 8% PATCH VERSUS ORAL NEUROPATHIC PAIN MEDICATIONS FOR THE TREATMENT OF PAINFUL DIABETIC PERIPHERAL NEUROPATHY

van Nooten FE1, Charokopitou M2, Poole C3, Treur M4, 1Astellas Pharma BV, Leiden, The Netherlands, 2Pharmerit International, Rotterdam, The Netherlands, 3Astellas Pharma Europe Ltd, Chertsey, UK

HOW ARE PAIN TREATMENT RESPONSE RATES IN PRIMARY CARE INFLUENCED BY CO-PRESCRIPTION OF CYP2D6 INHIBITORS?

Pockett RD1, O’Leary CJ2, Anderson P3, Nasser A4, Winfield TG5, Ansell D6, 1Swansea Centre for Health Economics, Swansea, UK, 2IMS Health, London, UK, 3Swansea University, Swansea, UK

REAL-WORLD EVIDENCE OF IRON CHELATION THERAPY IN TRANSFUSION-DEPENDENT MDS PATIENTS: A PORTUGUESE HOSPITAL REGISTRY

Rodrigues S1, Almeida A2, Viritado D3, Antunes M4, 1Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal, 2Novartis Farma – Produtos Farmacêuticos S.A., Porto Salvo, Portugal, 3Faculdade de Ciências da Universidade de Lisboa, Lisboa, Portugal

GUILLAIN-BARRE SYNDROME: CLINICAL PRESENTATION, TREATMENT PATTERN AND OUTCOME

Vijayanarayana K1, Beena AS2, Anuvrinda C3, Bhumika M4, Sreedharan N5, Shivashankar KN6, 1Dept. of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, Karnataka State., India, 2Dept. of Medicine, Kasturba Medical College, Manipal University, Manipal, Karnataka State., India
PSY8 L15 SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS IN MULTIDISCIPLINARY PAIN MANAGEMENT SERVICES FOR MANAGING PEOPLE WITH FIBROMYALGIA OR CHRONIC WIDESPREAD PAIN
AlAujan S, Elliott R, Knaggs R, University of Nottingham, Nottingham, UK

PSY9 L16 COMPARISONS OF FACTOR CONSUMPTION FOR ROUTINE PROPHYLAXIS AND BLEEDING DURING EPISODIC THERAPY WITH RECOMBINANT FACTOR VIII FC FUSION PROTEIN AND CONVENTIONAL RECOMBINANT FACTOR VIII
Iorio A1, Krishnan S2, Myrén K3, Lethagen S3, McCormick N4, Karner P5, McMaster University, Hamilton, ON, Canada, 2Biogen Hemophilia, Cambridge, MA, USA, 3Sobi, Stockholm, Sweden, 4Analysis Group, Boston, MA, USA

PSY10 L17 COMPARISON OF NETWORK META-ANALYSIS AND TRADITIONAL META-ANALYSIS FOR PREVENTION OF RELAPSES IN MULTIPLE SCLEROSIS
Aggarwal S1, Kumar S2, Topaloglu H1, NOVEL Health Strategies, Chevy Chase, MD, USA, 2GLOBAL ACCESS Monitor, Bethesda, MD, USA

PSY11 L18 ASSESSING THE TREATMENT OF PERIPHERAL NEUROPATHIC PAIN (PNEP) AND POSTHERPETIC NEURALGIA (PHN) IN CHINA USING A SIMULATION MODEL
Wang BC1, Liu D2, Fungback W3, Bifa F4, Dong P5, Xie L6, Zhang S7, Elysia Group, LLC, New York, NY, USA, 2Pfizer Investment Co., Ltd., Beijing, China, 3China-Japan Friendship Hospital, Beijing, China, 4Pfizer Investment Co. Ltd., Beijing, China

PSY12 L19 FACTOR CONSUMPTION FOR PROPHYLAXIS AND TREATMENT OF BLEEDING: RECOMBINANT FACTOR IX FC FUSION PROTEIN COMPARED WITH CONVENTIONAL RECOMBINANT FACTOR IX
Iorio A1, Krishnan S2, Myrén K3, Lethagen S3, McCormick N4, Karner P5, McMaster University, Hamilton, ON, Canada, 2Biogen Hemophilia, Cambridge, MA, USA, 3Sobi, Stockholm, Sweden, 4Analysis Group, Boston, MA, USA

PSY13 L20 MODELING THE IMPACT OF POTENTIAL DIFFERENCES IN REAL-WORLD ADHERENCE WITH EXTENDED-HALF-LIFE VS. CONVENTIONAL FACTOR VIII AND IX ON BLEEDING
Iorio A1, Krishnan S2, Myrén K3, Lethagen S3, McCormick N4, Karner P5, McMaster University, Hamilton, ON, Canada, 2Biogen Hemophilia, Cambridge, MA, USA, 3Sobi, Stockholm, Sweden, 4Analysis Group, Boston, MA, USA

PSY14 L21 COST EFFECTIVENESS OF MULTIDISCIPLINARY PAIN MANAGEMENT SERVICES FOR CHRONIC BACK PAIN: SYSTEMATIC REVIEW
Almazrou S1, Elliott R1, Knaggs R2, University of Nottingham, Nottingham, UK, 2University of Nottingham, Nottingham, UK

PSY134 L22 CHARACTERISTICS ASSOCIATED WITH ANNUAL BLEEDING FREQUENCY AMONG HEMOPHILIA PATIENTS IN THE UNITED STATES
Chen CX1, Ullman MM2, Jond HJ3, Kulkarni RR4, Konkle BA5, Baker JR6, Riske B7, Koerper M8, Lou M9, Wu J10, Nichol MB1, University of Southern California, Los Angeles, CA, USA, 2University of Texas at Houston, Gulf States Hemophilia and Thrombophilia Center, Houston, TX, USA, 3Akron Children's Hospital, Akron, OH, USA, 4Michigan State University, East Lansing, MI, USA, 5Bloodworks NW, Seattle, WA, USA, 6University of California, Los Angeles, Los Angeles, CA, USA, 7University of Colorado Hemophilia and Thrombosis Center, Aurora, CO, USA, 8University of California, San Francisco, San Francisco, CA, USA

PSY15 L23 PREVALENCE OF ANTIDEPRESSANTS PRESCRIBED TO TRAMADOL USERS IN THE UK PRIMARY CARE SETTING - A PRESCRIPTION SEQUENCE SYMMETRY ANALYSIS
Chen T1, Chen L2, Knaggs RD3, University of Nottingham, Nottingham, UK

PSY16 L24 PREVALENCE AND COST OF MYASTHENIA GRAVIS IN THE MEDICARE BENEFICIARY SAMPLE
Gordon BD1, Noone JM2, Van Doren BA3, Zacherle E4, Blanche CM5, University of North Carolina at Charlotte, Charlotte, NC, USA, 2Precision For Medicine, New York, NY, USA

PSY17 L25 SICKNESS FUNDS DATA ANALYSES ON PREVALENCE & INCIDENCE AND TREATMENT OF WALDENSTROM’S MACROGLOBULINEMIA (WM) IN GERMANY
Leisten M1, Tomezckowski J2, Janssen-Cilag GmbH, Neuss, Germany

PSY18 L26 IDENTIFICATION OF SUBGROUPS WITH LOW RATES OF WEIGHT LOSS IN ISRAEL
Srolovici E1, Levin D2, Zamir D3, Leventer-Roberts M4, Balicer R5, Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel, 2Department of Health Education and Promotion, Clalit Health Services, Tel Aviv, Israel

PSY19 L27 BURDEN OF ANEMIA AMONG INDIAN WOMEN: A SYSTEMATIC REVIEW AND META-ANALYSIS OF LITERATURE
Singhal R1, Independent Health and Outcome Researcher, S.A.S. Nagar (Mohali), Punjab, India

PSY20 L28 ASSESSMENT OF IRON DEFICIENCY AND ANEMIA IN PREGNANT WOMEN IN FRANCE: AN OBSERVATIONAL STUDY
Berdeaux G1, Zik A2, Clavel T3, Pierre Fabre, boulogne billancourt, France, 2Pierre Fabre, Boulogne Billancourt, France

PSY21 L29 PREVALENCE OF TRANSTHYRETIN FAMILIAL AMYLOID POLYNEUROPATHY IN PORTUGAL
Inês M1, Coelho T2, Conceição P3, Duarte-Ramos F4, Carvalho M5, Instituto de Medicina Molecular, Lisboa, Portugal, 2Unidade Clínica de Paraamiloidose, Hospital de Santo Antonio, Porto, Portugal, 3Centro Hospitalar de Lisboa Norte, Lisbon, Portugal, 4Faculty of Pharmacy Lisbon University, Lisboa, Portugal, 5Institute of Molecular Medicine, Lisboa, Portugal
PSY22 L30 CALCULATING THE PREVALENCE OF UREA CYCLE DISORDERS IN THE EU5 USING AN INCIDENCE–SURVIVAL MODEL
Megeed G, Stuntz M. Deerfield Institute, New York, NY, USA

PSY23 L31 RELATIONSHIP BETWEEN PATIENT CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH MULTIPLE MYELOMA

PSY24 L32 A SYSTEMATIC LITERATURE REVIEW OF RISK PREDICTION MODELS FOR MORTALITY, COMPLICATIONS AND DIABETES OUTCOMES AFTER BARIATRIC SURGERY

PSY25 L33 MODELLING THE LIKELY IMPACT OF THE OBESITY EPIDEMIC ON MORTALITY AND CAUSE OF DEATH IN OLDER ADULTS
Martin A, Martin C. Crystallise Ltd., London, UK

SYSTEMIC DISORDERS/CONDITIONS - Cost Studies

PSY26 M1 A FIVE YEARS BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF ADALIMUMAB FOR CROHN'S DISEASE PATIENTS FROM THE PERSPECTIVE OF THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM
Menezes FG, Chibana V, AbbVie Brazil, Sao Paulo, Brazil

PSY27 M2 BUDGET IMPACT ANALYSIS OF BLOOD CLOTTING FACTOR CONCENTRATES IN THE TREATMENT OF VON WILLEBRAND DISEASE
Yagudina R, Kulikov A, Babyi VV, I.M. Sechenov First Moscow State Medical University, Moscow, Russia

PSY28 M3 BUDGET IMPACT ANALYSIS OF DASATYNIB IN TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY IN POLAND
Mucha J, Steelmachowski J, Walczak J, Pieniazek I, Labak-Klimasara M, Obrzut G, Arcana Institute Ltd, Krakow, Poland, “Bristol-Myers Squibb Services Sp. z o.o., Warsaw, Poland

PSY29 M4 BUDGET IMPACT ANALYSIS OF CANACINUMAB IN THE TREATMENT OF PATIENTS WITH MUCKLE-WELLS SYNDROME IN THE RUSSIAN FEDERATION
Yagudina R, Kulikov A, Pochuprina A, I.M. Sechenov First Moscow State Medical University, Moscow, Russia

PSY30 M5 BIOLOGIC TREATMENTS FOR MODERATE TO SEVERE NAIVE PSORIATIC PATIENTS: A BUDGET IMPACT ANALYSIS IN ITALY
Povero M, Pradelli L, AdRes Srl, Torino, IA, Italy, “AdRes Srl, Torino, Italy

PSY31 M6 PHARMACOECONOMIC ANALYSIS OF USING GOLIMUMAB IN THE CARE OF PATIENTS WITH ULCERATIVE COLITIS
Krysanova V, Krysanov I, Tolushin A, I.M. Sechenov First Moscow State Medical University, Moscow, Russia, “Postgraduate Medical Institute, Moscow National University of Food Production, Moscow, Russia, “MSD, Moscow, Russia

PSY32 M7 ECONOMIC EVALUATION OF THE ARANESP APPLICATION FOR ANEMIA CORRECTION IN PATIENTS WITH CHRONICAL RENAL FAILURE ON HEMODIALYSIS OR PERITONEAL DIALYSIS IN RUSSIA
Fakeeva TS, Krysanov I, Postgraduate Medical Institute, Moscow National University of Food Production, Moscow, Russia, “Postgraduate Medical Institute, Moscow National University of Food Production, Moscow, Russia

PSY33 M8 EVICEL AND BLOODLESS PROTOCOL IN ORTHOPAEDICS SURGERY CLINICAL EVIDENCE AND COST-ANALYSIS: ITALIAN EXPERIENCE HUMANITAS RESEARCH HOSPITAL
Scardino M, Martorelli F, Grappiolo G, Humanitas research hospital, rozzano, Italy

PSY34 M9 ECONOMIC EVALUATION AND ADDED VALUE FOR STAKEHOLDERS OF SWITCHING FROM RITUXIMAB INTRAVENOUS INJECTION TO RITUXIMAB SUBCUTANEOUS INJECTION IN FRANCE
Plommet N, Pau D, Tehard B, Roche SAS, Boulogne-Billancourt, France

PSY35 M10 HEALTH CARE COST AND UTILIZATION ASSOCIATED WITH ALPHA-1 ANTITRYPSIN DEFICIENCY AMONG A COHORT OF MEDICARE BENEFICIARIES WITH COPD
Zacherle E, Noone JM, Runken MC, Blanchette CM, University of North Carolina at Charlotte, Charlotte, NC, USA, “Grifols, Inc., Research Triangle Park, NC, USA

PSY36 M11 ECONOMIC IMPACT OF EMPLOYMENT STATUS ON THE SOCIAL COST OF MORBID OBSESE PATIENTS SUBMITTED TO BARIATRIC SURGERY
Bellelli S, Turchetti G, Scuola Superiore Sant'Anna, Pisa, Italy

PSY37 M12 THE INDIRECT COSTS OF INFLAMMATORY BOWEL DISEASE (CROHN'S DISEASE AND ULCERATIVE COLITIS) ASSOCIATED WITH ABSENTEEISM IN POLAND IN 2013

PSY51 M26 ASSESSING THE BURDEN OF SYSTEMIC LUPUS ERYTHEMATOSUS IN BELGIUM USING A LONGITUDINAL HOSPITAL DATABASE
Gerlier L, Lamotte M, Chevalier P, IMS Health, Vilvoorde, Belgium

PSY52 M27 BIOPHARMA INTERVENTION VALUATION: AN EVIDENCE-BASED APPRAISAL FRAMEWORK FOR ONCOLOGY DRUGS
Doyle J, White C, Chawla V, Quintiles Advisory Services, New York, NY, USA

PSY53 M28 COST-EFFECTIVENESS OF PONATINIB FOLLOWED BY STEM CELL TRANSPLANT VERSUS BEST SUPPORTIVE CARE FOR UK PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKAEMIA AFTER FAILURE OF DASATINIB
Iannazzo S, Chirol S, Rowntree C, McGarry L, Briggs A, SiHS Health Economics Consulting, Torino, Italy, ARIAD Pharmaceuticals Europe Sàrl, Epalinges, Switzerland, University Hospital of Wales, Cardiff, UK, ARIAD Pharmaceuticals, Inc., Cambridge, MA, USA, Occam Research Ltd, Glasgow, UK

PSY54 M29 COST-EFFECTIVENESS ANALYSIS OF ROMIPLOSTIM FOR THE TREATMENT OF ADULT CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA (ITP) IN BRAZIL
dos Santos RF, Vargas-Valencia JJ, Giannopoulos A, Campioni M, Amgen, São Paulo, Brazil, Econopharma Consulting, Ciudad de México, Mexico, Amgen (Europe) GmbH, Zug, Switzerland

PSY55 M30 RE-EVALUATING THE COST-EFFECTIVENESS OF SCREENING FOR CONGENITAL ADRENAL HYPERPLASIA (CAH): THE SENSITIVITY TO CHOICE OF DISTRIBUTIONS IN PROBABILISTIC SENSITIVITY ANALYSES (PSAS)
Alzarea A, Alolayan S, Almutairi H, Alqahtani SS, Rittenhouse B, MCPHS University, Boston, MA, USA

PSY56 M31 COST-EFFECTIVENESS ANALYSIS OF PONATINIB IN THE TREATMENT OF CHRONIC PHASE CHRONIC MYELOID LEUKAEMIA (CP-CML) IN SWEDEN
Iannazzo S, McGarry L, Chirol S, SiHS Health Economics Consulting, Torino, Italy, ARIAD Pharmaceuticals, Inc., Cambridge, MA, USA, ARIAD Pharmaceuticals Europe Sàrl, Epalinges, Switzerland

PSY57 M32 THE COST-EFFECTIVENESS OF BIOLOGICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES: A SYSTEMATIC REVIEW
Huooponen S, Blom M, University of Helsinki, Helsinki, Finland

PSY58 M33 IS REGENERATIVE MEDICINE COST-EFFECTIVE? EVIDENCES FROM THE FIRST APPROVED STEM CELL BASED PRODUCT
Fordham R, Ciminiata G, Madoni A, Magni T, Sarnelli V, Domini B, University of East Anglia, Norwich, UK, Chiesi Farmaceutici Spa, Parma, Italy, Ernst & Young, Milano, Italy

PSY59 N1 ECONOMIC EVALUATION OF LIDOCAINE/TETRACAINE PATCH VERSUS LIDOCAINE/PRILOCAINE CREAM FOR TOPICAL ANAESTHESIA BEFORE VASCULAR ACCESS IN EGYPT
Elsisi G, Mohamed Abdallah H, Elmansy H, Central Administration for Pharmaceutical Affairs (CAPA), Ministry of Health, Cairo, Egypt, Canadian international college, Cairo, Egypt

PSY60 N2 AN IN SILICO HEALTH ECONOMIC MODEL APPLIED TO CRYOPYRIN ASSOCIATED PERIODIC SYNDROMES (CAPS): COST EFFECTIVENESS OF PREVENTION EFFECTS OF ULTRA-ORPHAN DRUGS FOR RARE DISEASES
Trieste L, Della Casa Alberighi O, Accame L, Lorenzoni V, Frenkel J, Gattorno M, Quartier P, Martini A, Turchetti G, Scuola Superiore Sant'Anna, Pisa, Italy, Institute Giannina Gaslini, Genova, Italy, University Medical Center Utrecht, Utrecht, The Netherlands, Assistance Publique-Hopitaux de Paris Hospital Necker, Paris, France

PSY61 N3 PHARMACOECONOMIC ANALYSIS OF TREATMENT PATIENTS WITH CRANIOCEBREAL INJURY IN UKRAINE
Solobiukova N, Yakovleva LV, Sur SV, Makarov O, Arterium Corporation, Kyiv, Ukraine, National Pharmaceutical University, Kharkiv, Ukraine

PSY62 N4 COST-EFFECTIVENESS OF RUXOLITINIB FOR THE TREATMENT OF MYELOFIBROSIS IN FINLAND: ECONOMIC EVALUATION BASED ON FINNISH AURIA BIOBANK DATA ON HEALTH CARE RESOURCE UTILIZATION
Hahl J, Kurki S, Miettinen T, Snitker K, AT Medical Affairs Consulting Oy (Medaffcon), Espoo, Finland, Auria Biobank, Turk University Hospital and University of Turku, Turku, Finland, Novartis Finland Oy, Espoo, Finland

PSY63 N5 COST-EFFECTIVENESS OF MANUAL THERAPY VERSUS PHYSICAL THERAPY IN PATIENTS WITH SUB-ACUTE AND CHRONIC NECK PAIN: A RANDOMIZED CONTROLLED TRIAL
van Dongen JM, Groeneweg R, Rubinstein SM, Bosmans JE, Oostendorp RA, Ostelo RW, van Tulder MW, VU Amsterdam University, Amsterdam, The Netherlands, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

PSY64 N6 COST-EFFECTIVENESS ANALYSIS OF PREGABALIN IN THE TREATMENT OF CENTRAL NEUROPATHIC PAIN
Karbusicka M, Kolek M, Duba J, Vothova P, Dolečková J, OAKS Consulting s.r.o., Prague 9, Czech Republic, Pfizer, spol. s r.o., Prague 5, Czech Republic

PSY65 N7 COST-EFFECTIVENESS OF USTEKINUMAB IN THE TREATMENT OF PSORIASIS IN FINLAND
Vääätäinen S, Soini EJ, Valgardsson VS, Mäkkönen T, ESIOR Oy, Kuopio, Finland, Janssen-Cilag AS, Oslo, Norway, Helsinki University Hospital, Skin and Allergy Hospital, Helsinki, Finland

PSY66 N8 COST-MINIMIZATION ANALYSIS AND TOTAL COST ANALYSIS FOR A WEIGHT RANGE IN CROHN'S DISEASE TREATMENT WITH ANTI-TNF BIOLOGICS UNDER BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE

PSY71 N13 COST-EFFECTIVENESS ANALYSIS OF TOCILIZUMAB SUBCUTANEOUS AS FIRST LINE BIOLOGIC MONOTHERAPY FOR RHEUMATOID ARTHRITIS MANAGEMENT IN GREECE

Athanasakis K1, Tarantilis F1, Skrumpellos A2, Kyriopoulos J3, National School of Public Health, Athens, Greece, 1Roche (Hellas) S.A., Athens, UK

PSY72 N14 COST-UTILITY OF BARIATRIC SURGERY IN FRANCE AND GERMANY

Borisenko O1, Burdukova E1, Hargreaves J2, Adam D1, Synergus AB, Stockholm, Sweden, 1Coviden (UK) Commercial Ltd, now part of Medtronic, Hampshire, UK, 2Aarhus University, and Aleris Hamlet Hospital, Aarhus, Denmark

PSY73 N15 COST-EFFECTIVENESS OF BARIATRIC SURGERY FOR THE TREATMENT OF OBESITY IN AUSTRALIA

Salton R1, Center for Applied Health Economics, Brisbane, Australia

PSY74 N16 COST–UTILITY ANALYSIS OF ANTIHEMOPHILIC FACTOR RFVIII-FS FOR SECONDARY PROPHYLAXIS VS ON-DEMAND THERAPY IN SEVERE HAEMOPHILIA A IN ITALY

Tagliaferri A1, Coppola A1, Amoresano S2, Aiello A3, Daniel F4, D'Ausilio A5, Touri M6, Reference Centre for Coagulation Disorders, Napoli, Italy, 1Bayer Healthcare, Milano, Italy, 2Creativ Ceutical, Milano, Italy, 3Aix-Marseille University, Marseille, France

PSY75 N17 ECONOMIC EVALUATION OF DASATYNIB IN TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE (PH+) ACUTE LYMPHOBlastic LEUKEMIA (ALL) WITH RESISTANCE OR INtolerANCE TO PRIOR THERAPY IN POLAND

Mucha J1, Stelmachowski J1, Walczak J1, Pieniazek I1, Obrutz G1, Labak-Klimasara M1, Arcana Institute Ltd, Krakow, Poland, 1Bristol-Myers Squibb Services Sp. z o.o., Warsaw, Poland

PSY76 N18 ASSOCIATION BETWEEN FEEDING TYPES AND IRON STATUS IN INDIA

Prieto Patron A1, Detzel P1, Nestlé Research Center, Lausanne, Switzerland

PSY77 N19 RETROSPECTIVE COHORT STUDY USING DATA FROM THE UK CLINICAL PRACTICE RESEARCH DATALINK AND HOSPITAL EPISODE STATISTICS TO ASSESS UNPLANNED HOSPITALISATION IN PATIENTS WITH MULTIPLE MYELOMA

Raluy-Callado M1, Lambrelli D1, DeCosta L2, Gonzalez-McQuire S3, Evidera, London, UK, 1Amgen Ltd., Uxbridge, UK, 2Amgen (Europe) GmbH, Zug, Switzerland

PSY78 N20 INPATIENT BURDEN AMONG PATIENTS WITH CYSTIC FIBROSIS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION

Hodgkins P1, Ayyagari R1, Guo J1, Wagener J3, O’Sullivan AK1, Vertex Pharmaceuticals, Boston, MA, USA, 1Analysis Group, Inc, Boston, MA, USA, 2University of Colorado, Aurora, CO, USA

SYSTEMIC DISORDERS/CONDITIONS - Patient-Reported Outcomes & Patient Preference Studies

PSY79 N21 TRANSTHYRETIN FAMILIAL AMYLOID POLYNEUROPATHY IMPACT ON HEALTH-RELATED QUALITY OF LIFE

Inês M1, Coelho T1, Conceição I2, Ferreira LN3, Carvalho M4, Costa J5, Instituto de Medicina Molecular, Lisboa, Portugal, 1Unidade Clínica de Paramióio, Hospital de Santo António, Porto, Portugal, 2Centro Hospitalar de Lisboa Norte, Lisboa, Portugal, 3University of Algarve, Faro, Portugal, 4Institute of Molecular Medicine, Lisbon, Portugal

PSY80 N22 HEALTH STATE UTILITIES FOR GAUCHER DISEASE TYPE 1

Ganz ML1, Stern S2, Ward AJ3, Selzer M4, Nalyshyn L5, Hamed A6, Weinreb N7, Evidera, Lexington, MA, USA, 1Evidera, Bethesda, MD, USA, 2Genzyme, a Sanofi Company, Cambridge, MA, USA, 3University Gaucher Disease - Fabry Disease Treatment Center, Coral Springs, FL, USA

PSY81 N23 SOCIAL UTILITY VALUES FOR PEMPHIGUS VULGARIS AND FOLIACEUS: A COMPOSITE TIME TRADE-OFF STUDY

Rencz P1, Gulácsi L1, Tamási B2, Kárpáti S2, Brodszky V3, Corvinus University of Budapest, Budapest, Hungary, 1Semmelweis University, Budapest, Hungary
PSY82 N24  “FIRST AND FOREMOST BATTLE THE VIRUS” - PATIENT PREFERENCES IN ANTIVIRAL THERAPY FOR HEPATITIS C
Mühlbacher AC, Bethge S, Sadler A, Hochschule Neubrandenburg, Neubrandenburg, Germany

PSY83 N25  TEN YEARS OF THE INTERNATIONAL POMPE SURVEY: PATIENT REPORTED OUTCOMES AS A RELIABLE TOOL FOR STUDYING TREATED ANDUNTREATED CHILDREN AND ADULTS WITH NON-CLASSIC POMPE DISEASE
van der Meijden J1, Güngör D1, Kruijijsaara M1, Broekgaarden H2, Muir A3, van der Ploeg A1, Erasmus University Medical Center, Rotterdam, The Netherlands, 2Vereniging Spierziekten Nederland, Baam, The Netherlands, 3Association for Glycogen Storage Disease, Droxford, UK

PSY84 N26  THE IMPACT OF ORTHOPAEDIC SURGERY ON THE QUALITY OF LIFE OF HAEMOPHILIA PATIENTS WITH OR WITHOUT INHIBITORS: A SYSTEMATIC REVIEW OF THE LITERATURE
Solimeno LP1, Santagostino E2, Giangrande PL2, Damera V2, Cure S4, Slothuus U5, Rosu GN6, Wilkinson L4, Ca’Granda Foundation, Maggiore Hospital, Milan, Italy, 2Hemophilia Unit, Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre, Milan, Italy, 3Oxford Haemophilia & Thrombosis Centre, Oxford, UK, 4Mapi Group, Uxbridge, UK, 5Novo Nordisk A/S, Søborg, Denmark, 6Novo Nordisk A/S, Zurich, Switzerland

PSY85 N27  HEALTH STATES WORSE THAN DEAD IN AN ELDERLY POPULATION – PREVALENCE AND THE SIGNIFICANCE OF CHRONIC PAIN
Bernfort L, Gerdle B, Levin L, Linköping University, Linköping, Sweden

PSY86 N28  CLUSTERING HEALTH STATUS AMONG ADULTS WITH HEMOPHILIA USING SF-12 HEALTH SURVEY
Niu X, Baker JR2, Riske B1, Ullman MM1, Wu J1, Lou M1, Nichol MB1, University of Southern California, Los Angeles, CA, USA, 2University of California, Los Angeles, Los Angeles, CA, USA, 3University of CO Denver Hemophilia and Thrombosis Ctr, Aurora, CO, USA, 4University of Texas at Houston, Gulf States Hemophilia and Thrombophilia Center, Houston, TX, USA

PSY87 N29  OPIOIDS SWITCH IN CHRONIC PAIN: IMPACT ASSESSMENT USING ELECTRONIC HEALTH RECORDS
Usai S1, Petelin R2, Young Against Pain (YAP) Group, Parma, Italy, Laboratorio Salute, Naples, Italy

PSY88 N30  VALIDATION OF A NEW HEMOPHILIA-SPECIFIC BURDEN SCALE FOR CAREGIVERS OF CHILDREN WITH HEMOPHILIA IN THE US – THE HEMOPHILIA ASSOCIATED CAREGIVER BURDEN SCALE (HEMOCABTM)
von Mackensen S1, Wisniewski T2, Urgo J3, Boggio L3, University Medical Centre Hamburg-Eppendorf, Hamburg, IL, USA, 2NOVO Nordisk, Plainsboro, NJ, USA, 3RUSH University Medical Centre, Chicago, IL, USA

PSY89 N31  ASSOCIATIONS BETWEEN PAIN SEVERITY AND QUALITY OF LIFE DOMAINS AMONG THOSE DIAGNOSED WITH VARIOUS PAIN TYPES IN EUROPE

PSY90 N32  ASSESSING THE IMPACT OF GROWTH HORMONE DEFICIENCY (GHD) IN CHILDREN: CONCEPT ELICITATION RESULTS SUPPORTING THE DEVELOPMENT OF THE TREATMENT-RELATED IMPACT MEASURE FOR CHILDHOOD GHD (TRIM-CGHD)
Brod M1, Heijbjergere L1, Wilkinson L2, Aologa SL1, Rasmussen MH1, The Brod Group, Mill Valley, CA, USA, 2Novo Nordisk A/S, Søborg, Denmark

PSY91 N33  IMPACT OF WEIGHT LOSS ON PATIENT-REPORTED OUTCOMES IN THE SCALE OBESITY AND PREDIABETES TRIAL OF LIRAGLUTIDE 3.0 MG AS ADJUNCT TO A DIET AND EXERCISE (D&E) PROGRAMME
Kolotkin RL1, Meincke HJ2, Manning LS3, Bjørner JB4, Quality of Life Consulting, Durham, NJ, USA, 2Novo Nordisk A/S, Søborg, Denmark, 3Optum, Lincoln, RI, USA

PSY92 O2  COGNITIVE TESTING OF A MODIFIED VERSION OF THE FACES PAIN SCALE-REVISED IN CHILDREN WITH SICKLE-CELL DISEASE
Naegeli AN1, Heath L1, Turner-Bowker DM1, Flood E4, Dampier C5, Happich M6, Eli Lilly, Indianapolis, IN, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 3Quintiles (work conducted while at ERT, Pittsburgh, PA), Cambridge, MA, USA, 4ICON, Morristown, NJ, USA, 5Emory University School of Medicine, Atlanta, GA, USA, 6Lilly Deutschland GmbH, Bad Homburg, Germany

PSY93 O2  REPORTING INSTRUMENTS OF PATIENT REPORTED OUTCOMES IN ORPHAN DISEASE
Kausnik P, Bhalla S, Jain A, PAREXEL, Chandigarh, India

PSY94 O3  IMPACT OF PAIN SEVERITY ON PATIENT-REPORTED OUTCOMES OF INDIVIDUALS WITH CHRONIC LOWER BACK PAIN IN JAPAN
Montgomery W1, Vietri J2, Shi J3, Kariyaso S1, Ogawa K3, Eli Lilly Australia, West Ryde, Australia, 2Kantar Health, Horsham, PA, USA, 3Kantar Health, Princeton, NJ, USA, 4Eli Lilly Japan K.K., Kobe, Japan

PSY95 O4  THE RELATIONSHIP BETWEEN DISEASE SEVERITY AND QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS
Geale K1, Henriksson M2, Schmitt-Egenolf M1, Umeå University, Umeå, Sweden, 2Linköping University, Linköping, Sweden

PSY96 O5  EVALUATION OF PATIENTS’ QUALITY OF LIFE OF PREOPERATION AND EARLY POSTOPERATION AFTER TOTAL HIP AND KNEE ARTHROPLASTY
Numanoglu Tekin R1, Yilmaz F1, Oksuz E2, Malhan S1, Baskent University, ankara, Turkey, 2Baskent University,
Ankara, Turkey

**PSY97 06** HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH TRANSTHYRETIN FAMILIAL AMYLOID POLYNEUROPATHY

Inês M¹, Coelho T², Conceição I³, Ferreira LN⁴, Carvalho M⁵, Costa J⁶, Instituto de Medicina Molecular, Lisboa, Portugal, ²Unidade Clínica de Parâniloidose, Hospital de Santo António, Porto, Portugal, ³Centro Hospitalar de Lisboa Norte, Lisboa, Portugal, ⁴Universidade do Algarve, Faro, Portugal, ⁵Institute of Molecular Medicine, Lisboa, Portugal

**PSY98 07** HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN SPLENECTOMIZED IMMUNE THROMBOCYTOPENIA (ITP) PATIENTS – A TARGETED LITERATURE REVIEW

Lebioda A¹, Batscheider A², Amgen GmbH, Munich, Germany, ²IMS Health, Munich, Germany

**PSY99 08** ASSESSING THE TREATMENT BURDEN FOR GROWTH HORMONE DEFICIENCY (GHD) IN CHILDREN: CONCEPT ELICITATION RESULTS SUPPORTING THE DEVELOPMENT OF THE TREATMENT BURDEN MEASURE FOR CHILDHOOD GHD (TB-CGH)

Brod M¹, Højbjerg L², Wilkinson L³, Alokga SL⁴, Rasmussen MH⁵, The Brod Group, Mill Valley, CA, USA, ²Novo Nordisk A/S, Søborg, Denmark

**SYSTEMIC DISORDERS/CONDITIONS - Health Care Use & Policy Studies**

**PSY100 09** TOWARDS CREATING A NATIONAL SYSTEM OF CARE FOR PATIENTS WITH ORPHAN DISEASES

Rubtsova I¹, Shkilina O, Lishchynshyna O, State Expert Centre of the Ministry of Health of Ukraine, Kyiv, Ukraine

**PSY101 10** MEDICAL CARE AND COSTS OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN TAIWAN

Cheng J¹, Huang C², Hsu C², Chang Gung University, Tao-Yuan, Taiwan, ²National Health Research Institutes, Miaoli, Taiwan

**PSY102 11** THE RHEUMATOLOGIST’S PERSPECTIVE IN DIAGNOSTIC COURSE AND MANAGEMENT OF FAMILIAL MEDITERRANEAN FEVER

Karadag O¹, Kilic L², Erden A³, Kasifoglu T², Karaaslan Y³, Kiraz S⁴, Dokuyucu O⁵, Hacetettepe University, Ankara, Turkey, ³Yenimahalle Research Hospital, Ankara, Turkey, ²Eskisehir Osmangazi University Medical School, Eskisehir, Turkey, ¹Ankara Numune Research Hospital, Ankara, Turkey, ²Novartis, Istanbul, Turkey

**PSY103 12** IMPACT OF BLOOD TRANSFUSIONS ON HOSPITAL LENGTH OF STAY AND MORTALITY: A SINGLE-CENTER EXPERIENCE

Félix J¹, Alcobia A², Soares A², Bastos A², Amaro A², Oliveira C³, Rabiais S¹, Afonso-Silva M², Andreozzi V¹, Vandewalle B¹, Ferreira D², Exigo Consultores, Alhos Vedros, Portugal, ²Pharmacy, Hospital Garcia de Orta, E.P.E., Almada, Portugal

**PSY104 13** CONVERGENT VALIDITY OF NEW DISEASE ASSESSMENT INSTRUMENTS (DAI) IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN RELATION TO SLEDAI-2K

Narayanan S¹, Collins CE², Busch HM³, Gaylis N³, Hautamaki E¹, Chatham WW⁴, Ipsos Healthcare, Washington, DC, USA, ²MedStar Washington Hospital Center, Washington, DC, USA, ³Science and Research Institute, Inc., Jupiter, FL, USA, ⁴Arthritis and Rheumatic Disease Specialties, Aventura, FL, USA, ⁵University of Alabama, Birmingham, AL, USA

**PSY105 14** THE RISE OF ORPHAN DRUGS IN EUROPE VS THE UNITED STATES: COMPARING ORPHAN DRUG DESIGNATIONS BETWEEN THE EMA AND FDA

Mildred M¹, Lee S, Boehringer Ingelheim Ltd, Bracknell, UK

**PSY106 15** ANALYSIS OF GOVERNMENT PROCUREMENTS OF MEDICINES FOR RARE DISEASES IN RUSSIA

Fedyaev D¹, Fedyaeva VK², Omelyanovskiy VV³, Financial Scientific Research Institute of the Ministry of Finance of Russia, Moscow, Russia, ²The Russian Presidential Academy of National Economy and International Administration, Moscow, Russia

**PSY107 16** COMPARATIVE ANALYSIS OF THE REIMBURSEMENT LANDSCAPE OF ORPHAN DRUGS ON AN INTERNATIONAL LEVEL

Nazha S¹, University of Montreal, Montreal, QC, Canada

**PSY108 17** SIMILARITIES AND DIFFERENCES IN ORPHAN DRUG REIMBURSEMENT IN 16 EUROPEAN COUNTRIES


**PSY109 18** REIMBURSED PRICE OF ORPHAN DRUGS: A VALUE BASED FRAMEWORK

Mincarone P¹, Leo CG², Sabina S², Tordrup D³, Taruscio D⁴, Kanavos P⁵, National Research Council, Rome, Italy, ²National Research Council, Lecce, Italy, ³Utrecht University, Utrecht, The Netherlands, ⁴National Institute of Health, Rome, Italy, ⁵London School of Economics and Political Science, London, UK

**PSY110 19** HORIZONTAL VS. VERTICAL EQUITY: MARKET ACCESS OF ORPHAN DRUGS IN FRANCE AND UK

Korchagina D¹, Pavella F², Rémuzat C³, Toumi M⁴, Falissard B⁵, University of Paris-Sud, Paris, France, ²Creactive-Ceutical, London, UK, ³Creactive-Ceutical, Paris, France, ⁴Aix-Marseille University, Marseille, France, ⁵Maison de Solenn, Paris, France

**PSY111 20** ORPHAN DRUG REGULATION IN THE USA, EUROPEAN UNION, JAPAN AND SOUTH KOREA: A COMPARATIVE ANALYSIS

Tomita N¹, Lee H², Korchagina D³, Toumi M⁴, Rémuzat C⁵, Falissard B⁶, National Institute of Public Health, Saitama, Japan, ²Seoul National University College of Medicine, Seoul, South Korea, ³University of Paris-Sud, Paris, France, ⁴Aix-
ECONOMIC IMPACT OF THE END OF THE MARKET EXCLUSIVITY FOR ORPHAN DRUGS

VALUE ASSESSMENT AND PRICING FRAMEWORKS FOR RARE DISEASE TREATMENTS: NEW APPROACHES FROM THE LITERATURE
Palaska C, Hutchings A, Dolon Ltd, London, UK

RECOMMENDATIONS AND REIMBURSEMENT STATUS OF ORPHAN DRUGS IN UE COUNTRIES
Kawalec P, Jagiellonian University Medical College Institute of Public Health, Krakow, Poland

THE FEASIBILITY OF APPLYING DEFINITIONS OF PERSISTENT OPIOID UTILISATION TO QUANTIFY THE PERSISTENCY OF TRAMADOL USERS
Chen T, Chen L, Knaggs RD, University of Nottingham, Nottingham, UK

EXPERTS CONSSENSUS ON THE FUTURE OF RARE DISEASES CARE AND ORPHAN DRUGS ACCESS IN SPAIN: A DELPHI STUDY
Paz S, Torrent J, Poveda JL, Perez J, Moreno JL, Martin A, Gonzalez L, Cruz J, Cornellas M, Abaitua I, Urcelay J, Outcomes 10, Universitat Jaume I, Castellon, Spain, Committee for Orphan Medicinal Products (COMP), London, UK, Hospital Universitario La Fe, Valencia, Spain, Hospital Vall d’Hebron, Barcelona, Spain, Shire, Madrid, Spain, H. U. Infantil Niño Jesús, Madrid, Spain, FEDER, Madrid, Spain, Instituto de Investigación de Enfermedades Raras, Madrid, Spain

ANAESTHESIA IN DEVELOPING COUNTRIES
Epulu I, Tindimwebwa JV, Mijimbi C, Chokwe T, Lugazia E, Ndarugirire F, Twagirumugabe T, Dubowitz G, Infectious Disease Institute, Kampala, Uganda, Makerere University, KAMPALA, Uganda, Mulago Hospital, Kampala, Uganda, University of Nairobi, Nairobi, Kenya, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania, Centre Hospitalo-Universitaire de Kamenge, Bujumbura, Burundi, National University of Rwanda, Kigali, Rwanda, University of California, San Francisco, San Francisco, CA, USA

HOSPITALIZATIONS IN HYPERCHYLOMICRONEMIA PATIENTS IN QUEBEC, CANADA; RESULTS FROM A REAL-WORLD OBSERVATIONAL STUDY
Lachaine J, Gaudet D, Miron A, Tremblay K, University of Montreal, Montreal, QC, Canada, Centre de médecine génique communautaire de l'Université de Montréal; ECOCONE-21, Chicoutimi, QC, Canada

REVERSAL OF NEUROMUSCULAR BLOCKADE: A DISCRETE EVENT SIMULATION MODEL OF CLINICAL AND OPERATING ROOM EFFICIENCY OUTCOMES OF SUGAMMADEX VERSUS NEOSTIGMINE IN CANADA

HEALTHCARE RESOURCE UTILIZATION COSTS RELATED TO ANAEMIA MANAGEMENT IN CHRONIC KIDNEY DISEASE NON-DIALYSED PATIENTS: A RETROSPECTIVE CLINICAL AND ADMINISTRATIVE DATABASE ANALYSIS
Pessina E, Degli Esposti L, Buda S, Saragoni S, Amgen S.R.L., Milano, Italy, CICon S.R.L., Ravenna, Italy

HEALTHCARE RESOURCE CONSUMPTION AND COST OF CARE IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC DISEASE (ADPKD) IN ITALY
Degli Esposti L, Veronesi C, Crovato E, Buda S, Santoro A, Piccinelli R, CICon S.R.L., Ravenna, Italy, Policlinico S Orsola-Malpighi, Bologna, Italy, Bergamo LUH, Bergamo, Italy

PATIENT UNDERSTANDING AND ATTITUDES ABOUT BIOSIMILARS: AN INTERNATIONAL CROSS-SECTIONAL SURVEY
Jacobs IA, Singh E, Sewell KL, AL-Sabbagh A, Shane LG, Pfizer Inc, New York, NY, USA, Pfizer Inc., Collegeville, PA, USA, Pfizer Inc, Cambridge, MA, USA

DIAGNOSIS OF LIVER DISEASES AMONG INDIVIDUAL WITH HEPATIC DYSFUNCTION DETECTED BY ANNUAL HEALTH CHECKUP BASED ON CLAIMS DATA IN JAPAN
Ito C, Nishikino R, Onishi Y, Japan Medical Data Center Co., Ltd., Tokyo, Japan, Creative-CEPTual K.K., Tokyo, Japan

Prada M, Bertozzi C, Proietti B, Urbiniati D, Intermo, Roma, Italy, IMS Health, Milano, Italy

MARKET ACCESS TRENDS IN RARE DISEASE APPROVALS IN EUROPE FROM 2005 TO 2014
Schultz NM, Sarangpur S, Tourmi M, Sherman S, Creative-CEPTual, Chicago, IL, USA, Aix-Marseille University, Marseille, France

CHALLENGES FOR ASSESSING THE ECONOMIC VALUE OF ORPHAN DRUGS - A LITERATURE REVIEW OF CURRENT AND ALTERNATIVE APPROACHES

ORPHAN AND ULTRA-ORPHAN TECHNOLOGIES: EUROPEAN AND AUSTRALIAN PAYER PERCEPTIONS
PSY128 P16 DOES A NEW PHARMACOECONOMIC MODEL IS DEMANDED FOR OBESITY’S PHARMACOTHERAPY ASSESSMENT?
Hogue S1, Brogan AP1, Croft E2, RTI Health Solutions, Research Triangle Park, NC, USA, 2RTI-Health Solutions, Manchester, UK

PSY129 P17 EPIDEMIOLOGY AND HEALTHCARE SERVICES UTILIZATION FOR RARE DISEASES IN ITALY
Riveros BS1, Luchetta RC2, Radominski R2, Correr CJ2, Wu O1, University of Glasgow, Glasgow, UK, 2Federal University of Parana, Curitiba, Brazil

PSY130 P18 COMPREHENSIVE REVIEW OF ORPHAN DRUGS POST-AMNOG IN GERMANY
Leibfried MJ, Jun K, Neuner C, Arsiwalla MY, Richardson SK, GfK Market Access, New York, NY, USA

PSY132 P19 THE CONTRIBUTION OF INFORMAL CAREGIVER BURDEN TO HTA IN HEMATOLOGICAL CANCERS IN FRANCE, GERMANY, AND THE US
Shingler SL1, Grant C1, McKendrick J2, PRMA Consulting, Fleet Hampshire, UK, 2PRMA Consulting, Hampshire, UK

PSY133 P20 ASSESSMENT OF REAL-WORLD TREATMENT PATTERNS AND OUTCOMES IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: EVIDENCE FROM A BRIEF MULTI-COUNTRY SURVEY OF EUROPEAN PHYSICIANS
Davis KL1, Lin HM2, Hui A2, Zhang S3, Kaye JA4, RTI Health Solutions, Research Triangle Park, NC, USA, 2Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA, 3Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA, 4RTI Health Solutions, Waltham, MA, USA